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ABSTRACT 
Obese individuals are at greater risk of various comorbidities including cancer, diabetes, 
and cardiovascular disease (CVD). Endocrine imbalances and dyslipidemia are likely 
contributors to the etiology of these diseases in obese individuals. 
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The objectives of this research project were: (1) to determine the effectiveness of a self-
selected diet and exercise weight loss (WtL) protocol in overweight and obese women; 
(2) to investigate the effects of moderate WtL on hormones associated with the regulation 
of energy balance, blood lipid levels, and low density lipoprotein (LDL) particle size; (3) 
to characterize changes in cholesterol metabolism as a result of moderate WtL through an 
examination of factors that likely play a role in its modulation, specifically body 
composition and single nucleotide polymorphisms (SNP) in ATP bi~ding cassette 
(ABC)G5 and ABCG8 transporter. 
In carrying out these objectives, 35 women were included in a 24-week WtL trial. 
Hormone, lipids, and cholesterol metabolism were assessed at the end of two stabilization 
periods. During these periods, body composition was also measured via magnetic 
resonance imaging (MRI). WtL was achieved through a 20% decrease in energy intake 
using diet combined with a 10% increase in energy expenditure through physical activity. 
Overall, participants lost an average of Il.7±2.5 kg. WtL resulted in improvements in 
blood lipid risk factors of CVD with minimal effect on LDL particle size. No 
associations were found between leptin, ghrelin, adiponectin, and insulin. Cholesterol 
synthesis decreased as a result of WtL, while cholesterol absorption and turnover did not 
change. Despite an absence of change in turnover, incre~ses were predicted by decreases 
in visceral adipose tissue, and decreases in cholesterol absorption were associated with 
losses in total and upper body skeletal muscle. This study also showed that changes in 
cholesterol concentrations and metabolism after WtL are associated with SNPs in 
ABCG5 and ABCG8 genes. 
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These findings suggest that hormones important in the regulation of energy homeostasis 
may exert their effects independently. Moderate WtL results in cardioprotective changes 
in blood cholesterollevels primarily due to changes in cholesterol synthesis. These 
findings also indicate that the responsiveness of blood cholesterollevels and metabolism 
to weight 10ss is modulated by changes in body composition and SNPs in ABCGS and 
ABCG8. 
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RÉSUMÉ 
L'obésité est un facteur de risque pour des co-morbidités telles le cancer, le diabète et les 
maladies cardiovasculaires (MCV). Les déséquilibres hormonaux et la dyslipidémie 
contribuent au développement de ces co-morbidités associées à l'obésité. 
Les objectifs de ce projet de recherche étaient de : 1) déterminer l'efficacité d'un 
protocole de perte de poids par la diète et l'exercice physique choisi par les sujets (PPP) 
chez les femmes ayant une surcharge pondérale ainsi que les femmes obèses, 2) 
investiguer les effets d'un PPP sur les hormones impliquées dans le maintien du bilan 
énergétique, le profile lipidique sanguin et la taille des particules de lipoprotéines à faible 
densité (LFD), 3) caractériser les altérations du métabolisme du cholestérol à la suite d'un 
PPP, en examinant les facteurs qui pourraient y jouer un rôle, spécifiquement la 
composition corporelle et les polymorphismes simples de nucléotides (PSN) des 
transporteurs ATP binding cassette (ABC)G5 et ABCG8. 
Afin de réaliser ces objectifs, trente-cinq femmes ont été recrutées pour participer à une 
étude de perte de poids incluant deux périodes de stabilisation durant lesquelles les 
mesures de composition corporelle étaient prises, et une période de perte de poids 
pendant laquelle une diminution des apports énergétiques de 20% et une augmentation de 
dépenses de 10% par l'exercice physique étaient imposées. 
Les participantes ont perdu une moyenne de 11.7±2.5 kg. Le PPP était à l'origine d'une 
amélioration du bilan lipidique, avec un effet minimal sur la taille des particules de LFD. 
Aucune association n'a été notée entre les hormones leptine, ghreline, insuline et 
adiponectine. La synthèse de cholestérol a diminué en réponse au PPP alors qu'aucun 
changement n'a été détecté quant à l'absorption et au renouvellement du cholestérol. 
Cependant, l'augmentation de ce dernier était inversement reliée à la réduction du tissu 
adipeux viscéral. De même, la diminution de l'absorption du cholestérol était inversement 
reliée à la perte de la masse musculaire totale et de la partie supérieure du corps. Cette 
étude démontre aussi que les changements du taux de cholestérol ainsi que de son 
métabolisme en réponse au ppp sont associés aux PSN des transporteurs ATP binding 
cassette (ABC)G5 et ABCG8. 
Nos résultats suggèrent que les hormones impliquées dans le maintien du bilan 
énergétique pourraient avoir des effets indépendants. Les effets protecteurs du ppp sont 
en grande partie dus aux altérations de la synthèse du cholestérol. Ces résultats 
démontrent aussi que les effets du ppp sur le profil lipidique et le métabolisme du 
cholestérol sont affectés par des changements de la composition corporelle et des PSN 
des transporteurs ATP binding cassette (ABC)G5 et ABCG8. 
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• Establishes successful motivation strategies, which when incorporated with a 
protocol of self-directed diet and exercise, resulted in the achievement of 
moderate weight loss in women. 
• Confirms that moderate weight loss in women results in cardioprotective 
improvements in blood lipid profiles. 
• Examines for the first time, the interaction of energy regulating hormones 
after moderate weight loss in women, and demonstrates that insulin, 
adiponectin, leptin, and ghrelin may affect weight loss independently. 
• Shows that a decrease in weight is predictive of an increase in adiponectin and 
a reduction in leptin, but is not predictive of other lipid or hormone 
parameters. 
• Demonstrates that initiallipid and insulin levels may be predictive of weight 
loss and therefore, indicates that knowledge of hyperlipidemia may be an 
important behavioural motivator for weight loss success. 
• Shows that moderate weight loss though diet and physical activity minimally 
affects LDL particle size and distribution. 
• Finds novel changes in cholesterol metabolism after moderate weight loss in 
women, where despite decreases in cholesterol synthesis, cholesterol 
absorption and turnover remain unchanged. 
• Demonstrates for the first time, that decreases in VAT and V AT:SAT ratio 
predict increases in cholesterol turnover, and that gains in SM predict 
augmentations in cholesterol absorption. 
• Provides original evidence that the SNPs in ABCG5 and ABCG8 are 
associated with changes in cholesterol concentrations and cholesterol 
metabolism. 
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INTRODUCTION 
The worldwide prevalence of obesity has reached epidemic proportions affecting 
approximately 1 billion adults globally (World Health Organization, 2003). In 
1 
Canada direct measurement of weight and height indicates that about 60% of 
Canadian are overweight or obese (Tjepkema, 2004). Thus, Canada is no exception to 
this global epidemic. It has been suggested that, if upwards trends in obesity continue, 
life expectancy of upcoming generations will be lower than that of their parents 
(Olshansky et al., 2005). Cancer, diabetes and cardiovascular disease (CVD) are 
among the well-established comorbidities associated with obesity. Obesity is not only 
associated with diminished quality of life, but is also associated with gross economic 
burden on the health care system (Daviglus et al., 2003; Katzmarzyk et al., 2004). 
Collectively, the cost and health risks associated with obesity have led to an emphasis 
on the importance of weight loss by organizations su ch as the Heart and Stroke 
Foundation of Canada, the American Heart Association, and the Canadian and 
American Diabetes Associations. 
Weight loss through decreasing energy intake by diet and increasing energy 
expenditure by physical activity remains the number one recommended strategy to 
prevent or treat obesity related comorbidities (Donnelly et al., 2005). Additionally, 
structured programs where diet and physical activity are closely monitored or 
supervised achieve greater weight loss compared to programs where participants self-
monitor (Andersen et al. 1999; Andersen et al. 2002; Evans et al. 1999; Janssen et al. 
2002; Jeffery et al. 2003; Miller et al. 2002; Nicklas et al. 2003; Ross et al. 1995; 
Volek et al. 2002; Wing et al. 1998). The major limitation in using weight 10ss 
regimens with such stringent controls is the time and cost involved in their 
implementation. Accomplishing weight 10ss by a more self-directed protocol might 
include the use of motivational strategies in lieu of close supervision. Various 
approaches to designing motivational strategies have been suggested (Anderson, 
2000). In the clinical setting, an optimal program would integrate these motivational 
strategies to produce comparable weight loss to more structured regimens, without the 
need for su ch rigorous controls. 
The success of decreases in body weight cannot only be attributed to the method used 
as body weight may also be affected by endocrine imbalances of hormones that 
2 
regulate energy homeostasis (Diez et al., 2003; Maffei et al., 1995; Pischon et al., 
2004; Spranger et al., 2003; Weyer et al., 2001; Wu et al., 2004). Not only do these 
hormones contribute to the etiology of obesity, they are also likely involved in the 
development of comorbidities associated with the disease. Adiponectin, found at 
reduced levels in obese individuals, is also lower in patients with insulin-resistance, 
type 2 diabetes, and CVD (Diez et al., 2003; Pischon et al., 2004; Spranger et al., 
2003; Weyer et al., 2001). Thus, adiponectin may have sorne function in regulation of 
blood glucose and lipid homeostasis. Though the roIe of adiponectin in blood glucose 
regulation is not as c1ear, the function of insulin in energy regulation by signalling 
glucose storage has been well established. Ghrelin and leptin are also hormones that 
are thought to affect energy homeostasis through opposing effects. Leptin signaIs 
satiety, while ghrelin stimulates food intake and energy storage (Maffei et al., 1995; 
Wu et al., 2004). Studies show that each of the above mentioned energy regulatory 
hormones are likely affected by weight loss (Baratta et al., 2004; Hansen et al., 2002; 
Zahorska-Markiewicz et al., 2004). Despite this, no study has examined the combined 
changes in the hormones as a result of weight loss. 
Weight loss also results in cardioprotective changes in blood lipids, yet the 
mechanism by which weight loss ameliorates blood lipid concentrations is not 
understood. In addition to low density lipoprotein (LDL) cholesterol concentrations, 
previous research indicates that LDL partic1e size and distribution may be an 
important consideration in CVD risk (Rizzo et al., 2006b). More specifically, small 
dense LDL partic1es have been shown to be atherogenic since they are prone to 
infiltra te arterial tissue and are associated with decreased receptor-mediated uptake 
(Austin et al., 1988; Bjornheden et al., 1996; Galeano et al., 1998; Stampfer et al., 
1996). Weight loss through dietary me ans has been observed to beneficially affect 
LDL size and distribution (Archer et al., 2003; Katzel et al., 1995; Markovic et al., 
1998; Purnell et al., 2000). The effects of physical activity on LDL size however, is 
not as clear as sorne studies have demonstrated a decrease in small LDL particles 
(Halle et al., 1999; Kang et al., 2002; Williams et al., 1990) and others have observed 
no change (Elosua et al., 2003) or slight increases (Varady et al., 2005). Therefore, 
whether moderate weight loss achieved through combined diet and physical activity 
affects LDL partic1e size remains to be seen. 
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Studies have shown that cholesterol synthesis decreases after weight loss (Di Buono et 
al., 1999a; Raeini-Sarjaz et al., 2001). The research suggests that a relationship exists 
between cholesterol absorption and synthesis, where such decreases in cholesterol 
synthesis would lead to increases in cholesterol absorption (Gylling et al., 2002a; 
Miettinen et al., 2003c). Whether cholesterol absorption and turnover respond to 
weight-related changes in cholesterol synthesis however, is unc1ear. Additionally, it 
has been suggested that changes in regional body composition, especially dec1ines in 
visceral adipose tissue (VAT), result in cardioprotective changes in lipid levels 
(Janssen et al., 2002; Leenen et al., 1993; Nieman et al., 2002). However, how 
regional changes in body composition affect cholesterol metabolism is yet to be 
determined. 
Genetics may also influence the effectiveness of weight loss in decreasing cholesterol 
levels. More specifically, ATP-binding cassette (ABC) G5 and ABCG8 transporters 
promote the efflux of cholesterol from hepatocytes and enterocytes (Klett et al., 2004). 
Single nucleotide polymorphisms (SNP) in these transporters may affect the efficacy 
with which ABCG5 and ABCG8 function, thereby affecting the response of 
cholesterollowering therapies (Kajinami et al., 2004a; Kajinami et al., 2004b). The 
effect of weight loss on cholesterollevels and metabolism has not been examined in 
the context of SNPs on ABCG5 and ABCG8. 
Study Objectives 
Accordingly, the objectives of this project were to: 
1. To determine the effectiveness of a self-selected diet and exercise weight loss 
protocol in overweight and obese women. 
2. To investigate the effects of moderate weight loss in overweight and obese 
hyperlipidemic females on hormones associated with the regulation of energy balance, 
blood lipid levels, and LDL partic1e size. 
3. To characterize changes in cholesterol metabolism as a result of moderate weight 
loss through an examination of factors that likely play a role in its modulation, 
specifically changes in body composition and SNP in ABCG5 and ABCG8 
transporter. 
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CHAPTERI. 
LITERATURE REVIEW 
1.1 Introduction 
The purpose of this literature review is to delve into the current research surround 
blood lipid risk factors of cardiovascular disease (CVD) and their metabolism as it 
relates to weight and weight loss. As such, the literature review is divided into to two 
parts. The first part examines the influences of dietary cholesterol on cholesterol 
kinetics, the effects of weight loss and changes in body composition on lipids, the 
effects of weight loss on low density lipoprotein (LDL) partic1e size, the potential 
effects of energy regulatory hormones on weight and blood lipids, and the effects of 
weight loss and changes in body composition on cholesterol metabolism. The second 
part is presented in the form of a manuscript and reviews the connection between 
cholesterol absorption and synthesis and the therapeutic and physiological factors that 
may affect their relationship. 
Part 1 
The influence of dietary cholesterol on cholesterol kinetics in vivo 
The effect of in vivo cholesterollevels on CVD risk and mortality has been weIl 
established in past research. A study by Wilson et al. (1998) showed that total 
cholesterol (TC) levels greater than 5.17 mmollL account for 27% and 34% increases 
in CVD event risk in men and women, respectively. Cui et al. (2001) found that 
elevations in LDL cholesterol (LDL-C) of 0.78 mmollL led to an augmentation in 
CVD risk of 15% in men and 8% in women. Contrary to the negative effects of TC 
and LDL-C on risk, higher levels of high-density lipoprotein cholesterol (HDL-C) 
have been shown to be cardioprotective (Cui et al., 2001; Kwiterovich, 2000). 
Levels of cholesterol in vivo are dependent on absorption, synthesis and turnover. 
Various studies have indicated the influence of diet on cholesterol metabolism. 
McNamara et al. (1987a) showed a 6% decrease in absorption in American males 
consuming a diet containing 840 mg/d of cholesterol compared to one containing 240 
mg/do The decreases in percent of absorption occurring in the presence of high 
cholesterol diets may act in a compensatory fashion to prevent increases in plasma 
cholesterol. A Finnish study on men indicated a positive correlation of absorption on 
plasma LDL-C and TC (Kesaniemi et al., 1987b; Miettinen et al., 1989). On average, 
5 
cholesterol absorption may account for up to 60% of circulating cholesterollevels 
(Bosner et al., 1999a; Bosner et al., 1993; Gremaud et al., 2001b). However, a large 
range of absorption efficiency has been observed in humans (Bosner et al., 1999a; 
Bosner et al., 1993; Gremaud et al., 2001b). In regards to synthesis, human trials have 
produced a variety of outcomes, with sorne indicating no change (Kestin et al., 1989; 
Keys et al., 1956; Kummerow et al., 1977; McNamara et al., 1987a) and others 
associating increases in synthesis with the reduction of cholesterol in the diet (Connor 
et al., 1961; Connor et al., 1964; Hopkins, 1992; Jones et al., 1996; Keys, 1984; 
Roberts et al., 1981). Conversely, a human feeding trial by Jones et al. (1996) 
indicated a suppression of synthesis on increasing levels of dietary cholesterol. 
1.3 Effects of weight loss and changes in body composition on lipid levels 
Decreases in weight of 10% to 15% have been shown to pro duce cardioprotective 
changes in blood lipid profiles of overweight individuals (Wing et al., 1995). A meta-
analysis of 70 studies by Dattilo and Kris-Etherton (1992b) found that every kilo gram 
of weight loss through dietary me ans accounted for a 0.05 mmollL de cline in TC, a 
0.02 mmol/L reduction in LDL-C and a 0.015 mmol/L decrease in triglycerides (TG). 
The same meta-analysis also found that increases in HDL-C of 0.009 mmol/L per 
kilo gram of weight loss usually occurred at stabilized weights and increases in HDL-C 
of 0.007 mmol/L per kilogram weight loss were found in subjects activerly losing 
weight (Dattilo et al., 1992b). Many trials have been conducted that examine the 
effects of weight loss on lipids (Miller et al., 2005; Nordmann et al., 2006; Wood et 
al., 2006). However, most have focused on males with very few examining females. 
In these studies, weight loss was often achieved through diet only. Even less 
examined are the effects of changes in body composition on blood lipid levels. 
Table 1-1 summarizes four trials conducted on women that examined the effects of 
weight loss and body composition on blood lipid levels. Overall, body weight was 
successfully reduced in programs that contained both diet and exercise (Janssen et al., 
2002; Nieman et al., 2002; Stefanick et al., 1998). Trials by Stefanick et al. (1998) 
and Lofgren et al. (2005b) showed an average decrease of 3 - 4 kg and studies by 
Nieman et al. (2002), and Janssen et al. (2002), found reductions of 8 and 10 kg, 
respectively. 
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These studies found that groups which underwent a regiment of diet and exercise 
exhibited a significant decrease in TC and LDL-C levels (Janssen et al., 2002; Lofgren 
et al., 2005b; Nieman et al., 2002; Stefanick et al., 1998). The diet and exercise group 
in the trial by Stefanick et al. (1998) saw reductions in TC and LDL-C of 17.5 mg/dL 
(0.45 mmol/L) and 14.5 mg/dL (0.37 mmol/L), respectively. Similarly, the trial by 
Lofgren et al. (2005b) observed decreases in TC, LDL-C, and TG by 8%,12.3%, and 
19.5%, respectively, whi1e no changes in HDL-C were found. The shorter term study 
by Janssen et al. (2002) which also examined individu ais who underwent treatments 
of diet and exercise, exhibited TC and LDL-C dec1ines of up to 0.60 mmol/L and 0.34 
mmol/L respectively. Nieman et al. (2002) found that the diet and exercise groups 
had average decreases in TC (5.34 mmol/L at baseline vs. 4.70 mmol/L at week 12) 
and in LDL-C (3.49 mmol/L at baseline vs. 2.96 mmol/L at week 12). Although 
slight decreases of HDL-C in the diet and resistance group were indicated in the 16-
week trial by Janssen et al. (2002), the results of the meta-analysis by Dattilo and 
Kris-Etherton (1992b) showed increases to occur after further treatment. Therefore, 
although HDL may decrease initially, increases may occur over the long term. The 
same study by Janssen et al. (2002) indicated no relation between the type of fat loss 
and lipid levels. However, dec1ines in body fat percent were related to favourable 
changes in blood lipid profiles (Janssen et al., 2002; Nieman et al., 2002). 
Additionally, a review by Leenen et al. (1993) indicated that weight loss, resulting in 
decreases of visceral fat, were related to favourab1e changes in blood lipid profile. 
Other weight loss trials that examined the effects of diet on cho1esterollevels also 
found significant decreases in TC and LDL-C after losses in adipose tissue in the 
trunk region (Famsworth et al., 2003; Noakes et al., 2005). 
Though these studies indicate an influence of changes in body composition after 
weight loss by diet and physical activity, the relationship between regionallosses and 
cholesterol changes remains to be more c10sely examined. 
1.4 Effects of weight loss on LDL particle size 
Various studies have indicated that weight loss exerts postitive effects on low-density 
lipoprotein (LDL) size and distribution (Archer et al., 2003; Katzel et al., 1995; 
Lofgren et al., 2005a; Markovic et al., 1998; Pumell et al., 2000; Wood et al., 2006). 
More specifically, weight loss has been associated with reductions in smaller, more 
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atherogenic LDL particles (Archer et al., 2003; Katzel et al., 1995; Lofgren et al., 
2005a; Markovic et al., 1998; Purnell et al., 2000; Wood et al., 2006). Despite this, 
studies in the current literature focus on the effects of diet-related weight changes on 
these parameters. A recent study by Wood et al. (2006) examined the effects of 7.5 kg 
of weight loss in men on LDL particle subfraction distribution and size. The weight 
loss in this study was produced from a diet that consisted of 10% carbohydrate, 65% 
fat, and 25% protein and resulted in 35% increase in large LDL particles and a 24.7% 
decrease in very small LDL particles (Wood et al., 2006). LDL particle size was also 
beneficially affected through 2% weight loss from a low fatlhigh carbohydrate diet in 
a study conducted by Archer et al. (2003). Another trial that produced 6.2 kg of 
weight loss through a low fat diet found a higher proportion of large LDL particles in 
the plasma (Markovic et al., 1998). Similarly, a study by Katzel et al. (1995) observed 
increases in LDL peak particle diameter after 10 kg of weight loss in men. One study 
that examined 70 premenopausal women found that weight loss of about 3.5 kg from 
diet and exercise resulted in increase in particle size and a decrease in smaller LDL 
subfractions (Lofgren et al., 2005a). Though the present literature shows that diet-
induced weight loss positively alters LDL electrophoretic characteristics, the effect of 
moderate weight loss from combined low fat diet and exercise, another commonly 
implemented weight loss strategy, has yet to be tested. 
1.5 Hormone interaction with weight and risk factors of cardiovascular disease 
Insulin, ghrelin, adiponectin, and leptin are hormones implicated in exerting metabolic 
regulation of blood lipid risk factors of cardiovascular disease. Since these hormones 
are also play a role in maintaining energy homeostasis, they may influence or be 
modulated by weight loss. 
The regulation of insulin in blood glucose control has been well established (James et 
al., 1994). More specifically, the release of insulin from the l3-cell of the pancreas is 
key to glucose transport into myocytes and adipocytes (James et al., 1994). 
Resistance to insu lin has been associated with an increase risk in cardiovascular 
events (DeFronzo et al., 1991). Indeed, insulin resistance has been linked to low 
HDL-C and high TG (DeFronzo et al., 1991; Howard et al., 1994; Riemens et al., 
1999; Taskinen, 1990). Additionally, insulin may react with LDL receptors to 
stimulate clearance of LDL from the blood (Mazzone et al., 1984). 
Though adiponectin is a cytokine released by adipose tissue (adipocytokine), its 
secretion has been shown to be reduced in obesity (Arita et al., 1999). Adiponectin 
has also been implicated in the regulation of blood glucose levels, since it has been 
shown to be attenuated in people with type 2 diabetes and patients with insulin 
resistance (Arita et al., 1999; Berg et al., 2002; Spranger et al., 2003; Weyer et al., 
2001). Studies in mice indicate that adiponectin may decrease insulin resistance by 
stimulating fatty acid oxidation and decreasing the presence of TG in the muscle and 
liver (Yamauchi et al., 2001). Though the mechanism by which adiponectin 
modulates blood glucose homeostasis has not yet been elucidated, experiments in rats 
showed that adiponectin decreased hepatic glucose production through inhibiting 
enzymes of gluconeogenesis (Berg et al., 2001). Lower levels of adiponectin have 
also been shown to associated with CVD and has been implicated in the development 
of atherosclerosis (Diez et al., 2003; Ouchi et al., 1999; Ouchi et al., 2001; Pischon et 
al., 2004). 
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Although leptin is also an adipocytokine, its function is different than that of 
adiponectin. More specificaIly, lep tin has been found to signal satiety, through a 
direct effect on the hypothalamus, and stimulate energy expenditure (Halaas et al., 
1995; Lee et al., 1996; Maffei et al., 1995; Wu et al., 2004). Additionally, leptin has 
been shown to be elevated in people with higher body fat, as is found in obesity 
(Maffei et al., 1995; Ostlund et al., 1996). The importance of leptin to the 
contribution of obesity is made evident through the ob/ob mouse, that lacks a gene 
encoding leptin, and is significantly more obese than their normal counterpart 
(Pelleymounter et al., 1995). Not only has absence of leptin been shown to contribute 
to obesity, patients with aberrant leptin-secreting adipocytes have been shown to 
develop lipotoxicity and abnormal fat distribution (Garg, 2004; Garg et al., 2004). 
Indeed, leptin may act to maintain lipid homeostasis through limiting food intake and 
thus prevent the excess storage of lipids, and upregulate capacity of nonadipose 
tissues to oxidize excess lipids, which may have resulted from overnutrition (Unger, 
2005). 
In contrast to leptin, ghrelin, which is primarily secreted from the stomach, signaIs 
food intake and energy storage (Maffei et al., 1995; Wu et al., 2004). Indeed, studies 
have shown that ghrelin is negatively correlated to BMI and fat cell size (Purnell et 
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al., 2003; Ravussin et al., 2001; Tschop et al., 2001). Though the influence of ghrelin 
on cardiovascular disease risk in unclear, a recent study by Pumell et al. (2003) 
observed a positive correlation between ghrelin and HDL cholesterol. Ghrelin may 
also affect lipids indirectly through its action on insulin as experiments in mice and 
rats have found that ghrelin may inhibit insulin secretion from pancreatic islet cells 
(Qader et al., 2005; Salehi et al., 2004). 
Despite the implications of insulin, adiponectin, leptin, and ghrelin in weight control 
and lipid risk factors of cardiovascular disease, these hormones have never been 
studied in combination in the context of weight changes produced through diet and 
exercise. 
1.6 Effects of weight and changes in body composition on cholesterol metabolism 
Very few studies have examined the effects of weight and more specifically, weight 
loss on cholesterol kinetics. A trial by Miettinen and Gylling (2000a) showed higher 
cholesterol synthesis in ten obese versus ten normal weight males. Additionally, the 
obese group was found to have lower dietary absorption (Miettinen et al., 2000a). 
Weight loss has been indicated to affect cholesterol synthesis in experiments 
conducted on men as well as men and women together (Di Buono et al., 1999a; 
Griffin et al., 1998; Raeini-Sarjaz et al., 2001). Di Buono et al. (1999a) looked at 
weight loss in six males with average baseline BMI of 30.3±3.8 kg/m2• A six month 
period of weight loss using a caloric deficit of 1000 kJ/d following the AHA StepI diet 
led to reductions of 3 kg - 8 kg (Di Buono et al., 1999a). This was accompanied with 
decreases in fractional cholesterol synthesis (FSR) from 8.42%±3.90%/d to 
3.04%±1.90%/d (P<0.05), as weIl as reduced absolute cholesterol synthesis rate from 
1.66±0.84 g/kg/d to 0.59±0.38 g/kg/d (Di Buono et al., 1999a). Similar results were 
found in a randomized cross-over trial by Raeini-Sarjaz et al. (2001). This study fed 
participants (n=l1) normal and low energy diets that either contained typical amounts 
of fat or low amounts of fat for 4 weeks with 6 weeks between phases (Raeini-Sarjaz 
et al., 2001). The low energy diets resulted in weight loss of approximately 3 kg and 
were accompanied by FSR decreases of 27.7% and 25.5% (in the low energy and low 
energy-Iow fat diet, respectively). 
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Contrary to this, the trial by Griffin et al. (1998) found no differences in fasting 
synthesis measured by C14-acetate. In their trial, obese reduced insulin resistant (RI; 
n=7) and insulin resistant (IR; n=6) participants with diabetes were given a diet 
designed to decrease daily caloric intake by 25% and fat intake to less than 30% or a 
diet reducing calorie intake by 800 kcal, whiehever was less (Griffin et al., 1998). 
This diet resulted in weight changes in the RI and IR groups from 92.5±6.4 kg to 
85.3±5.5 kg and 107.9±5.5 kg to 99.8±5.2 kg, respectively (Griffin et al., 1998). 
Another study in overweight, people with type 2 diabetes by Simonen et al. (2000) 
also observed no signifieant changes in cholesterol synthesis after a 3-month weight 
loss program, followed by a one and a half year maintenance period (n=19). The 
same experiment attributed an average rise in cholesterol absorption from 29.5% to 
37.6% with a weight loss of 6 kg (Simonen et al., 2000). However, no significant 
changes were observed in cholesterollevels despite these variances in absorption 
(Simonen et al., 2000). It should be noted that, despite this loss in weight, the lack of 
signifieant results in these studies may have been due to the limited number of 
participants. 
Absorption of dietary cholesterol occurs in the intestine, whereas endogenous 
production of cholesterol occurs in many ce Ils including adipocytes and hepatocytes. 
In obesity, both adipocytes and hepatocytes increase in number. The meta-analysis of 
Datillo and Kris-Etherton (1992b) estimated the cholesterol synthetic rate of fat as 20 
mg/kg/do However, they indicate that in vitro studies of cholesterol synthesis 
demonstrate limited ability for human adipose tissue to convert labeled precursors into 
sterols (Dattilo et al., 1992b). Since the liver is known to be the primary source of 
cholesterol synthesis, its higher rate of occurrence in obesity is likely due to hepatic 
rather than adipose tissue increases (Dattilo et al., 1992b). Indeed, cholesterol 
synthesis per gram of hepatie tissue has been found to be equivalent in obese and non-
obese individu ais (Miettinen et al., 2000a). In weight 10ss, the mobilization of adipose 
tissue stores of cholesterol during caloric restriction may result in the inhibition of 
hepatic cholesterol synthesis (Dattilo et al., 1992b). 
Studies examining the effects of weight loss on cholesterol metabolism have 
traditionally used diet as the only method of achieving weight loss. Current guidelines 
11 
for a healthy lifestyle also emphasize the importance of physical activity. To our 
knowledge, the effect of weight loss through diet and exercise on cholesterol kinetics 
has yet to be studied. Additionally, none of these studies examine the effects of 
changes in body composition on cholesterol metabolism. A decrease in cholesterol 
synthesis through weight loss may have effects on cholesterol absorption. However, 
there are no known trials in overweight healthy individuals that examine this 
relationship. 
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1. 7 Abstract 
Cholesterol absorption and synthesis contribute to maintaining cholesterol 
homeostasis. Several physiological and therapeutic factors affect cholesterol 
homeostasis, inc1uding: genetics, circadian rhythm, body weight, plant sterols, 
ezetimibe, and statin therapy. The present objective is to determine the main vector, 
i.e. cholesterol absorption or synthesis, affected by each of the se factors, and to 
examine whether an alteration in one vector is linked to a reciprocal change in the 
other. Current techniques used to assess cholesterol absorption and synthesis are also 
reviewed. Review of physiological factors affecting cholesterol metabolism suggest a 
reciprocal relationship between these two vectors. Carriers of the E2 isoform of 
apolipoprotein E and ATP binding cassette (ABC) G8 19H (exon 1 mutation) show a 
decrease in cholesterol absorption accompanied by a corresponding increase in 
synthesis. Circadian rhythm affects cholesterol synthesis, however, its effect on 
absorption has yet to be established. Obese subjects show an increase in cholesterol 
synthesis with a subsequent decrease in cholesterol absorption. Weight loss down 
regulates cholesterol synthesis, but has little or no effect on absorption. In the case of 
therapeutic factors, plant sterols and stanols inhibit cholesterol absorption, which 
results in a compensa tory increase in synthesis. Ezetimibe also decreases intestinal 
absorption, while reciprocally increasing synthesis. Statin therapy down regulates 
synthesis, which is accompanied by a cise in absorption. These findings suggest that a 
change in one vector, fairly consistently, results in a compensatory and opposing 
change in the other. An understanding of this reciprocal relationship between 
cholesterol absorption and synthesis may allow for the development of more effective 
interventions for dyslipidemic disorders. 
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1.8 Introduction 
Circulating cholesterollevels are a primary target of therapy for the prevention and 
treatment of coronary heart disease (NCEP Adult Treatment Panel III, 2001). 
Cholesterol absorption and synthesis contribute to maintaining cholesterol 
homeostasis, and thus, cholesterollevels in the blood. Exogenous cholesterol is 
absorbed within the small intestine, whereas endogenous cholesterol is produced in 
both hepatic and peripheral tissues (Dietschy et al., 1967; Spady et al., 1983). 
Cholesterol homeostasis has been shown to be affected by several key physiological 
factors, such as: an individual's genetics, the body's circadian rhythm, and body 
weight. In addition to these internaI modula tors of cholesterol metabolism, certain 
external therapeutic factors may also affect cholesterol balance. Examples of 
commonly implemented therapeutic options inc1ude: plant sterol or stanol 
supplementation, ezetimibe treatment, statin therapy, and body weight loss. Each of 
these physiological or therapeutic factors directly affects one of the vectors involved 
in cholesterol homeostasis, i.e. cholesterol absorption or synthesis. For instance, in 
the case of ezetimibe therapy, these agents decrease circulating cholesterollevels by 
directly inhibiting cholesterol absorption, while having no direct effect on cholesterol 
synthesis. In view of the selective effect of these factors either on cholesterol 
absorption or synthesis, certain questions that arise inc1ude: Does an alteration in one 
vector result in a reciprocal effect in the other? What is the magnitude of the 
reciprocal effect? What are current methodologies implemented in measuring 
cholesterol absorption and synthesis? Moreover, what are the implications of these 
reciprocal effects with regard to cholesterollowering therapy? Thus, in order to 
address these questions, the objective of this paper is to determine the main vector 
affected by each of the physiological and therapeutic factors mentioned above, and to 
examine whether an alteration in one vector is linked to a reciprocal change in the 
other. In assessing the relationship between cholesterol absorption and synthesis, the 
current methods used to examine these kinetic parameters will also be discussed. 
1.9 Methods of measuring cholesterol absorption and synthesis 
A variety of techniques exist to measure cholesterol absorption and synthesis. The 
following section briefly describes the most common methods currently implemented, 
and also touches upon the advantages and limitations of each. 
1.9.1 Cholesterol absorption assessment methods 
Sterol balance approach 
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The gold standard approach to measuring cholesterol absorption is the sterol balance 
method (Grundy et al., 1969a; Wilson et al., 1965). This technique measures the mass 
absorption of cholesterol as the difference between dietary intake of exogenous 
cholesterol and fecal excretion of exogenous cholesterol. So as to not underestimate 
the amount of exogenous cholesterol absorbed, the quantity of endogenous cholesterol 
excreted in the feces is accounted for by the administration of intravenous radio 
labeled cholesterol. Thus, the mass absorption (mg/d) of cholesterol is calculated as 
the balance between dietary cholesterol intake and fecal cholesterol excretion. 
Although this method is limited in that it is time consuming, this technique is 
advantageous in that it allows for the absolute mass absorption of cholesterol to be 
calculated. 
Plasma isotope ratio technique 
The plasma isotope ratio technique differs from the balance method in that, instead of 
quantifying cholesterol absorption, it estima tes the fraction of cholesterol absorbed 
over a defined period of time (Bosner et al., 1999b; Gremaud et al., 2001a; Jones et 
al., 2000a). Cholesterol absorption is calculated from the ratio of oral cholesterol 
tracer enrichment, taken to represent the amount of exogenous cholesterol absorbed, 
to intravenous tracer enrichment, taken to represent the total cholesterol pool in the 
blood. This method requires that volunteers receive a stable or radioactive isotope 
labeled cholesterol tracer orally (e.g. 2HPH-cholesterol) while simultaneously 
receiving a second tracer intravenously (e.g. 13C;I4C-cholesterol). Following isotope 
administration, blood samples are collected over several days. Free cholesterol is 
isolated from plasma or red cells, and is subsequently combusted to 2HPH -labeled-
hydrogen gas and 13C;I4C -labe1ed-C02 gas (Jones et al., 2000a). Isotopic 
enrichments are then analyzed and expressed against international standards (Jones et 
al.,2000a). Alternatively, on-line GCI combustion and Gel pyrolysisl IRMS has been 
employed. Once the steady state ratio of the 2HPH - to 13C;I4C -cholesterol 
enrichments are reached, generally within 2 to 3 days of isotope administration, the 
fraction cholesterol absorbed can be determined. The plasma isotope ratio technique 
has been shown to be beneficial in clinical settings in that it allows for the direct 
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quantification of the percent of cholesterol absorbed. This method, however, may be 
seen as invasive due to intravenous isotope administration. 
Plant sterol-to-cholesterol ratio determination 
Evidence suggests that plant sterol metabolism is related to cholesterol absorption. 
Results of recent human studies indicate that circulating plant sterollevels are 
correlated with cholesterol absorption rates. More specificaIly, in a study by (Tilvis et 
al., 1986), it was shown that the ratio of serum campesterol-to-cholesterol was 
strongly correlated to percent cholesterol absorption. In support of these findings, in a 
trial performed in 63 randomly selected Finish subjects, campesterol-to-cholesterol 
ratios were shown to vary directly with percent cholesterol absorption (Miettinen et 
al., 1990). These findings indicate that circulating levels of non-cholesterol sterols are 
proportional to the amount of cholesterol absorbed. This method of absorption 
assessment is advantageous as it is quick and relatively easy to perform by way of 
gas-liquid chromatography. Thus, it is feasible for application in large sample 
populations. This technique, however, is limited in that it only indicates whether 
absorption has increased or decreased, and does not provide any indication of the 
absolute amount of cholesterol absorbed. Also, identification of plant sterol peaks is 
sometimes difficult, confounded by the presence of other substances co-eluting off the 
Ge column at the same retention time. 
1.9.2 Cholesterol synthesis assessment methods 
Deuterium incorporation approach 
The deuterium incorporation approach de termines cholesterol synthesis as the rate of 
incorporation of deuterium from body water into red cell membrane free cholesterol 
over a 24 h period (Wang et al., 2004b; Woollett et al., 2003). Employing this 
technique requires that subjects consume a small amount of deuterated water 
following the study intervention. Shortly after ingestion, the deuterated water 
equilibrates with intra- and extra-cellular body water pools. In this way, any newly 
formed cholesterol synthesized within 24 h will have a certain number of H atoms 
replaced by deuterium. The fractional cholesterol synthesis rate (FSR) (pools/d) over 
a 24 h period is then ca1culated as the amount of enriched free cholesterol relative to 
the total cholesterol pool. Although this method allows for the direct measurement of 
the cholesterol pool synthesized over a 24 h period, the laboratory techniques 
employed to quantify isotope enriehments are quite time-intensive and laborious. 
Cholesterol precursor quantification 
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Previous studies suggest that circulating cholesterol precursors, i.e. lathosterol, 
lanosterol, squalene, and desmosterollevels, may reflect whole body cholesterol 
synthesis (Kempen et al., 1988; Pfohl et al., 1999). The rationale for using precursor 
levels as an indieator of cholesterol synthesis lies in the assumption that these 
compounds leak into plasma lipoproteins at a rate proportional to that of their 
formation in the cholesterol synthetie pathway (Ordovas et al., 2002). Levels of 
cholesterol precursors are determined by gas-liquid chromatography from the non-
saponifiable material of serum or plasma lipids. This cholesterol synthesis assessment 
method benefits from being efficient and inexpensive. On the other hand, the method 
is limited in that it does not allow for the direct quantification of the amount of 
cholesterol synthesized. Instead, this method simply indieates whether or not 
increases or decreases in cholesterol precursors occur as a result of specifie 
interventions. 
In view of the above discussion of methodologies, the advantages and limitations of 
these various methods should be taken into consideration when reviewing the studies 
employing these techniques. 
1.10 Physiological factors affecting cholesterol absorption and synthesis 
Certain physiological factors, such as geneties, circadian rhythm, and body weight, 
have been shown to affect cholesterol homeostasis by directly modulating either 
cholesterol absorption or synthesis. The following section aims to discuss the primary 
effect of each of these factors on either one of these vectors, and attempts to delineate 
whether a corresponding effect between the two vectors exists. A summary of the 
effects of these physiological factors on cholesterol absorption and synthesis is 
displayed in Table 1-2. 
Genetic factors 
Cholesterol metabolism is regulated by a host of different proteins and transporters, 
many of whieh have been shown to possess genetie polymorphisms. The involvement 
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of hereditary fadors in cholesterol absorption and synthesis is supported by human 
studies showing inter-individual variability in response to cholesterollowering by 
statins (Miettinen et al., 2002, 2003a; O'Neill et al., 2001), heritability of indicators of 
cholesterol synthesis and absorption (Boomsma et al., 2003; Gylling et al., 2002b), 
and differences in cholesterol absorption between different mouse strains (Carter et 
al., 1997; Jolley et al., 1999; Schwarz et al., 2001; Wang et al., 200la). 
Apolipoprotein E (apoE) has been shown to play a major role in lipid transport and 
metabolism. Three common isoforms of the apoE gene exist, these being E2, E3, and 
E4. Carriers of the E2 isoform may have lower rates of cholesterol absorption and 
higher rates of cholesterol synthesis compared to carriers of the E3 or E4 isoform 
(Gylling et al., 1995; Kesaniemi et al., 1987a; Miettinen et al., 1992). In contrast, 
carriers of the E4 isoform exhibit increased cholesterol absorption rates, accompanied 
by a reciprocal decrease in bile acid synthesis (Kesaniemi et al., 1987a). As a result, 
carriers of the E4 isoform may be better candidates for cholesterol-Iowering drugs that 
inhibit absorption, i.e. plant sterols or ezetimibe. These effects, however, have not 
been consistently observed. For instance, Miettinen et al. (1992) showed that the 
effect of apo E polymorphism is poorly related to cholesterol metabolism at low 
cholesterol intakes. In addition, Jones et al. (1993b) found no relationship between 
apo E genotype and cholesterol synthe sis rate in subjects on self-selected low 
cholesterol and high cholesterol diets. Therefore, the effect of the apo E isoforms on 
cholesterol absorption, and their possible reciprocal effect on cholesterol synthesis, 
may only be apparent at high intakes of dietary cholesterol. 
Sitosterolemia, a rare autosomal recessive disorder characterized by high absorption 
and retention of sterols, is caused by mutations in the ATP binding cassette (ABC) 
transporters, ABCG5 and ABCG8 (Berge et al., 2000; Lee et al., 2001). ABCG5 and 
ABCG8 genes express transporters at the intestine and the liver, whieh play a key role 
in regulating cholesterol absorption (Ordovas et al., 2002). Although their specifie 
functions are undear, it has been postulated ABCG transporters may be responsible 
for the selective reverse transport of cholesterol from the enterocyte into the intestinal 
lumen. Studies examining non-sitosterolemic individuals were carried out to 
investigate the effect of sequence variants in ABCG5 or ABCG8 on cholesterol 
metabolism. Berge et al. (2002) reported that two variants in ABCG8, D19H and 
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T400K, are linked to lower plasma plant sterols concentrations. Further research 
found that the 19 H allele (exon 1 mutation) of the ABCG8 gene was associated with 
low cholesterol absorption markers and high cholesterol synthesis markers (Gylling et 
al.,2004a). An intervention study that examined genetic associations in 337 subjects 
after 52 weeks of treatment with 10 mg atorvastatin also observed lower total 
cholesterol (TC) levels in carriers of at least one mutant 19H alle1e (Kajinami et al., 
2004b). The same study did not find any differences according to the Q604E on 
ABCG5 and T400K polymorphisms (Kajinami et al., 2004b). Additionally, a novel 
ABCG8 exon 2 mutation was identified on the Island of Kosrae (Sehayek et al., 
2004). The carriers of the mutant alle1e had increased plasma plant sterols levels and 
decreased lathosterollevels, indicating enhanced absorption, and a reciprocal decrease 
in synthesis. These findings indicate that the existence of a relationship between 
absorption and synthesis may be mediated by mutations in ABCG8. 
Niemann Pick Cl Like 1 (NPC1L1), a protein with a sterol-sensing domain, was 
recently discovered as the intestinal cholesterol transporter (Altmann et al., 2004). A 
recent investigation on the Dallas Heart Study participants by Cohen et al. (2006) 
resulted in the identification of various mutations in NPC1L1 that were common in 
individuals with low cholesterol absorption. Additionally, variant alle1es were 
associated with a 10% lower low-density lipoprotein (LDL) cholesterol (Cohen et al., 
2006). The variations were found to be common in 6% of 1832 African-American 
men and women, however, the investigators were unable to determine which alleles 
may lead to functional impairment of NPC1L1 (Cohen et al., 2006). Though it is 
unc1ear whether individual variations in NPC1L1 affect its function, a haplotype 
common to 1 in 8 subjects was found to be associated with inter-individual variation 
in the response of plasma LDL-C to 12 week treatment with ezetimibe, a drug that 
inhibits cholesterol absorption (Hegele et al., 2005). Further studies have indicated 
that feeding a cholesterol/cholate diet to wild type mice results in down regulation of 
intestinal mRNA expression of NPC1Ll (Davis et al., 2004). Moreover, mice that 
were deficient in NPC1L1 had upregulated intestinal 3-hydroxy-3-methylglutaryl 
(HMG) CoA synthase mRNA and increased cholesterol synthesis (Davis et al., 2004). 
Thus, NPC1L1 mutations may play a major role in the indirect control of cholesterol 
synthesis through regulation of cholesterol absorption. 
Studies using knockout mouse models have identified additional genes that express 
pro teins that may affect cholesterol absorption and synthesis including sterol 
regulatory element binding protein-1 (SREBP-1), acyl CoA:cholesterol 
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acyltransferase 2 (ACAT2) , farnesoid X-receptor (FXR), and mucin gene 1 (Muc1) 
(Table 1-2) (Buhman et al., 2000; Lambert et al., 2003; Shimano et al., 1997). Sterol 
regulatory element binding protein-1 is a membrane-bound transcription factor that 
regulates cholesterol synthesis and uptake from circulating LDL. Mice lacking the 
SREBP-1 gene had elevated levels of levels of mRNAs for 3-hydroxy-3-
methylglutaryl coenzyme A synthase and reductase and squale ne synthase, 
consequently cholesterol synthesis was elevated threefold in livers of these mice and 
hepatic cholesterol content was increased by 50% (Shimano et al., 1997). Buhman et 
al. (2000) showed that ACAT2 is the enzyme responsible for cholesterol 
esterification in mouse small intestine as well as liver. In addition, it was 
demonstrated that ACAT2-deficient mice had reduced capacity to absorb dietary 
cholesterol when fed high cholesterol diet but not when fed a chow diet (Buhman et 
al. 2000). Thus, deficiency of ACAT2 has a protective effect against 
hypercholesterolemic diet in mice. Farnesoid X-receptor is a nuclear hormone 
receptor that play regulate many aspects in cholesterol metabolism inc1uding reverse 
cholesterol transport, intestinal cholesterol absorption and enterohepatic circulation of 
cholesterol and thus FXR-deficient mice had increased intestinal cholesterol 
absorption (Lambert et al. 2003). Recently, it was shown that disruption of Muc1, one 
of the genes that regulate mucin secretion in the small intestine, resulted in 50% 
reduction in intestinal cholesterol absorption in mice (Wang et al., 2004a). Another 
regulatory protein, scavenger receptor c1ass B type 1 (SR-BI) which may facilitate 
cholesterol uptake by enterocytes, has also been identified (Altmann et al., 2002; 
Mardones et al., 2001). However, existing evidence indicates that SR-BI may not be 
necessary for cholesterol absorption (Altmann et al., 2002; Mardones et al., 2001). 
Therefore, studies in human are needed to investigate whether genetic variations in 
genes mentioned above may play a role in explaining absorption and synthesis 
responsiveness to various therapeutic factors. Candidate genes that play a role in 
cholesterol absorption and synthesis are potential targets for the development of 
cholesterollowering drugs or functional ingredients. 
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Circadian rhythm 
A circadian rhythm of cholesterol biosynthesis has been identified in animaIs and 
humans. In studies involving rats and hamsters, maximum cholesterol synthe sis was 
shown to occur at midnight while minimum synthesis occurs at noon (Edwards et al., 
1972; Hamprecht et al., 1969; Ho, 1975, 1979; Jurevics et al., 2000). The peak in 
synthesis likely corresponds to the nocturnal feeding cycle of rats and hamsters 
(Edwards et al., 1972; Ho, 1979). When rats are fed during the light period, the 
maximum rate of cholesterol synthe sis occurs 9 h after feeding (Edwards et al., 1972). 
Another study in hamsters further indicates that regardless of the lighting period, the 
peak in cholesterol synthesis occurs 4 to 6 h after feeding and the nadir occurred at the 
end of the fasting period (Ho, 1979). In humans, circadian rhythm in cholesterol 
synthesis has been measured directly by deuterium incorporation and indirectly by 
blood concentration of cholesterol precursors (Cella et al., 1995; Jones et al., 1990; 
Miettinen, 1982; Pappu et al., 1994; Parker et al., 1982). Deuterium incorporation 
from body water into plasma cholesterol indicates that free cholesterol FSR values 
peak at 06:00 h and attain a nadir at 14:00 to 18:00 h (Jones et al., 1990). Another 
study showed maximal cholesterol FSR to occur at 22:00 h while minimal FSR 
occurred at 11:30 h (Cella et al., 1995). Plasma concentrations of cholesterol 
precursors also demonstrate circadian variation with highest blood concentrations of 
mevalonic acid observed at midnight (Pappu et al., 1994; Parker et al., 1982). 
Furthermore, increased blood concentrations of squale ne and lipid soluble methyl 
sterols occur at midnight and 04:00 h (Miettinen, 1982). In humans, delaying meal 
time 6.5 h, resulted in 8.6 h and 6.5 h delay in maximum and minimum cholesterol 
synthesis rates, respectively (Cella et al., 1995). Thus, akin to what was seen to occur 
in animaIs, the circadian rhythm of cholesterol synthesis in humans also seems to be 
affected by food intake. 
Many animaIs and hum ans studies have examined circadian rhythm in cholesterol 
synthesis but not circadian rhythm in cholesterol absorption. Nevertheless, the 
possibility of diurnal variation of cholesterol absorption is supported by data obtained 
in rats (Edwards et al., 1972; Ishida et al., 2000). Here, hepatic cholesterol synthesis 
appears low at noon, and also indicated that maximal expression and activity of sterol 
I2a-hydroxylase (CYP8B) occurred at mid-afternoon in animaIs subjected to 
light/dark cyc1ing (Edwards et al., 1972; Ishida et al., 2000). The CYP8B enzyme is 
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responsible for the synthesis of cholic acid and the determination of the cholic acid-to-
chenodeoxycholic acid ratio (Vlahcevic et al., 2000). In mice lacking the gene 
encodes CYP8B enzyme, cholesterol absorption was reduced and cholesterol 
synthesis was unregulated (Murphy et al. 2005). Seeing as cholic acid facilitates 
cholesterol absorption in the intestine, and since cholic acid supplementation 
enhanced cholesterol absorption in humans, it can be hypothesized that maximal rates 
of CYP8B results in maximal rates of cholesterol absorption (Chiang, 2004; Woollett 
et al., 2004). The mechanism by which circadian rhythm affects cholesterol synthesis 
and absorption could be explained at the molecular level. The expression of many 
genes encoding enzymes involved in cholesterol metabolism have demonstrated 
circadian rhythm, such as the expression of HMG-CoA (Jurevics et al. 2000) and 
CYP8B enzymes (Ishida et al. 2000). Future research in this area should examine the 
level or the expression of the newly discovered proteins that have a role in cholesterol 
absorption such as NPC1Ll, as well as ABCG5 and ABCG8 genes. 
Body weight 
Dyslipidemia is common in individu aIs who are overweight and obese (Dattilo et al., 
1992a). These abnormal fasting lipid profiles may be due to altered cholesterol 
metabolism commonly found in overweight populations (Di Buono et al., 1999b; 
Miettinen et al., 2000a). Compared to normal weight individuals, obese subjects 
demonstrate elevated cholesterol synthesis (Miettinen et al., 2000a). Liver biopsies 
taken from normal and overweight individu ais reveal that the expression of HMG 
CoA reductase, the enzyme catalyzing the rate-limiting step in hepatic cholesterol 
synthesis, is augmented in those who are overweight (Stahlberg et al., 1997). 
Additionally, the activity of other enzymes participating in the cholesterol synthesis 
pathway are elevated in obese individuals (Stahlberg et al., 1997). Furthermore, it 
was observed that the livers of obese participants are enlarged (Stahlberg et aL, 1997). 
Since synthesis of cholesterol per g of hepatic tissue is similar in le an and obese 
individuals, the larger livers of obese compared to lean individuals results in an 
ove raIl augmentation in synthesis (Angel et al., 1979; Angelin et al., 1982). This 
increase in cholesterol synthesis in obese subjects has been associated with a decrease 
in cholesterol absorption (Miettinen et al., 2000a). Thus, it can be speculated that 
elevations in cholesterol synthesis in the overweight may reciprocally down regulate 
cholesterol absorption. 
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1.11 Therapeutic factors affecting cholesterol absorption and synthesis 
In addition to the physiological mediators of cholesterol metabolism mentioned above, 
certain therapeutic factors have also been shown to modulate cholesterol homeostasis. 
These factors inc1ude plant sterol and stanol supplementation, ezetimibe treatment, 
statin therapy, and weight loss. Table 1-3 summarizes the effect of the se various 
therapeutic interventions on cholesterol absorption and synthesis. 
Plant sterol and stanol supplementation 
The chemical structures of plant sterols and stanols are similar to that of cholesterol 
(Katan et al., 2003; Mel'nikov et al., 2004; Vanstone et al., 2002a). This similarity 
results in the displacement of micellular cholesterol at the level of the small intestine 
(Mel'nikov et al., 2004; Vanstone et al., 2002a). Since brush border cells do not 
readily take up plant sterols and stanols, attenuation in cholesterol absorption occurs 
(Mel'nikov et al., 2004; Vanstone et al., 2002a). Even though ingestion of plant 
sterols and stanols effectively lowers cholesterol absorption, studies indicate a 
compensatory rise in cholesterol synthesis. The effect of sitostanol ester 
supplementation (3 gld) on cholesterol metabolism was examined in women with 
angiographically documented coronary artery disease (Gylling et al., 1997). After 7 
weeks of treatment, cholesterol absorption was reduced by 45%, while cholesterol 
synthesis reciprocally increased by 39%. A similar reciprocal relationship between 
cholesterol absorption and synthesis was identified by Jones et al. (2000a). This study 
(Jones et al., 2000a) tested the effect of 1.84 gld of plant sterol or stanol margarine on 
cholesterol metabolism in hypercholesterolemic patients. Cholesterol absorption and 
synthesis were measured following each intervention period by employing the plasma 
isotope ratio technique. Following sterol and stanol interventions, intestinal 
absorption of cholesterol decreased while synthesis increased. Comparable results 
were noted by Vanstone et al. (2002a). Results of this trial (Vanstone et al., 2002a) 
revealed that absorption diminished while the fractional rate of synthesis rose 
accordingly in response to 4 weeks of either plant sterol or stanol supplementation 
(1.84 gld). Increased synthe sis was also found in a study by Jakulj et al. (2005) after 
participants underwent treatment of 2 gld of plant sterols. Collectively, the se studies 
indicate a reciprocal response of cholesterol synthesis to changes in cholesterol 
absorption. 
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The mechanism by which a compensa tory elevation in cholesterol synthesis occurs 
upon abatement of absorption may be explained through closer examination of the 
pathway of plasma cholesterol production. In this pathway, the rate-limiting enzyme, 
HMG CoA reductase, is regulated by intracellular cholesterol through negative 
feedback. More specifically, intracellular cholesterol regulates HMG CoA reductase 
concentrations through its ability to influence transcription, mRNA translation, and 
degradation of the enzyme (Liscum, 2002). Suppression in cholesterol absorption by 
plant sterols results in lower circulating cholesterol concentrations. As a result, 
negative feedback of cholesterol on HMG CoA reductase is inhibited, leading to 
increases in cholesterol synthesis. The reciprocal effect of decreasing cholesterol 
absorption on cholesterol synthesis is therefore, biologically plausible. 
Ezetimibe treatment 
Ezetimibe, also known as SCH 58235, is the first of a series of new pharmaceutical 
agents developed to reduce cholesterol absorption (Jeu et al., 2003). The inhibition of 
cholesterol absorption by ezetimibe is thought to occur through its interference with 
the function of the NPC1L1 transporter (Altmann et al., 2004; Davies et al., 2005). 
Ten mg/d of ezetimibe may lower total cholesterol up to 15% and LDL- cholesterol up 
to 20% (Jeu et al., 2003). Sud hop et al. (2002) recently examined the effect of 
ezetimibe on cholesterol absorption and synthesis in humans. The study was a 
randomized, double-blind, placebo-controlled crossover trial in individuals with mild 
to moderate hypercholesterolemia. In comparing ezetimibe with placebo, researchers 
found a 54% decrease in cholesterol absorption. Not surprisingly, the decline in 
absorption was accompanied by a corresponding rise in cholesterol synthesis. Thus, 
as with plant sterols, inhibiting cholesterol absorption through ezetimibe results in 
compensatory increases in cholesterol synthesis. 
Statin therapy 
Statins lower circulating levels of cholesterol by inhibiting the action of HMG CoA 
reductase (Smith et al., 2000). The reduction of HMG CoA reductase at the 
hepatocytes leads to increased expression of LDL receptors, which bind circulating 
LDL in turn effecting plasma LDL levels (Lennernas et al., 1997; Rayet al., 2004). 
As a result of this inhibition of hepatic cholesterol synthe sis, statin therapy has been 
shown to reduce cholesterol concentrations by 20-30% (Miettinen et al., 2003d). 
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Since statin therapy aims to lower cholesterol synthesis, the effect of these 
pharmaceutical agents on overall cholesterol metabolism has been investigated. Smith 
et al. (2000) conducted a study where 31 gallstone patients participated in a 
randomized, parallel-arm, placebo-controlled trial examining the effect of statin 
therapy on cholesterol kinetic parameters. Seventeen of these patients received 20 
mg/d of simvastatin and the other 14 served as controls. Cholesterol precursor-to-
cholesterol ratios were used as indicators of hepatic cholesterol synthesis. Mter 3 
weeks of treatment, the plasma lathosterol-to-cholesterol ratio decreased, suggesting a 
decrease in cholesterol synthesis. Despite these reductions, no changes in cholesterol 
absorption occurred. More recently, the absorption markers, campesterol, sitosterol 
and cholestanol, were used to determine the effects of statin therapy in subjects with 
high initial cholesterol absorption versus those with low absorption (Gylling et al., 
2002a). After one year of statin treatment, no differences in circulating total 
cholesterollevels were observed between the two groups. Conversely, a greater 
suppression in synthesis in those with low baseline cholesterol absorption levels was 
noted following treatment. Furthermore, cholesterol absorption was shown to increase 
more in those who had greater declines in synthesis. Thus, although the study by 
Smith et al. (2000) did not observe an association, this study (Gylling et al., 2002a) 
indicates that cholesterol absorption responds reciprocally to alterations in cholesterol 
synthesis. 
The long-term effect of simvastatin treatment on cholesterol metabolism was studied 
in a subset of the Scandinavian Simvastatin Survival Study (4S) Group (Miettinen et 
al., 2000b). Eight hundred and sixt Y seven patients were first divided into fqur 
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quartiles based on cholestanol-to-cholesterol ratios, and were then randomized to 
receive either placebo or simvastatin (20 to 40 mg/d) for five years. The cholestanol-
to-cholesterol ratio served as an indicator of baseline cholesterol absorption. Results 
revealed that lower baseline cholesterol absorption was associated with higher 
baseline synthesis precursor concentrations. After five years, the magnitude by which 
simvastatin decreased cholesterol synthesis was positive1y related with initiallevels. 
In turn, cholesterol absorption parameters rose accordingly. Another study observed 
that 6 months of atorvastatin therapy in men with type 2 diabetes led to decreases in 
serum markers of cholesterol synthesis and an increase in markers of cholesterol 
absorption (Miettinen et al., 2003b). A trial which also studied the 4S group found a 
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similar relationship between synthesis and absorption in a double-blinded trial 
comparing supplementation of atorvastatin and simvastatin (Miettinen et al., 2003d). 
After one year of treatment, those who were taking atorvastatin displayed significantly 
lower cholesterol synthesis rates than those who were taking simvastatin. As a result 
of this decrease in synthesis, a reciprocal increase in cholesterol absorption was 
observed as was seen in other studies. Interestingly, cholesterol absorption was shown 
to be higher in those taking atorvastatin compared to those taking simvastatin. This 
study therefore supports the hypothesis that cholesterol absorption responds 
reciprocally to changes in cholesterol synthesis. It should be noted, however, that the 
compensatory elevation in cholesterol absorption was not equivalent to the decrease in 
cholesterol synthesis caused by the drugs. Thus, a beneficial effect on circulating 
cholesterollevels was still observed. 
Weight 1088 
The assertion that weight loss decreases cholesterol synthesis is supported by the work 
of Di Buono et al. (1999b) who showed that a weight loss of 3 to 8 kg by diet in six 
overweight and obese men, resulted in a dec1ine in whole body cholesterol synthesis. 
The reciprocal effect of weight loss on cholesterol absorption, however, has yet to be 
c1arified. Though the action of insulin and glucose on cholesterol metabolism may 
confound the results (Pihlajamaki et al. 2004), weight loss of approximately 15 kg in 
10 overweight people with type 2 diabetes decrease TC by 21 % (Simonen et al., 
2002b). The decrease in cholesterol was accompanied by a suppression in cholesterol 
synthesis and an elevation cholesterol absorption (Simonen et al., 2002b). Although a 
cause and effect relationship has yet to be established, it can be hypothesized that a 
synergy exists whereby changes in cholesterol synthesis result in an opposite response 
of cholesterol absorption to main tain cholesterol homeostasis. Further studies that 
examine the effects of weight loss on cholesterol metabolism in normoglycemic 
individuals are needed to c1arify whether this relationship does indeed exist. 
Additionally, the question still remains as to how a decrease in hepatic synthesis 
signaIs an upregulation in intestinal cholesterol absorption. Future investigation 
should aim to establish a c1ear mechanistic cause and effect relationship between 
synthesis at the liver, and absorption at the intestine. 
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1.12 Summary and conclusion 
In SUffi, cholesterol absorption and synthesis are affected by an array of physiological 
and therapeutic factors. The purpose of this paper was to identify the primary vector 
affected by each of these factors, and to determine whether a reciprocal effect in the 
other vector occurs in response to this initial change. Studies examining the effect of 
physiological factors on cholesterol metabolism suggest that a reciprocal relationship 
does indeed exist (Table 1-2). More specifically, in trials examining human genetic 
polymorphisms, a decrease in cholesterol absorption was consistently accompanied by 
an increase in synthesis. Such a relationship was shown in carriers of the E2 isoform 
of apoE, and also in those who carry a mutation on exon 1 of the ABCG8 19H alle1e. 
In the case of circadian rhythm, though this factor likely affects cholesterol synthesis, 
its effect on absorption has yet to be established. With regards to body weight, 
evidence suggests that the obese state results in an increase in cholesterol synthesis, 
which is accompanied by a reciprocal decrease in absorption. On the other hand, a 
loss of body weight down regulates cholesterol synthesis, while having little or no 
effect on absorption. Similarly, the majority of studies examining the effect of 
therapeutic interventions on cholesterol metabolism also support a reciprocal 
relationship between the two vectors (Table 1-3). Plant sterols and stanols inhibit 
cholesterol absorption, which often results in a compensatory increase in synthesis. 
Ezetimbe also decreases intestinal absorption, while reciprocally increasing synthesis. 
Conversely, statin therapy down regulates synthesis, which is frequently accompanied 
by an increase in cholesterol absorption. In view of these findings, it can be 
conc1uded that a change in one vector appears to, fairly consistently, result in a 
reciprocal and opposing change in the other. 
Since the majority of these studies support a reciprocal relationship between these two 
vectors, an important question that arises is the magnitude of this effect. Such a 
question is imperative as the reciprocal response of the second vector may completely 
account for the initial change in the first. If such an effect occurred in response to 
therapy, the effect of the intervention would be obsolete. The magnitude of the 
reciprocal response was only established in trials examining the effect of plant sterols 
and statins on cholesterol metabolism. In the case of plant sterols, the treatment-
induced decrease in absorption was consistently more pronounced than that of the 
reciprocal rise in synthe sis. As for statins, the drug-induced decrease in synthesis was 
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generally larger than of the complementary increase in absorption. In this way, the 
reciprocal change in the second vector did not fully compensate for the change in the 
first, thus allowing for a reduction circulating cholesterollevels to occur. Establishing 
the magnitude of response for each factor is not possible due to the techniques 
employed in certain studies. The magnitude of the reciprocal effect can only be 
established when certain direct methods are used, such as: sterol balance approach, 
plasma isotope ratio technique, and the deuterium incorporation method. Since these 
direct methods were not always implemented, the magnitude of the reciprocal effect 
could not be established for certain factors. 
In conclusion, findings from the current review suggest that a change in one vector is 
generally accompanied by a reciprocal and opposing change in the second. This 
relationship however, is not fully compensatory, allowing for the net reduction in 
body pools of cholesterol by therapeutic treatments. Physiological factors that affect 
cholesterol homeostasis may be implemented as future targets in the development of 
effective cholesterollowering agents. Furthermore, the presence of such a 
relationship suggests that combination therapies which simultaneously affect both 
vectors would be more advantageous than therapies that effect one. 
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Table 1-1 Summary of trials ,examining the effects of weight loss and changes in 
body composition through diet and exercise on blood lipid levels in overweight 
women. 
Author Subjects Methods Type of Weight & Changes 
Diet/Exercise Body in Lipids 
Composition 
Changes 
Stefanick 180 overweight, 1 year NCEP Step II + -3 kg and +TC 
et al. postmenopausal -3.5 kg, no ~ LDL-C 
(1998) women 4 Groups 3 x 60 change in in Diet & 
Diet, min/wk, waist:hip Exercise 
-t LDL-C, Exercise, aerobic in Diet and 
-t HDL-C Diet & Diet& 
Age: 45-64 yrs Exercise, Exercise 
Control 
Lofgren 70 women, lOweeks + energy + 3.6 kg +TC 
et al. premenopausal intake 15%/d ~ 2.4 kg fat ~ LDL-C 
(2005b) DEXA mass ~TG 
Age: 20-45 yrs Diet & -t increase ~ 0.5 kg fat 
BMI: 25-37 kg!m2 Exercise 4500 steps/d free mass 
~ 1.3 kg 
trunk fat 
~ 0.3 kg 
trunk lean 
Nieman 91 women 12 weeks 1,200 -1,300 + -8 kg, + TC, 
et al. slightly -t TC, Underwate kcal/d, NCEP ~ BMIand ~TGinD 
(2002) -t LDL-C r weighing Step 1 ~ body fat and 
Age: 45.6 ± 1.1 yr percent DE vs. 
BMI: 33.1 ± 0.6 4 Groups 5 x 45 in D and DE controls 
kg!m2 Diet (D), min/wk, vs. control 
Exercise aerobic ~ LDL-C 
30 control (DE), in DE vs. 
normal C Diet& controls 
Age: 43.2 ± 2.3 yr Exercise 
BMI: 21.4 + 0.34 (DE), 
kg!m2 Control 
Janssen et 38 premenopausal 16 weeks + 1000 kcal/d + -10 kg to + TC aIl 
al. women MRI 11 kg in aU ~ LDL-C 
(2002) Aerobic: in DA and 
normolipidemic 3 Groups 5 x 60 min/wk DR 
Age: - 37 yrs Diet alone ~ total, ab, ~ HDL-C 
BMI: - 33 kg/m2 (DO), Resistance: subcutaneou in DR 
WHR: -0.8 Diet& 3 x seven ex, s, visceral 
Aerobic one set 8-12 and no relation 
(DA), Diet rep intermuscula to type of 
& r fat in aU fat loss 
Resistance and lipid 
(DR) levels 
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Table 1-2. Physiological factors that play a role in modulating cholesterol absorption 
and synthesis. 
Physiological factors 
Genetic effects 
Human model 
Apolipoprotein E 
Isoform E2 
Isoform E4 
ABCG8 (alle1e) 
19H (exon 1 
mutation) 
19H (exon 2 
mutation) 
Genetic effects 
Knockout mou se 
model 
NPC1L1 
SREBP-1 
ACAT-2 
Farnesoid x-receptor 
Mucin gene 1 
Circadian rhythm 
effects 
Human model 
06:00 and 22:00 hr 
14:00 - 18:00 hr 
Body weight effects 
Obese subjects (BMI 
>30) 
Cholesterol 
absorption 
t 
i 
t 
i 
t 
? 
t 
i 
t 
i 
Cholesterol 
synthesis 
i 
t Bile acid 
synthe sis 
i 
t 
? 
i 
-mRNAHMG 
CoA reductase 
w/high chol diet 
? 
? 
? 
? 
i 
Reference 
(Gylling et al., 1995) 
(Kesaniemi et al., 
1987a; Miettinen et 
al., 1992) 
(Berge et al., 2002; 
Gylling et al., 2004a) 
(Sehayek et al., 2004) 
(Altmann et al., 2002) 
(Shimano et al., 1997) 
(Buhman et al., 2000) 
(Lambert et al., 2003) 
(Wang et al., 2004a) 
(Cella et al., 1995; 
Jones et al., 1990) 
(Jones et al., 1990) 
(Di Buono et al., 
1999b; Miettinen et 
al., 2000a; Stahlberg et 
al.,1997) 
SREBP-1: Sterol regulatory element binding protein-1, ACAT-2: Acyl 
CoA:cholesterol acyltransferase 2, NPC1L1: Niemann-Pick Cl Like 1 protein, BMI: 
body mass index. 
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Table 1-3. Therapeutic factors that play a role in modulating cholesterol absorption 
and synthesis. 
Therapeutic factors 
Plant sterol/stanols 
Plant sterol 
Plant stanol 
Ezetimibe therapy 
Short term 
10 mg/d for 2 weeks 
Statin therapy 
Short term 
20 mg/d for 3 weeks 
Long term 
20-40 mg/d for 5 years 
Weight loss 
3-8 kg weight loss 
Cholesterol 
absorption 
i 
? 
Cholesterol 
synthesis 
i 
i 
i 
Reference 
(Jones et al., 2000a; 
Vanstone et al., 
2002a) 
(Gylling et al., 1997; 
Jones et al., 2000a; 
Vanstone et al., 
2002a) 
(Sud hop et al., 2002) 
(Smith et al., 2000) 
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2.1 Abstract 
Objective: To examine the efficacy of a self-directed diet and physical activity 
program as a prospective method for moderate weight loss in women. 
Design: Twenty-four week weight intervention study. 
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Subjects/setting: Thirty-five overweight and obese hyperlipidemic WOmen completed 
a 24-week weight loss study. The WOmen were between the ages of 35-60 years with 
body mass indices between 28-39 kg/m2• 
Intervention: The weight loss intervention consisted of a 20% decrease in energy 
intake through diet and a 10% increase in energy expenditure through physical 
activity. The diet was based on an exchange system and consisted of 50-60% 
carbohydrates, 20% protein, and 20-30% fat. A personal trainer prescribed physical 
activity regimens. A star system and monthly group session were applied to main tain 
subject motivation throughout the weight loss period. 
Results: Participants lost an average of 11.7±2.5 kg (P<O.OOl). The pattern of weight 
loss was linear (P<O.OOI) throughout the study period. Average weight loss per week 
was 0.59 ± 0.55 kg. There was no significant re1ationship between age and weight 
loss (r = -0.180; P = 0.302), and initial weight and weight loss (r = -0.115; P = 0.509). 
Conclusions and Applications: A pro gram combining both structured self-selected 
diet and independent pre-planned physical activity with a successful motivational 
strategy resulted in weight loss comparable to that observed in more controlled 
interventions. The lower cost, ease of use, and outcome success makes this approach 
a potential option for the clinical setting. 
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2.2 Background 
With about 60% of Canadians and 2 out of 3 Americans classified as overweight or 
obese, it is no surprise that billions of dollars are spent on weight loss products and 
services (Cleland R, 1997; Hedley et al., 2004; Tjepkema, 2004). Diet books, pills, 
programs, and even surgeries are among the products used to offer consumers ways to 
lose weight. However, few weight loss methods have demonstrated consistent and 
sustained results. 
The life expectancy of an obese individu al has been found to be about seven years 
shorter than their normal weight counterparts (Peeters et al., 2003). Obese individuals 
are at greater risk for numerous metabolic complications including sleep apnea, 
infertility, dyslipidemia, hypertension, type 2 diabetes mellitus (DM), infertility in 
women and cardiovascular disease (CVD) (Must et al., 1999). Research examining 
the extent to which weight loss ameliorates these comorbidities and the mechanism by 
which weight loss may improve these conditions remains limited. One of the 
challenges in determining the effects of weight loss on various mechanisms is the 
achievement of desired weight loss by study participants. Despite the various 
treatments that exist, the number one recommended weight loss strategy remains 
changing energy balance by modifying energy intake and energy expenditure 
(Donnelly et al., 2005). 
Many different combinations of diet and physical activity have been used to achieve 
weight loss in clinical trials. The success of these strategies in losing weight depends 
on the extent to which diet and exercise are controlled. Participants in studies that 
have supervised physical activity programs have been reported to lose more weight 
than those with less structured self monitored programs (Andersen et al. 1999; 
Andersen et al. 2002; Evans et al. 1999; Janssen et al. 2002; Jeffery et al. 2003; Miller 
et al. 2002; Nicklas et al. 2003; Ross et al. 1995; Volek et al. 2002; Wing et al. 1998). 
Additionally, when the diet component of these programs is closely monitored by 
weekly meetings, daily diet records or through the provision of study meals, achieved 
weight 10ss is also greater (Andersen et al. 1999; Andersen et al. 2002; Evans et al. 
1999; Janssen et al. 2002; Jeffery et al. 2003; Miller et al. 2002; Nicklas et al. 2003; 
Ross et al. 1995; Volek et al. 2002; Wing et al. 1998). These results suggest that 
motivation is a big factor determining the success. Without tight control, and without 
motivation tools, weight loss success is less likely. Since supervising diet and 
exercise is costly, time consuming, and labour intensive few programs can afford to 
offer such controls. 
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In the clinical setting, the monitoring of diet and physical activity is not as rigorous as 
in a structured and supervised research setting. There is more freedom of choice in 
the diet and physical activity patients will conduct to achieve weight loss success. 
Thus, it is important to establish a weight loss protocol in which moderate weight loss 
can be obtained by diet and exercise in the absence of rigorous treatment control. It 
has been suggested in the literature that successful motivational strategies for weight 
loss should incorpora te behavioural goals, emphasize personal contact, personalize 
intervention, provide feedback, and multiple contacts over a substantial period of time 
(Anderson, 2000). As a result, we developed motivational strategies that were 
incorporated in a weight loss pro gram that combined a self-selected diet and 
independently conducted exercise. The objective of this study is to examine the effect 
of a lower cost method on altering energy balance in a group of overweight and obese 
women under a typical clinical setting. 
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2.3 Methods 
Experimental design 
The trial was 24 weeks in duration and consisted of a two week pre-loss stabilization 
period, a 20 week weight loss period, and a two week post-loss stabilization period. 
Subjects served as their own controls in a longitudinal before and after study design. 
Participants were asked to maintain a stable weight by keeping usual food and 
exercise habits during the two week pre- and post-loss stabilization periods. During 
the two week stabilization periods subjects were weighed at days 1, 5, 8, 12, and 15 to 
ensure stable weight. 
Subjects 
Forty-two overweight and obese hyperlipidemic women were recruited by newspaper 
advertisements and word of mouth from the Montreal area to participate in a 24-week 
weight loss trial. The number of women included in the trial was based on a power 
calculation that accounted for parameters that were measured for other separate 
analyses specifically, cholesterol absorption, synthesis and turnover based on an 
anticipated difference of 20% using a within group coefficient of variation (CV) of 
15-25% at an a level of 0.05 and a I3level of 0.80. Inclusion criteria required that the 
women were 35 and 60 years of age with body mass indices (BMI) of 28-39 kg/m2• 
Women with BMI less than 28 kg/m2 were not included because of the extent of 
weight loss that was targeted, which was 0.75 kg/wk or 15 kg. Since other analyses 
were being conducted, subjects were also screened for fasting plasma low density 
lipoprotein cholesterol (LDL-C) concentrations of 3.4-6.7 mmol/L and triacylglycerol 
(TAG) concentrations> 1.5 mmol/L. Use of oral anti-hypertensive agents and thyroid 
hormones were permitted, provided they were stable and continued throughout the 
duration of the study. The women were included regardless of menopausal status, 
provided they had been on a consistent dose of hormone replacement therapy at least 
three months prior to commencement and remained on the same dose throughout the 
study if it was being taken. Fasting blood samples were collected for serum 
biochemistry and haematology and subjects were also required to undergo a complete 
physical examination by a certified medical doctor before acceptance into the study. 
Subjects were excluded if they had taken oral hyperlipidemic therapy less than six 
months prior to commencement or if they had a history of chronic illness, including 
hepatic, renal, gastrointestinal, and cardiac dysfunction. Additionally, those who 
reported previous history of eating disorders, chronic laxative use, or exercise in 
excess of 4000 kcal/week were excluded. 
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Before commencing, a copy of the study protocol was given to the subjects and the 
primary investigator or the study co-ordinators answered any questions before signing 
the consent form. The study protocol was carried out in compliance with HIPPA 
guidelines. Ethical approval for the experimental protocol was obtained from the 
Faculty of Medicine Ethics Review Board at McGill University, Montreal, QC, 
Canada and the Human Investigation Review Committee of Tufts University, Boston, 
MA, USA. 
Weight loss protocol 
A 20 week weight loss period was undertaken after the two week pre-Ioss stabilization 
period. Resting energy expenditure (REE) was estimated using the Harris-Benedict 
equation (HBE) adjusted for habituaI activity levels (Harris, 1919). Since the HBE 
may overestimate REE (Frankenfield et al., 2005), we compared the values we 
obtained to what would have been indicated using 25 kcal/kg. The weight loss 
protocol required subjects ta decrease energy intake 20% by diet and increase energy 
expenditure 10% by exercise, resulting in a 30% total energy deficit. 
Diet 
In general, individually prescribed energy intake was between 1400-1600 kcal/d. 
Participants were instructed to follow a diet composed of 50-60% of energy from 
carbohydrates, 20% of energy from protein, and 20-30% of energy from fat. 
Principles of the diet were taught to each volunteer on an individual basis using an 
established protocol by a dietitian or nutritionist, de pen ding on the spoken language 
(ie. French or English) of the participant. To help subjects adhere ta dietary 
principles, we used the exchange lists for meal planning, consisting in the following 
groups: (1) starchlbread, (2) fruits and vegetables, (3) meat and alternates, (4) milk 
foods, (5) fat, (6) free foods and (7) foods for occasional use (The American Dietetic 
Association and American Diabetes Association, 1995; Canadian Diabetes 
Association, 1999; Health Canada, 1992). More specifically, subjects were given 
exchange units for each food group and taught the serving sizes of common foods 
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within each group. To further help apply the dietary principles, participants received 
pamphlets containing basic nutrition information, as weIl as sample recipes and 
ex amples of menus. A group dinner was organised to show the subjects examples of 
healthy me aIs that met the criteria of the exchange system. Monthly individu al 
consultations, usually lasting 15-30 minutes, with the dietitian or nutritionist aided the 
participants in ensuring dietary adherence throughout the weight loss period. A 
grocery store tour where subjects learned to read labels was also undertaken. 
Exercise 
Semi-private meetings of 2-3 participants were conducted with a personal trainer at 
the beginning and midway through the weight loss period. Sessions covered the 
teaching of general concepts to the group, individu al coaching for practicing the 
exercises, and adjustment of the routine according to individual needs. The trainer 
worked with subject exercise preferences in designing exercise routines that would 
help individuals achieve a 10% increase in energy expenditure. Though both aerobic 
and strength training exercises were inc1uded in the routines, emphasis was on aerobic 
activity to increase energy expenditure. Proper techniques were also demonstrated to 
ensure exercises were carried out safely. Participants were given the option to 
perform the exercises independently or using the exercise equipment at the CNRU at 
McGill University. 
Compliance and motivation 
Subjects were weighed once a week throughout the weight loss period. A star system 
was created to help the subjects keep track of their progress and increase motivation. 
A chart was put up with each subject's number to conceal their identity and a weekly 
weight loss goal was assigned to each participant, calculated based on the 30% energy 
deficit. When the weekly weight loss goal was met, the individu al was given a star 
sticker to put up by her number, if she desired. Each star stood for the weight loss 
goal for one week. Thus, if half of the weight loss goal was achieved, the subject was 
awarded half a star. Accordingly, if the participant lost two weeks worth of weight, 
then two stars were allocated. Participants were also provided with a graph on which 
they were able to plot their weekly progress. To further increase motivation and 
adherence to the weight loss protocol, monthly 60 minute group sessions were held 
where subjects were provided with additional guidance about diet and physical 
activity from guest speakers. Small rewards, such as movie passes and gift 
certificates, were also distributed at the meetings to individuals who achieved their 
monthly weight loss goal. 
Statistics 
AlI data are expressed as me ans ± SDs. Changes in body weight between the initial 
and final stabilization periods were assessed using a Student's paired t-tests. An 
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inde pendent sample t-test was used to determine whether the initial weight of dropout 
subjects were different than the initial weight of subjects who completed the study. 
Repeated measures ANOV A was used to determine whether the decrease in weight 
over the 20 week weight loss period was linear. Pearson's correlations were used to 
examine potential relationships between age or initial weight and weight loss. AlI 
values were defined to be statistically significant at P < 0.05. Data were analysed 
using SPSS for Windows (version 12.0.0; SPSS Inc., Chicago, IL). 
2.4 Results 
Of the 42 subjects recruited to participate, 35 completed the study. Two participants 
withdrew from the study before the weight loss period due to inability to undergo 
investigative procedures and five participants dropped out because of difficulty in 
adhering to the scheduled study visits. Therefore, of the subjects that began the 
weight loss pro gram, 87% completed the study. Of the participants who completed 
the study, two decided to come in to use the exercise facilities at the Mary Emily 
Clinical Nutrition Research Unit (CNRU) at McGill University, while others decided 
to conduct their exercises independently. 
AlI results shown are for subjects that completed the trial. Initial subject 
characteristics are shown in Table 2-1. The average age of the subjects was 49.4 ± 
6.7 years, mean initial weight at the end of the pre-loss stabilization period was 81.4 ± 
9.5 kg and average BMI was 31.4 ± 2.8 kg/m2• There was no difference between the 
initial weight of dropout subjects and the initial weight of subjects who completed the 
trial (P = 0.641). At the end of the weight loss period, average weight of the subjects 
was 69.7 ± 9.1 kg. At the end of the post-loss stabilization period average weight was 
69.9 ± 9.3 kg. Overall, participants lost an average of 11.7 ± 2.5 kg (14.5 ± 3.1 % of 
original body weight) (P < 0.001) between the last day of the pre-loss stabilization 
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period and the first day of the post loss stabilization period (see Figure 2-1). Figure 
2-2 shows the average weight for each week throughout the weight 1088 period. 
Decrease in weight throughout the 20 week weight 10s8 period was linear (P < 0.001). 
Average weight loss per week was 0.59 ± 0.55 kg. There was no significant 
relationship between age and weight loss (r = -0.180; P = 0.302), and initial weight 
and weight loss (r = -0.115; P = 0.509). 
2.5 Discussion 
In this study, participants were able to steadily lose 12 kg over a 20 week period. To 
achieve weight loss we incorporated motivational strategies with a healthy, weIl 
balanced diet, and independently conducted exercise routine. Weight 10ss achieved in 
our pro gram was not related to subject age or initial weight, indicating a potential for 
this method to be used successfully in a wide range of overweight and obese 
individuals. The weight loss protocol is appropriate for application to a clinical 
setting since, participants are able to choose the types of food to be consumed and the 
kinds of exercises they want to do. 
Other studies that used self selected diet and inde pendent exercise often incorporated 
sessions led by behaviour therapists or psychologists in order to increase weight loss 
(Andersen et al., 2002; Andersen et al., 1999; Jeffery et al., 2003; Wing et al., 1998). 
The use of this method has been reported to result in weight losses of between 8-10 kg 
over a 24-week period (Wing et al., 1998). Other studies that incorporated 
behavioural therapy as an adjunct to diet and exercise reported somewhat greater rates 
of weight loss of 6 kg over 12 weeks and 8 kg over 16 weeks (Andersen et al., 2002; 
Andersen et al., 1999). We achieved at least comparable or greater rates of weight 
loss using an approach that was less resource dependent since it required minimal 
contact with a personal trainer, and limited contact with the dietitian/nutritionist. 
Since the energy deficits and physical activity levels were comparable among the 
current and prior studies, we suggest the motivational techniques, specifically frequent 
contact with study investigators, monthly group meeting, and the award point system, 
we employed contributed to the success of our subjects (Andersen et al., 2002; 
Andersen et al., 1999; Wing et al., 1998). In contrast, a meta-analysis of weight loss 
studies that examined the effect of structured diet and aerobic exercise programs on 
weight loss reported an average weight loss of 11 kg over an average study period of 
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13 weeks (Miller et al., 1997). This was greater than that attained in the present study. 
However, the meta-analysis did not control for the types of diet and exercise protocols 
that were used (Miller et al., 1997). As a result, it is difficult to make further 
comparisons in the weight loss protocol. 
Other more recent studies which used structured diet and exercise interventions 
without behavioural therapy had comparable weight loss to that found in the present 
study (Evans et al., 1999; Janssen et al., 2002; Miller et al., 2002; Ross et al., 1995; 
Volek et al., 2002). A shorter experiment by Volek et al. (2002) observed a decrease 
in weight of 4-5 kg in 8 weeks after a moderately decreased energy diet and 
supervised exercise over 4-5 weeks. Another short trial that lasted 9 weeks, provided 
meals to participants and supervised moderate intensity exercise, achieved a weight 
loss of 5.5 kg (Miller et al., 2002). Longer trials, such as that conducted by Ross' 
group (Janssen et al., 2002; Ross et al., 1995), saw decreases in weight of 10-11 kg 
after a 16-week intervention of self-selected diet which provided 1000 kcal/d energy 
deficit and supervised aerobic exercise. 
One of the limitations of the present study is that it was only conducted in women and 
therefore, the success of the protocol on weight 10ss in men is unknown. However, a 
review by Donnelly and Smith (2005) found that men had larger decreases in body 
weight in response to exercise than women. Thus, it may be hypothesized that the use 
of the present weight loss protocol in men would result in increased weight loss. 
Further studies will need to be conducted to de termine whether this would be the case. 
Testing the protocol in larger more diverse populations would provide more 
information on its potential to succeed in other subject groups. The inclusion of a 
control group to which the motivational strategies are not applied would help to better 
assess their effect on weight loss. Another limitation in this study is that participants 
had pre-existing hyperlipidemia. This may have added an additional motivational 
factor, resulting in larger weight loss. However, the majority of overweight and obese 
individuals have been shown to have associated comorbities (Must et al., 1999). 
Therefore, the additionally motivational effect of hyperlipidemia in our subjects may 
not be much different than in other overweight and obese individuals who likely have 
other comorbidities. 
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There are many advantages in using the described protocol. The amount of time and 
manpower required to carry out the intervention is much 1ess than that with a more 
controlled diet and exercise program, whi1e achieving similar decreases in weight. As 
a result, it is cheaper and easier to impIe ment our protocol. Because of this, our 
protocol can feasibly be used in the clinical setting. After an initial period, it is natural 
that the difficulty in 10sing weight increases. As seen in Figure 2-2, weight 10ss 
throughout the 20-week intervention period was proportiona1 across time. Therefore, 
the protocol is effective in reducing weight in a longer run. The weight loss in this 
trial was achieved through moderate calorie reduction and exercise which the 
participants selected and enjoyed. As a result, patients are more like1y to adhere more 
close1y to the protocol. Lastly, our protoco1 follows dietary and physica1 activity 
principles set out in guidelines defined by many associations including the Heart and 
Stroke Foundation of Canada, Laboratory Center for Disease Control at Health 
Canada, American Heart Association, and the American Dietetic Association (Cleroux 
et al., 1999; Cummings et al., 2002; Krauss et al., 2000). Thus, it can be safely used 
in the clinical settings for weight loss in a diverse group of patients. 
2.6 Conclusions and applications 
We have introduced a protoco1 that combines self-selected diet and independent 
exercise with a successful motivationa1 strategy to produce weight loss comparable to 
that obtained in more controlled interventions. The lower cost, ease of use, and 
outcome success of our protocol make it a good candidate for use in the clinica1 
setting. 
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2.8 Figure legends 
Figure 2-1. Individua1 weights (kg) before and after weight 10ss period. 
Figure 2-2. Average week1y weight during the 20 week weight 10ss period. 
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Table 2-1. Baseline characteristics of the subjects. 
Variables 
Age (y) 
Weight (kg) 
BMI (kg/m2) 
Participants (n = 35) 
49.4 + 6.7 
81.4 + 9.5 
31.4 + 2.8 
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Figure 2-1. Individual weights (kg) before and after weight 10ss period. 
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Figure 2-2. Average week1y weight during the 20 week weight 10ss period. 
48 
BRIDGE 1. 
Various hormones that play a role energy metabolism may have influenced the weight 
loss that was achieved with the self-directed protocol from the previous study. More 
specificaIly, insulin, adiponectin, leptin, and ghrelin have been shown to be important 
hormones in maintaining energy homeostasis (Arita et al., 1999; Berg et al., 2002; 
Halaas et al., 1995; James et al., 1994; Lee et al., 1996; Maffei et al., 1995; Spranger 
et al., 2003; Weyer et al., 2001; Wu et al., 2004). Weight loss has been shown to 
result in individu al changes in these hormones, as weIl as reductions in TC, LDL-C, 
and TAG, and increases in HDL-C (Baratta et al., 2004; Dattilo et al., 1992b; Esposito 
et al., 2003; Hansen et al., 2002; Ryan et al., 2003; Xydakis et al., 2004). However, 
no study has examined the assciations between changes in lipids and hormones as a 
result of weight loss. AdditionaIly, we also set out to investigate whether baseline 
metabolic characteristics affected the ability of subjects to loose weight. 
AIl measures were taken at the end of the two-week stabilization periods, which 
preceded and succeeded the 20-week weight loss period. During these stabilization 
periods, subjects returned to their usual food and exercise habits. The aim of taking 
measurements at the end of these stabilization periods was to minimize the effect of 
changes in diet and exercise so that weight loss itself could be measured. Use of 
female participants in this study added another unique aspect, since most of the 
existing studies that examine the effects of weight loss on hormones and lipids are 
conducted in males. 
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3.1 Abstract: 
Objective: The objectives of this study were to de termine 1) whether the extent of 
weight loss is predictive of the degree of changes in hormone and lipid 1evels; 2) the 
interactions between energy regulating hormones after weight loss through an energy 
deficit/exercise protocol diet and exercise; 3) whether initial metabolic parameters are 
indicative of the extent of weight loss. 
Methods: Thirty-five hyperlipidemic females (BMI 28-39 kg/m2) 35-60 years old 
participated in a six month weight loss triaL Weight loss resulted from a diet and 
exercise pro gram that when combined produced a 30% energy deficit. Fasting plasma 
taken during 2 wk stabilization periods at the beginning and end of the study was 
analysed for lipids, hormone and glucose levels. 
Results: Average weight loss was 11.7±2.5 kg (p < 0.0001). TC, LDL-C, and 
triacylglycerols decreased 9.3±9.5% (p < 0.0001), 7.4±12.2% (p < 0.001), and 
26.8±19.6% (p < 0.05), respectively, while HDL-C increased (p < 0.05) by 
8.2±16.3%. Leptin levels declined (p < 0.001) 48.9±16.0% and ghrelin levels rose (p 
< 0.001) 21.2±26.7%. While overallieveis of adiponectin did not differ, individual 
values changed such that weight loss predicted increases in adiponectin levels. 
Though initial weight did not predict weight loss, baseline lipid and insulin levels 
positively predicted weight loss. 
Conclusion: Initial metabolic parameters may be predictors of weight loss. 
BeneficiaI effects of weight loss as achieved through diet and exercise on measured 
parameters indicate moderate weight loss reduces key risk factors of cardiovascular 
disease in overweight individuals. 
Keywords: weight loss, women, cholesterol, adipocyte hormones, ghrelin 
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3.2 Introduction 
The most recent revisions of dietary guidelines by the American Heart Association 
emphasize the importance of weight management to decrease CVD risk (Krauss et al., 
2000). Similarly, weight management is emphasized by the American Diabetes 
Association (Franz et al., 2004). Since CVD and diabetes are of the primary 
consequence to obesity and major causes of death and disability in the Western world, 
it is important to understand the role of weight loss on management and prevention of 
these diseases. 
One of the main reasons that overweight individuals are at increased risk of 
developing CVD is due to the dyslipidemia that often accompanies this condition. 
Many trials have been conducted that examine the effects of weight loss on plasma 
lipid concentrations (Dattilo et al., 1992b; Wing et al., 1995). However, few studies 
-Iiave combined moderate energy expenditure and intake reduction in a highly 
controlled manner in females. Additionally, the relationship between extent of change 
in weight versus lipid leve1s has not been fully elucidated. 
Ghrelin, adiponectin, and leptin are three hormones that are likely affected by weight 
loss. Adiponectin and leptin are adipocytokines, while ghrelin is predominantly 
released from stornach. Ghrelin and lep tin affect energy horneostasis through 
opposing effects. Leptin decreases feeding by signalling satiety and stimulating 
energy expenditure, while ghrelin stimulates food intake and energy storage (Maffei et 
al., 1995; Wu et al., 2004). Studies have shown that leptin is often elevated in people 
with higher body fat, as is found in obesity (Maffei et al., 1995; Ostlund et al., 1996). 
In contrast, adiponectin levels have been shown to be reduced in obese subjects (Arita 
et al., 1999). Adiponectin is also attenuated in patients with insulin-resistance and 
type 2 diabetes and thus, may have sorne function in regulation of blood glucose 
horneostasis (Spranger et al., 2003; Weyer et al., 2001). Levels of adiponectin have 
also been shown to be lower in those with CVD (Diez et al., 2003; Pischon et al., 
2004). However, whether changes in adiponectin reduce risk of CVD and type 2 
diabetes is uncertain. Despite the implications of ghrelin, adiponectin, and leptin in 
weight loss, no studies yet exist that examine changes in these hormones combined in 
the context of weight 10ss through diet and exercise. 
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Previous research has shown that initial metabolic status may influence extent of 
weight loss. However, studies examined have only accounted for the effect of initial 
insulin levels and weight (Hansen et al., 2001; McLaughlin et al., 2001). Baseline 
levels of other hormones, specifically leptin, adiponectin, and ghrelin, that regulate 
appetite may affect ability to loose weight. Thus, determining the extent to which 
baseline metabolic characteristics result in successful weight loss may help in 
deciding the most effective course of treatment of overweight individuals. 
The present study uses energy restriction to investigate the potential effects and 
associations between lipid and hormone parameters, which have not previously been 
examined in combination after moderate weight loss. Though the se parameters have 
been studied individually after weight loss in men, few studies examine women. In 
this study, only women were included to investigate the potential of weight loss to 
affect hormone and lipid risk factors of CVD and type 2 diabetes in this population. 
Additionally, the novel incorporation of pre and post periods of stabilization will 
minimize variation and enhance the isolation of the effect of weight loss. In this 
study, we hypothesized that significant weight loss in overweight and obese 
hyperlipidemic women results in favourable changes to blood lipid profiles, glucose, 
insu lin, and adiponectin, while decreasing levels of leptin and increasing levels of 
ghrelin. It is also hypothesized that changes in body weight will be reflected in the 
degree of changes in the measured parameters. Furthermore, we hypothesized that 
baseline weight and initiallevels of blood lipid, c-reactive protein (CRP), insulin, 
glucose, adiponectin, leptin, and ghrelin would be predictive of weight loss. 
3.3 Materials and methods 
Subjects 
Hyperlipidemic, but otherwise healthy, free-living overweight and obese female 
volunteers were recruited. The subjects, aged between 35 and 58 y, had initial body 
mass indices of 28-39 kg!m2• Premenopausal and postmenopausal subjects were 
included, as well as those who were perimenopausal provided they were either not 
taking or on stable hormone replacement therapy (HRT) for at least 6 months prior to 
the commencement of the study. Subjects were screened for circulating LDL-C and 
TAG concentrations. Inclusion criteria included fasting plasma LDL-C concentrations 
of 3.4-6.7 mmollL and TAG concentrations> 1.5 mmollL. Use of oral anti-
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hypertensive agents and thyroid hormones were permitted, provided they were stable 
and continued throughout the duration of the study. Before acceptance, subjects were 
required to provide a medical history and to undergo a complete physical examination. 
Fasting blood samples were collected for serum biochemistry and hematology. 
Subjects were screened for chronic illness, inc1uding hepatic, renal, gastrointestinal, 
and cardiac dysfunction, before admission into the study. Additionally, those who 
were found to have previous history of eating disorders, chronic laxative use, or 
excessive exercise were exc1uded. Those undergoing oral hyperlipidemic therapy less 
than six months prior to commencement of the study were also exc1uded. Before the 
start of the study, subjects received the study protocol and discussed any queries with 
the primary investigator or the study co-ordinators before signing the consent form. 
The experimental protocol was approved by the Faculty of Medicine Ethics Review 
Board at McGill University, Montreal, QC, Canada and the Human Investigation 
Review Committee of Tufts University, Boston, MA, USA. 
Experimental design 
Subjects served as their own controls in a longitudinal before and after study design. 
Overall, the trial consisted of three dietary periods; pre-loss stabilization, weight loss 
and post-loss stabilization periods. 
The first and third dietary periods were identical, with each lasting two weeks in 
duration. During these periods subjects were required to main tain a stable weight, as 
well as, usual food and exercise habits. To ensure weight maintenance during the 
stabilization periods, subjects were weighed at days 1, 5, 8, 12, and 15 during period 1 
and days 155, 159, 162, 166, 169 during period 3. Compliance during the 
stabilization period was defined as average weight during the stabilization periods ± 1 
kg. Data are reported for days 15 and 169. 
Following the initial two week stabilization period, subjects underwent the 20 week 
weight loss period, during which, they were counselled to decrease energy intake by 
20% and increase energy expenditure by 10%. To achieve the 20% decrease in 
energy consumption, each subject was provided with individual dietary instruction at 
the start and for the duration of the weight loss period. Diets were formatted for each 
volunteer using an exchange system that provided 50-60% of energy from 
carbohydrates, 20% of energy from protein and <30% of energy from fat. Subjects 
also received pamphlets containing basic nutrition information, as well as, sample 
recipes and menus to aid them in the application of dietary principles. 
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To achieve a 10% increase in energy expenditure, subjects worked with a personal 
trainer who demonstrated and taught proper exercise techniques, and assigned 
exercise routines. Subjects were given the option to perform exercise independently, 
or within the gym facility at the Mary Emily Clinical Nutrition Research Unit at 
McGill University. 
Compliance to the protocol was monitored by weight loss at weekly weigh-ins. 
Additionally, participants were encouraged through the use of an award point system 
and visual graphs on which they were able to plot weight loss. 
Fasting blood samples were taken at day 1, 8, and 15 during the first stabilization 
period and at day 155, 162, and 169 during the second stabilization period for 
measurement of circulating lipid concentrations. Baseline and endpoint lipid 
measurements, as well as apolipoproteins (apo) Al and BlOO concentrations, were 
analysed at days 15 and 169. Glucose, insulin, adiponectin, and leptin and ghrelin 
were measured at days 14, 15, 168 and 169. Days 14 and 15, and days 168 and 169 
were then averaged to reduce day-to-day variation. 
Plasma analyses 
Fasting plasma was separated from red blood cells (RBC) by centrifugation at 20°C 
for 15 min at 520 x g within 30 minutes of phlebotomy. Samples were then stored at -
20°C until analysis. Plasma TC, HDL-C, and T AG concentrations were analysed in 
duplicate by automated methods through a Hitachi 911 automated analyzer (Roche 
Diagnostics, Indianapolis, IN) using enzymatic or immunoturbidometric reagents 
(McNamara et al., 1987b). LDL-C was determined directly by the dextran/magnesium 
sulfate method in order to separate it from HDL-C (N-geneous LDL C assay, Equal 
Diagnostics) (Rifai et al., 1998; Wang et al., 2001b). Apo Al and B100 were 
measured using an Abbott Spectrum CCX Analyzer (Abbott Laboratories, Dallas, TX) 
using reagents and calibrators from INCSTAR (Sti11water, MN). Immunoprecipitates 
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of antibody-apoprotein complexes were quantified by turbidimetry (Contois et al., 
1996a; Contois et al., 1996b). The assays are standardized through the Lipid 
Standardization Pro gram of the Centers for Disease Control (Atlanta, GA). C-reactive 
protein (CRP) was measured using a Tina-quant CRP (Latex) High Sensitive 
immunoturbidimetric assay (Roche Diagnostics). In brief, anti-CRP antibodies 
coupled to latex microparticles react with CRP to form a complex which is measured 
turbidimetricaHy using a Hitachi 911 automated analyzer (Roche Diagnostics). 
Glucose was analysed by enzymatic method using the glucose (trinder) reagent from 
Sigma Diagnostics (St Louis, MO, USA). Concentrations of insulin, adiponectin, 
leptin, and ghrelin were determined by the RIA method using kits from Linco 
Research Inc. (St. Charles, MO) (Morgan et al., 1962). 
Statistics 
AH data are expressed as me ans ± SDs. The statistical significance of changes in body 
weight, and lipoprotein cholesterol, TAG, apo Al, apo B100, and CRP was 
determined using a Student's paired t-tests on values obtained after the two 
stabilization periods on days 15 and 169. Log transformations were conducted on apo 
Al and apo BlOO before applying Student's paired t-tests. A Wilcoxon signed rank 
test was used to compare changes in CRP. Days 14 and 15 and days 168 and 169 
were first averaged for glucose, insulin, leptin, adiponectin, and ghrelin concentrations 
before a Student's paired t-test was carried out on their averages. Log transformations 
were conducted on leptin and adiponectin before applying Student's paired t-tests. 
Stability of plasma lipid cholesterol concentrations during the stabilization periods 
was verified using repeated measures analysis of variance (ANOV A). Linear 
regression analysis was used to determine the relationship between weight loss and 
changes in lipid, CRP, glucose, and hormone measures. Forward stepwise regression 
and best subset analyses were used to determine the predictive values of baseline 
weight and initial biochemical parameters to weight loss. Pearson correlations were 
used to determine the relationship between lipid parameters, glucose, insulin, leptin, 
adiponectin, and ghrelin. AU values were defined to be statisticaUy significant at p < 
0.05. Data were analysed using SPSS for Windows (version 12.0.0; SPSS Inc., 
Chicago, IL). 
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3.4 Results 
Forty-two subjects were enrolled in the study. Two dropped out at the beginning of 
the study due to inability to fulfill study requirements and five dropped out because 
they had difficulty adhering to the weight loss regime and could not adhere to the 
study visit schedules. Therefore, complete data were collected for 35 participants and 
analysed as per the study protocol. The average age of the subjects who completed 
the study was 49.4 ± 6.7 years. Individual weight loss throughout the study is shown 
in Figure 3-1. Overall, participants lost an average of 11.7 ± 2.5 kg (14.5 ± 3.1 % of 
original body weight) (p < 0.001). 
Changes in biochemical parameters in response to weight loss 
No significant differences in lipoprotein cholesterol were found between days 1, 8, 
and 15, and between days 155, 162, and 169 of the stabilization periods (data not 
shown). Average circulating plasma lipoprotein cholesterol, TAG, apo Al, apo BlOO, 
CRP, glucose, insulin, leptin, adiponectin, and ghrelin levels before and after the study 
period, as well as, me an changes after weight loss are shown in Table 3-1. Both TC 
and LDL-C levels decreased (p < 0.001) 0.62 ± 0.65 mmol/L, and 0.32 ± 0.51 
mmol/L (p = 0.001), respectively. Weight loss also resulted in a reduction (p < 
0.001) of TAG levels by 0.55 ± 0.46 mmol/L and an increase (p = 0.03) in HDL-C 
levels by 0.08 ± 0.21 mmol/L. Additionally, there was a de cline (p = 0.001 and p < 
0.001) in both apo Al and apo BlOO levels of 0.06 ± 0.11 mmol/L and 0.12 ± 0.12 
mmol/L, respectively. Further examination of the LDL-C:apo BlOO ratio indicated a 
rise (p = 0.002) of 0.13 ± 0.23. 
After weight loss, glucose levels were lowered (p = 0.02) by 0.24 ± 0.59 mmol/L and 
insu lin by 5.43 ± 5.00 mUnits/L (p < 0.001). There was a reduction (p < 0.001) in 
leptin of 16.0 ±-7.8 ngIL and ghrelin rose (p <0.001) 204.9 ± 274.9 pg/mL. In 
contrast, adiponectin levels were not significantly altered by weight loss taking the 
group as a who le. 
Ability of weight loss to predict changes in biochemical parameters 
No significant relationship was observed (p = 0.43) between changes in weight and 
changes in total cholesterol (131 = -0.04; r2 = 0.02) nor between changes in weight and 
changes in LDL-C (131 = -0.01; r2 = 0.00, p = 0.88) and changes in weight and changes 
in TAG ([31 = -0.06; r2 = 0.10, P = 0.07). Weight loss was also not predictive (p = 
0.50) of changes in HDL-C ([31 = -0.01; r2 = 0.01). 
57 
Higher weight loss resulted in larger decreases (p < 0.001) in leptin levels ([31 = -1.82; 
r
2 
= 0.35) (Figure 3-2a) and increases (p = 0.009) in adiponectin levels ([31 = 0.62; r2 
= 0.19) (Figure 3-2b). Changes in weight did not predict changes in glucose, insulin, 
or ghrelin levels. 
Ability of initial biochemical parameters to predict weight loss 
Change in weight was best explained by initial apoB (36.2%) and LDL-C levels 
(13.1 %) to a final r = 0.702 in forward stepwise regression. Best subset analyses 
indicated the sarne initial pararneters explained 52 % of the variation in weight loss 
(LDL-C p = 0.004 and apoB p < 0.001). Initial insulin (p = 0.021), TC (p < 0.001), 
TG (p = 0.004), HDL-C (p < 0.001) and LDL-C (p = 0.002) collectively eXplained 
63% of the variation in weight loss. Only the initialleptin level contributed (both in 
forward stepwise and best subset) to final weight, where r2 = 0.208 (i.e. 20.8% 
variation) for p = 0.007. The analyses indicated that baseline weight and initiallevels 
of adiponectin, leptin, and ghrelin were not as strongly associated with the extent of 
weight loss. 
Relationship between lipid parameters, glucose, insu lin, leptin, adiponectin, and 
ghrelin 
Calculation of Pearson correlations indicated sorne relationships between lipid 
pararneters, glucose, insulin, leptin, adiponectin, and ghrelin. Changes in adiponectin 
levels were positively associated with changes in TAG levels (r = 0.41,p = 0.01) and 
apo A1levels (r = 0.38, P = 0.02) (Figure 3-3a,b). Additionally, differences in leptin 
levels were negatively correlated with changes in TC levels (r = -0.39, p = 0.02), apo 
A1levels (r = -0.41,p = 0.01), and apo B100 levels (r = -0.34,p = 0.05) (Figure 3-
3c-e). No significant relationships were found between differences in lipid pararneters 
and changes in glucose, insulin, and ghrelin levels. There were also no significant 
correlations found between adiponectin, leptin, ghrelin, and insulin. 
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3.5 Discussion 
To our knowledge, our study is the only one which attempts to isolate the effect of 
weight loss through pre- and post- stabilization periods. A steady state was 
emphasized with the fact that no significant changes were observed during the 
stabilization periods. Additionally, the exclusion of males in this study is unique 
because few weight loss trials include only females. This study found that weight loss 
in females resulted in significant declines in glucose, insu lin, leptin, increases in 
ghrelin, and no changes in adiponectin. The decline in glucose and insulin seen in this 
study are well established and consistent with findings from other weight loss studies 
(Esposito et al., 2003; Ryan et al., 2003; Xydakis et al., 2004). However, the effect of 
weight loss on leptin, adiponectin, and ghrelin levels is not as clear. Only a limited 
number of existing studies have examined effects of weight loss on ghrelin through 
diet and exercise on women. The increases in ghrelin found through weight loss in the 
current study are similar to that found in other weight loss studies (Hansen et al., 
2002; Zahorska-Markiewicz et al., 2004). 
Although no significant differences in absolute adiponectin levels were found after 
weight loss in the present trial, individual increases and decreases changed such that 
weight loss positively predicted changes in adiponectin levels. This fin ding is 
consistent with the existing evidence which shows that adiponectin is inversely 
correlated with fat mass (Kazumi et al., 2004; Xydakis et al., 2004). In addition, a 
trial that examined the effect of weight loss through surgical procedures found 
changes in BMI to be negatively associated with adiponectin (r = -0.20) (Baratta et al., 
2004). The lack of studies examining the consequences ofweight loss on adiponectin 
in women is especially noteworthy since adiponectin concentrations are gender 
specific; with women having higher concentrations than men (Nishizawa et al., 2002). 
An investigation of hormonal effects on adiponectin would be use fuI in further 
eXplaining the effect of weight loss on adiponectin levels in females. 
Weight loss was also predictive of decreases in leptin in this experiment. Similar 
relationships were found in other studies that assessed weight loss and changes in 
leptin levels (Baratta et al., 2004; Hansen et al., 2002). However, the se prior studies 
were conducted in a population that had a much higher initial BMI than was used in 
this study, and employed surgical procedures or pharmaceutical methods to promote 
weight loss (Baratta et al., 2004; Hansen et al., 2002). 
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Few studies measure aU of insulin, adiponectin, 1eptin, and ghrelin simultaneously and 
none examine them in the context of weight loss through diet and exercise. Though 
weight loss was predictive of changes in adiponectin and leptin concentrations, 
changes in these parameters, as weU as changes in insulin and ghrelin, were not 
correlative. Thus, though adiponectin, leptin, insulin, and ghrelin are aIl involved in 
energy expenditure and storage, the present results show that they change 
independently of each other. This may indicate that each hormone contributes 
differently to weight loss. 
Regression analyses in this study show that the amount of weight loss was not 
predictive of any change in lipid parameters. A meta-analysis of 70 studies by Dattilo 
and Kris-Etherton (1992b) found an association whereby TC, LDL-C, and TAG 
decreases and HDL-C increases for every kilo gram loss. However, an earlier study by 
Andersen et al. (1995), which examined the effects of diet induced weight loss in 
women, found weight loss to account for no more th an 6% of the variation in 
reductions of TC and TAG. The fact that no relationship was found between lipid 
parameters could have occurred because there was not enough power with the number 
of subjects that participated in the trial. However, the meta-analysis examined data 
from both men and women and the association may not be as strong in women 
(Dattilo et al., 1992b). AdditionaIly, the associations found between percent weight 
change and TC, LDL-C, and HDL-C were highly insignificant; indicating an unlikely 
relationship between the extent of weight loss and changes in lipid parameters. We 
therefore suggest a threshold effect whereby, after 10% loss such as in the present 
study, the extent of lipid lowering produced by weight loss in itself is minimized, thus 
diluting any existing dose-response relationship between weight loss and lipid 
parameters. This is further supported by the finding by Wing and Jeffery (1995) who 
found that decreases in weight of 10% to 15% produced cardioprotective changes in 
blood lipid profiles of both overweight men and women. 
A notable finding of the present study was that baseline lipid and insulin levels were 
predictors of total weight loss, even though initial weight did not predict total weight 
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loss. Previous research has shown a relationship between initial weight and final 
weight loss (Hansen et al., 2001). The lack of association between initial weight and 
final weight loss is unexpected since the higher energy expenditure in those with 
higher initial weight may result in easier weight loss through energy restriction. As 
well, higher initial weight may play a motivating role in weight loss. The ability of 
baseline insulin to predict final weight loss has been seen in other studies 
(McLaughlin et al., 2001). Trials in Pima Indians and the San Luis Valley Diabetes 
study have indicated that insulin resistance may limit weight gain (Hoag et al., 1995; 
Swinburn et al., 1991). Thus, the presence of initial hyperinsulinemia may be 
predictive of increased weight loss. No study has yet determined that baseline lipids 
may play a role in predicting weight loss. In this study, participants were screened to 
have higher baseline TC, LDL-C, and TAG concentrations and thus had knowledge of 
these levels. The predictive relationship found between initiallipid parameters and 
final weight loss may indicate the importance of patient knowledge of these risk 
factors as behavioural motivators for weight loss. 
Such favourable changes in lipid profile may be explained by the effect of weight loss 
on cholesterol metabolism. Although very few studies have examined the effects of 
weight loss on cholesterol metabolism, those that did have indicated that weight loss 
may decrease cholesterol synthesis (Di Buono et al., 1999a; Raeini-Sarjaz et al., 
2001). Endogenous production of cholesterol occurs in many cells including 
adipocytes and hepatocytes (Dietschy et al., 1993). Cholesterol synthesis per gram of 
hepatic tissue has been found to be equivalent in obese and non-obese individuals 
(Miettinen et al., 2000a). However, in obesity, both adipocytes and hepatocytes 
increase in number, explaining the higher rates of cholesterol synthesis seen in 
overweight individu ais (Di Buono et al., 1999a; Raeini-Sarjaz et al., 2001). In weight 
loss, the mobilization of adipose tissue stores of cholesterol during calorie restriction 
may result in the inhibition of hepatic cholesterol synthesis, and th us explaining a 
possible mechanism by which changes in blood lipid concentrations occur (Dattilo et 
al., 1992b). Further studies that examine the effect of weight loss on cholesterol 
metabolism are needed to strengthen this hypothesis. 
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3.6 Conclusion 
In summary, though present results show decreases in leptin and increases in ghrelin, 
beneficial effects of weight loss as achieve through diet and exercise were seen on 
blood lipid, glucose, and insulin levels of overweight and obese hyperlipidemic 
women. Such favourable changes in blood lipid profile likely results in decreased risk 
of morbidity from type 2 diabetes and CVD. Additionally, knowledge of initiallipid 
risk factors may be behavioural motivators that predict weight loss success. Thus, 
moderate weight loss is a key factor in the prevention of cardiovascular disease in 
overweight individuals. 
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3.8 Figure legends 
Figure 3-1. Weekly changes in weight of individual participants throughout the 
study. Line shown is based on regression lines of each study period. Formulas for the 
regression lines are y = -O.Olx + 0.22; r2 = 0.016, p > 0.05 for the pre weight loss 
stabilization period (days 1-15), y = -0.10x + 0.76; r2 = 0.997,p < 0.001 for the weight 
loss period (days 0-155), and y = 0.02x -17.43; r2 = 0.167,p < 0.02 for the post 
weight loss stabilization period. 
Figure 3-2a. Regression ofleptin (ng/L) (131 = -1.81; r2 = 0.35;p < 0.001) on weight 
loss after a 20 week period. 
Figure 3-2b. Regression of adiponectin (mcg/L) (131 = 0.62; r2 = 0.19; p = 0.009) on 
weight loss (kg) after a 20 week period. 
Figure 3-3a. Correlations between changes in TAG and adiponectin (r = 0.41; p = 
0.01). 
Figure 3-3b. Correlations between change in apo Al and adiponectin (r = 0.38; P = 
0.02). 
Figure 3-3c. Correlations between changes in TC and leptin (r = -0.39; p = 0.02). 
Figure 3-3d. Correlations between changes in apo Al and 1eptin (r = -0.41; P = 0.01). 
Figure 3-3e. Correlations between changes in apo BlOO and leptin (r = -0.34; p = 
0.05). 
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Table 3-1. Before and after weight and biochemical parameter concentrations. 
Before and after weight and lipid parameters were determined at days 15 and 169. 
The average of days 14 and 15, and days 168 and 169 were used for determination of 
CRP, glucose and hormone levels. Differences of biochemical parameters are shown 
as integers and percentages. 
Variable Before After Change Change 
(percent) 
Weight (kg) 81.4 + 9.5 69.7 + 9.1 11.7 + 2.5 6 -14.5 + 3.1 
BMI (kg/m2) 31.4 + 2.8 26.9 + 2.9 -4.5 + 0.9a -14.5 + 3.1 
Total cholesterol 6.08 + 0.94 5.46 + 0.64 -0.62 + 0.65a -9.3 + 9.6 
(mmol/L) 
LDL cholesterol 3.76 + 0.68 3.44 + 0.53 -0.32 + 0.51 b -7.4 + 12.2 
(mmollL) 
Triacylglycerol 1.83 + 0.70 1.28 + 0.43 -0.55 + 0.46d -26.8 + 19.6 
(mmol/L) 
HDL cholesterol 1.16 + 0.29 1.24 + 0.31 0.08 + 0.21d 8.2 + 16.3 
(mmollL) 
Apolipoprotein Al 1.27 + 0.20 1.21 + 0.18 -0.06 + O.l1c -4.6 + 7.9 
(mmol/L) 
Apolipoprotein 1.03 + 0.17 0.91 + 0.13 -0.12 + 0.12b -10.9 + 9.9 
B100 (mmollL) 
LDL-C:Apo B100 3.64 + 0.33 3.77 + 0.27 0.13 + 0.23c 3.8 + 6.4 
CRP (mg/L) 3.45 + 4.47 2.03 + 1.66 -1.41 + 4.55c -24.7 + 37.3 
Glucose (mmol/L) 5.50 + 0.81 5.26 + 0.67 -0.24 + 0.59d -3.6 + 10.2 
Insulin (mUnits/L) 17.15 + 6.63 11.73 + 4.24 -5.43 + 5.00b -28.4 + 20.3 
Leptin (ng/L) 33.43 + 8.09 17.41 + 8.88 -16.02 + 7.77b -48.9 + 21.9 
Adiponectin (mg /L) 17.63 + 7.29 17.20 + 7.21 -0.43 + 3.62 -0.2 + 21.8 
Ghrelin (pg/mL) 1102.0 + 464.8 1307.0 + 562.5 204.9 + 274.9b 21.2 + 26.7 
Data are reported as mean +/- SD. ap <O.OOOl, l'îp <O.OOl, cp <0.005, dp <0.05 
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Figure 3-1. Weekly changes in weight of individual participants throughout the 
study. Line shown is based on regression lines of each study period. Formulas for the 
regression lines are y = -O.Olx + 0.22; r2 = 0.016, p > 0.05 for the pre weight loss 
stabilization period (days 1-15), y = -O.lOx + 0.76; r2 = 0.997,p < 0.001 for the weight 
loss period (days 0-155), and y = 0.02x - 17.43; r2 = 0.167, p < 0.02 for the post 
weight loss stabilization period. 
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Figure 3-2a. Regression ofleptin (ngIL) (131 = -1.81; r2 = 0.35;p < 0.001) on weight 
10ss after a 20 week period. 
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Figure 3-2b, Regression of adiponectin (mcglL) (131 = 0.62; r2 = 0.19;p = 0.009) on 
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Figure 3-3a. Correlations between changes in TAG and adiponectin (r = 0.41; 
p = 0.01). 
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Figure 3-3b. Correlations between change in apo Al and adiponectin (r = 0.38; 
p = 0.02). 
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Figure 3-3c. Correlations between changes in TC and 1eptin (r = -0.39; P = 0.02). 
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Figure 3-3d. Correlations between changes in apo Al and leptin (r = -0.41; p = 0.01). 
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Figure 3-3e. Correlations between changes in apo B100 and leptin (r = -0.34; 
P = 0.05). 
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BRIDGE 2. 
In addition to absolute LDL-C concentration, it has been suggested that LDL particle 
size and distribution may negatively impact cardiovascular health (Rizzo et al., 
2006a). More specifically, small, dense LDL particles are thought to contribute 
negatively to CVD and health since they are less likely to be taken up by the LDL 
receptor and therefore, persist in the circulation for a longer duration (Rizzo et al., 
2006a). Current evidence indicates that weight loss beneficially modulates LDL size 
and distribution (Archer et al., 2003; Katzel et al., 1995; Markovic et al., 1998; Pumell 
et al., 2000). Existing studies, however, have only examined the effect of diet-induced 
weight loss. Current guidelines recommend energy modification by physical activity, 
in addition to dietary changes. Thus, the following study was conducted to examine 
how moderate weight 10ss, induced by diet and physical activity, affects LDL size and 
distribution. 
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4.1 Abstract 
Background: Weight loss resulting from diet interventions has been shown to 
favourably affect LDL particle size and distribution, and hence, decrease 
cardiovascular disease risk. However, the effect of a dietary weight loss strategy 
when combined with exercise, on LDL electrophoretic characteristics, has yet to be 
tested. 
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Objective: This study examined the effect of a weight loss intervention that combined 
a low fat diet with moderate endurance training, on LDL particle size and distribution 
in obese women. 
Design: Thirty obese, hypercholesterolemic women participated in controlled 
longitudinal weight loss trial, which consisted of: 1) a 2-wk pre-stabilization phase, 2) 
a 20-wk weight loss phase, and 3) a 2-wk post-stabilization phase. Weight reduction 
resulted from a low fat diet «30% fat, 50-60% carbohydrate, 20% protein) combined 
with an endurance training program (>40 min moderate training 3x/wk). 
Results: Mean weight loss was 14.8% (P < 0.01) of initial body weight. Total, LDL-
cholesterol, and triacylglycerol concentrations decreased (P < 0.01) by 8.9%, 7.5%, 
and 27.1 %, respectively, while HDL-cholesterol concentrations increased (P < 0.01) 
by 9.9%. No significant differences were noted for LDL peak or integrated particle 
size. The relative proportion of small, medium, and large particles were not 
significantly different post-treatment. Estimated cholesterol concentrations in large 
and medium size LDL particles decreased (P < 0.05) by 15.3% and 5.9%, 
respectively, as a result of weight loss. No effect was noted for estimated cholesterol 
concentrations in small size LDL particles. Increased weight loss over the course of 
the trial was associated with a decrease in peak particle size (r = -0.14, P = 0.03). 
Conclusions: These findings suggest that weight loss, resulting from a low fat 
diet/exercise program, has only a minimal effect on LDL particle size and distribution. 
Keywords: weight loss, LDL particle size, low fat diet, exercise, cholesterol, 
cardiovascular disease 
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4.2 Introduction 
Results from several recent epidemiological and clinical intervention trials indicate 
that obesity is a major independent risk factor for cardiovascular disease (Scaglione et 
al., 2004). Accordingly, weight loss has been shown to favourably effect several 
indicators of cardiovascular risk, such as plasma lipid (Gerhard et al., 2004; Yancy et 
al., 2004), homocysteine (Noakes et al., 2004), and C-reactive protein (Brook et al., 
2004) concentrations. In addition to these commonly investigated parameters, weight 
loss has also been shown to beneficially modulate low-density lipoprotein (LDL) size 
and distribution (Archer et al., 2003; Katzel et al., 1995; Markovic et al., 1998; Pumell 
et al., 2000). More specifically, Archer et al. (2003), demonstrated that a low fat/high 
carbohydrate diet reduced the average body weight of overweight men by 2%, while 
causing reductions in the cholesterol content of small and medium size LDL particles. 
Similarly, Markovic et al. (1998) found that after consuming a low fat diet for 28 
days, mildly obese patients lost an average of 6.2 kg and increased the proportion of 
large LDL particles in plasma. Furthermore, in a study by Katzel et al. (1995), it was 
shown that an average loss of 10 kg of body weight, induced by a low fat die t, resulted 
in a significant increase in LDL peak particle diameter. Although these data indicate 
that diet-induced weight loss positively alters LDL electrophoretic characteristics, the 
effect of a low fat diet when placed in combination with exercise, another commonly 
imp1emented weight loss strategy, on LDL particle diameter, has yet to be tested. 
Additionally, the effect of substantial weight loss, i.e. loss of more than 10% of initial 
body weight, on LDL size and distribution still needs further clarification. 
Thus, the objective of the present study was to examine the effect of a 24-week weight 
10ss intervention that combined a low fat diet with moderate endurance training, on 
LDL particle size and distribution in obese, hypercholesterolemic women. In 
addition, the extent to which substantial changes in body weight modulated LDL 
electrophoretic was also examined. 
4.3 Subject and methods 
Subjects 
Subjects were recruited from the greater Montreal area by means of newspaper 
advertisements. After a preliminary questionnaire, blood screening, and physical 
exam, 42 subjects were deemed eligible to partake in the trial. Key inclusion criteria 
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were as follows: non-pregnant females; age 35 to 60 years; body mass index (BMI) 
between 28 and 37 kg/m2; LDL-cholesterol concentrations greater than 4.5 mmol/L; 
triacylglycerol concentrations greater than 1.5 mmol/L; free of cardiovascular disease; 
free of gastrointestinal, renal, pulmonary, hepatic or biliary disease; free of cancer; no 
history of disordered eating; a1cohol intake of less than 2 drinks/d; use of fiber or 
stimulant laxatives less than 2 doses/wk; not taking lipid lowering medications for the 
past 6 months; less than 4000 kcal/wk expended by endurance training. The protocol 
was approved by the Ruman Ethical Review Committee of the Faculty of Medicine at 
McGill University. Prior to the commencement of the study, aU volunteers gave their 
written informed consent to participate in the trial. 
Experimental design 
A 24-week longitudinal design was implemented as a means of testing the study 
objectives. Each subject acted as her own control, and therefore, no control group was 
required (Donnelly et al., 2000). The trial consisted of three consecutive dietary 
periods: 1) a 2-week pre-loss stabilization phase, 2) a 20-week weight loss phase, and 
3) a 2-week post-loss stabilization phase. During the first and third phases, subjects 
were required to maintain a stable weight, and were instructed to continue with their 
usual food habits. In contrast, during the second phase, subjects were required to 
reduce their energy intake by 20% and increase their energy expenditure by 10%. As 
a result, target weight loss was approximately 0.75 kg/wk. Pre-menopausal women 
started each of the three phases at identical points during their menstrual cycles. 
Dietary protocol 
In order to decrease energy intake by 20% throughout the weight loss phase, each 
subject attended individual dietary counselling sessions with a Registered Dietician or 
Nutritionist on a bi-weekly basis. During these sessions, volunteers were taught how 
to attain daily caloric goals using an exchange system that provided 50-60 % of 
energy from carbohydrates, 20% of energy from protein, and <30% of energy from 
fat. Teaching aids, which outlined the caloric contents of commonly ingested food 
items, as weU as sam pIe menus and recipes, were distributed to the volunteers. 
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Exercise protocol 
As a me ans of increasing energy expenditure by 10% throughout the 20-week weight 
loss phase, subjects were instructed to perform moderate aerobic training 3 times per 
week, for a minimum of 40 minutes. During the trial, each subject met with a 
personal trainer and was taught proper training techniques and routines. The exercise 
was performed independently at home, or at the Mary-Emily Clinical Nutrition 
Research Unit. 
Weight loss assessment and compliance 
Compliance with both the dietary and exercise protocol was determined by way of 
weigh-ins that took place once per week throughout the trial. Continuous, regular 
weight loss throughout the second phase of the study was encouraged by means of a 
point system as well as visu al graphs which plotted weekly weight changes. 
Blood collection protocol 
Twelve-hour fasting blood samples were collected on the mornings of day 0, 13, 14, 
15 (phase 1), and 167, 168, and 169 (phase 3) of the trial. Blood was centrifuged for 
15 min at 520 x g and 4°C to separate plasma from RBCs, and was stored at -20°C 
until analysed. 
Analyses 
Plasma lipid profile determination 
Plasma total cholesterol, high-density lipoprotein (HDL) cholesterol, and 
triacylglycerol concentrations were measured in duplicate by automated methods 
through Hitachi 911 automated analyzer (Roche Diagnostics, Indianapolis, IN) using 
enzymatic or immunoturbidometric reagents (McNamara et al., 1987b). LDL-
cholesterol was determined directly by the dextran/magnesium sulfate method in order 
to separate it from HDL-cholesterol (N-geneous LDL C assay, Equal Diagnostics) 
(Rifai et al., 1998; Wang et al., 2001b). 
LDL partide size determination 
LDL particle diameter analysis was performed on whole plasma using nondenaturing 
2-16% polyacrylamide gradient gel electrophoresis (St-Pierre et al., 2001). Plasma 
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samp1es (3.5 !!L) were mixed with a sampling buffer containing 20% sucrose and 
0.25% bromophenol blue in a 1:1 (v/v) ratio. The 6 samples, representing day 13, 14, 
15, 167, 168, and 169, for each individual subject were placed on one unique gel. 
After a 15 min pre-run, electrophoresis was performed at 150 V for 3 h. Gels were 
then stained for 1 h with Sudan black (0.07%) and stored in a 0.81 % ace tic acid/4% 
methanol solution until analysis. The Imagemaster 1-D Prime computer software 
(Amersham Pharmacia Biotech, Piscataway, NJ) was used to analyze the gels. Mean 
LDL particle size was computed by integrating the relative contribution of each LDL 
particle subfraction within a sample and corresponded to the weighted me an of aU 
LDL subfractions. Integrated LDL particle size was ca1culated as the sum of LDL 
subspecies' diameter multiplied by its relative proportion. The relative proportion of 
\ 
LDL having a diameter <255 Â (termed LDL% <255 Â) was obtained byèomputing the 
relative area of the densitometric scan <255 Â. The absolute concentration of 
cholesterol within the LDL subfraction characterized by a diameter <255 Â (termed 
LDL-C <255 Â) was crudely estimated by multiplying total plasma LDL-cho1esterol 
concentrations by LDL% <255 Â as previously described (St-Pierre et al., 2001). In 
order to assess the relative and absolute concentrations of cholesterol in the LDL 
subfractions with a diameter >260 Â (LDL% >260Â and LDL-C >260Â, respectively) and 
in those with a diameter between 255 and 260 Â (LDL% 255-260 Â and LDL-C 255-260 Â, 
respectively), a similar approach was employed. 
Statistics 
Results are presented as means ± standard error of the mean (SEM). A paired t-test 
was implemented as a means of comparing baseline and post-treatment weight, lipid, 
LDL particle size and distribution values. Pearson's correlation coefficients were 
ca1culated to test for associations between treatment-induced changes in body weight, 
plasma lipid concentrations, and LDL electrophoretic characteristics. A level of 
statistical significance at P < 0.05 was used in aIl analyses. Data were analyzed using 
SAS software (version 8.0; SAS Institute Inc, NC). 
4.4 Results 
Subject baseline characteristics and compliance 
Forty-two subjects commenced the study, with 35 completing the entire 24-week trial. 
The seven subjects who did not complete the trial dropped out due to an inability to 
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comply with the study protocol. In addition, data from five subjects were not analysed 
due to plasma sam pie loss. Therefore, after accounting for these loses, a total of 30 
complete subject data sets were used for LDL particle size and distribution analysis. 
On day 0 of the trial, the me an age, body weight, and BMI of the 30 participants was 
48.9 ± 1.24 years, 82.1 ± 1.74 kg, and 31.5 ± 0.52 kg!m2, respectively. During the 
weekly meetings with the Registered Dietician/Nutritionist, compliance with the 
calorie-reduced, low fat diet was reported to be adequate, as demonstrated by proper 
use of the checklist exchange system. Aiso during these meetings, reported increases 
in energy expenditure during the weight loss phase of the study were shown to be 
satisfactory, as the subjects reported increasing their physical activity levels by a 
minimum of 120 minutes per week. 
Body weight and plasma lipid profiles 
Changes in body weight, BMI, and plasma lipid profiles over the course of the 24-
week trial are presented in Table 4-1. The mean rate ofweight loss over the 20-week 
weight loss phase was 0.59 kg!week. From the beginning to the end of the trial, the 30 
volunteers experienced a significant (P < 0.01) mean reduction in body weight of 12.0 
± 0.41 kg. When expressed as the difference between day 15 and day 169 values, 
subjects were shown to have decreased their overall body weight by 14.8 %. Body 
mass index decreased significantly (P < 0.01) from 31.5 kg!m2 to 26.9 kg!m2 from 
baseline to post-treatment. 
As reported previously (Santosa S, 2006), plasma lipid parameters were significantly 
altered as a result of weight loss. Total and LDL-cho1esterol concentrations decreased 
significantly (P < 0.01) by 8.9% and 7.5%, respectively, after the intervention period. 
In addition, HDL-cholesterol concentrations increased (P < 0.01) by 9.9%, while 
triacylglycerol concentrations decreased by 27.1 % from baseline to the end of the 
trial. 
LDL peak partide size, integrated size, and distribution 
LDL peak particle size, integrated size, and distribution over the course of the trial are 
presented in Table 4-2. No differences were noted with respect to LDL peak particle 
size from the beginning to the end of the trial. Similarly, no significant differences 
were noted for LDL integrated size when baseline values were compared to post-
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treatment values. Furthermore, the relative distributions of cholesterol among small 
«255 Â), medium (255-260 Â), and large (>260 Â) LDL partic1es showed no 
significant differences from baseline to post-treatment. However, with respect to the 
absolute distribution of the different LDL partic1e subfractions, the estimated 
cholesterol concentration in large size LDL particles was shown to decrease 
significantly (P < 0.05) by 15.3% (0.80 to 0.68 mmol/L) from the beginning to the end 
of the trial. In addition, the estimated cholesterol concentration in medium size LDL 
particles was shown to decrease (P < 0.05) by 5.9% (1.39 to 1.31 mmol/L) post-
treatment. No significant changes were noted for the estimated cholesterol 
concentration in small LDL particles. 
Correlation between body weight and LDL particle size 
Body weight has been shown to correlate with variations in LDL particle size and 
distribution. For this reason, analyses were performed to see if the substantial 
decrease in body weight resulting from the diet/exercise intervention had an effect on 
LDL electrophoretic characteristics. Correlational analysis revealed that the greater 
change in body weight over the course of the trial was associated with increased LDL 
peak particle size post-treatment (r = -0.14, P = 0.03). 
Correlation between triacylglycerol concentrations and LDL particle size 
Post-treatment triacylglycerol concentrations were not significantly correlated with 
any of the post-treatment LDL particle size or distribution parameters measured. In 
addition, post-treatment triacylglycerol concentrations showed no significant 
associations with either percent body weight change or post-treatment body weight. 
4.5 Discussion 
The results of the present study indicate that a substantial amount of weight loss, i.e. 
loss of approximately 15% of initial body weight, resulting from a low fat diet 
combined with exercise, decreases the estimated cholesterol concentrations of large 
and medium LDL particles. The relative proportion of small, medium, and large 
particles, however, were not significantly altered by this decrease in body weight. 
Results of several recent clinical trials show that losing a considerable amount of body 
weight has favourable effects on certain indicators of cardiovascular disease risk 
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(Anderson et al., 2001; Janssen et al., 2002; Tanaka et al., 2004). Therefore, it would 
be expected that in the present intervention trial, which produced a substantial amount 
of weight loss, certain cardiovascular risk factors su ch as LDL partic1e size would be 
ameliorated. Although such favourable alterations have been previously reported 
(Archer et al., 2003; Katzel et al., 1995; Markovic et al., 1998), the results of the 
present study demonstrate that this magnitude of weight loss has a minimal effect on 
LDL partic1e distribution. More specifically, this study reports a decrease in 
cholesterol concentrations in both large and medium LDL partic1es, as a result of a 
15% diet/exercise-induced weight reduction. No increase in the cholesterol content of 
small LDL partic1es, however, was noted in response to these cholesterol shifts 
between subfractions. There are several possible explanations that may account for 
these unexpected findings. First and foremost, these results could partially be 
explained by the low-fat diet regimen. Recent findings suggest that LDL partic1es 
shift from larger, less atherogenic, to smaller, more atherogenic, partic1es in direct 
proportion to the degree to which dietary fat is replaced by carbohydrate (Desroches et 
al., 2004). Thus, since the subjects were required to lower their fat intake to <30% of 
total energy, and hence, increase their carbohydrate intake to approximately 60% of 
total energy, it can be assumed that this shift in macro-nu trient distribution may be 
responsible for the present findings. Secondly, it is possible that the decrease in 
cholesterol within large and medium LDL subfractions may be attributed to the 
physical activity component of the study. More specifically, in a recent study by 
Varady et al. (2005), it was demonstrated that participation in a moderate intensity 
exercise program decreased the peak partic1e size of previously sedentary, 
hypercholesterolemic adults. However, contradictory to these findings (Varady et al., 
2005), other studies that have examined this relationship have reported either an 
increase in LDL peak partic1e size as a result of exercise (Beard et al., 1996; Halle et 
al., 1999; Kang et al., 2002; Williams et al., 1990), or no effect (Elosua et al., 2003). 
For instance, in two trials (Halle et al., 1999; Williams et al., 1990) that examined the 
effect of endurance training on LDL partic1e size in obese men, the number of small, 
dense LDL partic1es was shown to decrease as a result of training. In line with the se 
findings, Kang et al. (2002), demonstrated that physical activity had a beneficial effect 
on LDL partic1e diameter in obese adolescents. In contrast, Elosua et al. (2003), 
demonstrated that after a 16-week training period, no changes were observed with 
regards to LDL partic1e diameter in previously sedentary men and women. In view of 
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the se findings, since the majority of the studies in the area suggest a beneficial effect 
of exercise on LDL electrophoretic characteristics, it is unlikely that the exercise 
intervention produced these slightly deleterious changes in LDL particle size. Thus, 
before it can be concluded that exercise is responsible for these unfavourable effects, 
it is essential that the results of the Varady et al. (2005) trial be supported by other 
independent studies testing similar objectives. 
Interestingly, correlational analysis revealed a weak but significant association 
between greater weight loss and an increase peak LDL particle size (r = -0.14, P = 
0.03). These associative findings are, evidently, contrary to the causal findings 
reported in the present paper. The reason for the se conflicting results is not clear. 
However, one possible expIa nation for these contradictory findings may again be the 
change in diet composition. Since replacing fat with carbohydrate leads to a decrease 
in particle size, it can be hypothesized that, if this change in diet was not implemented, 
LDL size may have increased in response to weight loss. Then again, since these 
findings are merely associative, and also quite weak, these correlational results should 
not put into question the results of the causative findings. Nevertheless, these 
contradictory results may suggest that, when attempting to assess the effect of weight 
loss on vascular disease risk, LDL particle size analysis should be performed in 
conjunction with other more well-established indicators (Sacks et aL, 2003). 
In summary, results of the present study demonstrate that a substantial amount of 
weight loss resulting from a low-fat diet and exercise regimen has no effect on the 
distribution of small, medium and large LDL particles. Additionally, these data 
suggest that this weight loss regimen decreases the estimated cholesterol 
concentrations of large and medium size LDL particles. However, no increase in 
cholesterol within small LDL particles was observed in response to these cholesterol 
shifts between subfractions. These findings suggest that low fat diet/exercise-induced 
weight 10ss only minimally affect LDL particle size and distribution. Therefore, when 
viewed in terms of modulating LDL electrophoretic characteristics, the effect of low 
fat diet/exercise-induced weight loss on cardiovascular risk reduction cannot be 
inferred from the present data. 
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Table 4-1. Body weight, body mass index, and plasma lipid concentrations at 
baseline and post-treatment. 
Baseline Post-treatment % Change 
n = 30 Mean SEM Mean SEM Mean SEM 
Body weight (kg) 82.14 ± 1.74 70.09 ±1.71 -14.80 ±0.52 
BMI (kg!m2) 31.53 ± 0.52 26.90 ±0.52 -14.80 ±0.52 
Total cholesterol 
(mmol/L) 6.05 ± 0.16 5.46 ±0.11 -8.94 ± 1.78 
LDL-cho1esterol 3.77 ±0.12 3.44 ±0.09 -7.54 ± 2.21 
(mmol/L) 
HDL-cholesterol 1.17 ±0.04 1.27 ±0.05 9.92 ± 3.01 
(mmol/L) 
Triacylglycerol 1.80 ±0.13 1.25 ±0.08 -27.14 ±3.59 
(mmol/L) 
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P-value1 
<0.01 
<0.01 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
'P-value within group: Student's paired t-test comparing day 15 values to day 169 
values. 
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Table 4-2. Low density lipoprotein peak partic1e size, integrated size, and distribution 
at baseline after a 24-week diet/exercise weight 10ss intervention. 
Baseline1 Post-treatmene % Change3 
n = 30 Mean SEM Mean SEM Mean SEM 
LD L peak partic1e 256.26 ± 0041 256.23 ±0.26 -0.01 ±0.12 
size (Â) 
LDL integrated size 256.27 ± DAO 256.15 ±0.20 -0.05 ±0.11 
(Â) 
LDL %>260Â(%) 20.93 ±2.34 20.07 ± 1.37 -4.12 ±6.20 
LDL %260-255 Â (%) 36.96 ± 1.47 37.95 ± 1.34 2.68 ±4.07 
LDL%<255Â(%) 42.26 ±2.27 42.10 ± 1.81 -0.38 ±5.36 
LDL-C>260Â 0.80 ±0.1O 0.68 ±0.05 -15.35 ±7.96 
(mmollL) 
LDL-C260-255 Â 1.39 ±0.07 1.31 ±0.06 -5.87 ± 3.79 
(mmollL) 
LDL-C<255Â 1.58 ±0.09 1.46 ±0.09 -7.82 ±S.37 
(mmol/L) 
1 Mean of day 13,14,15 values. 
2 Mean of day 167,168,169 values. 
3 Percent change comparing the mean of day 13,14,15 values to the mean of day 
167,168,169 values. 
4 P-value within group: Student's paired t-test comparing the mean of day 13,14,15 
values to the mean of day 167,168,169 values. 
P-
value4 
0.913 
0.678 
0.574 
0.317 
0.909 
0.043 
0.048 
0.100 
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BRIDGE 3. 
The cardioprotective changes in blood lipid levels, specifically decreases in TC, LDL-
C and TAG and increases in HDL-C found in the previous manuscript and other 
studies may be explained by changes in cholesterol metabolism inc1uding absorption, 
synthesis, and turnover. Weight loss studies in men or in both men and women have 
indicated decreases in cholesterol synthesis (Di Buono et al., 1999a; Griffin et al., 
1998; Raeini-Sarjaz et al., 2001), however, none have examined these decreases in 
relation to changes in cholesterol absorption and turnover. Previous studies have also 
indicated that changes in lipid levels may be attributed to changes in regional body 
composition (Janssen et al., 2002; Nieman et al., 2002). No studies yet determine, 
however, whether changes in regional body composition affect cholesterol 
metabolism. Therefore, this study set out to investigate how weight loss affects 
cholesterol absorption, synthesis, and turnover, and the effect that changes in regional 
body composition may have on these parameters. Understanding how weight loss 
modulates cholesterol metabolism is important because it allows for better treatment 
focus and therapy of obesity-associated dyslipidemia. 
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5.1 Abstract 
Objective: To de termine how moderate weight loss protocol through diet and 
exercise may affect changes in body composition, to determine the effects of weight 
loss on cholesterol metabolism, and to examine the relationship between cholesterol 
metabolism and changes in body composition. 
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Design: Thirty-five otherwise healthy, hypercholesterolemic women completed a 24-
week weight loss study. A 20% decrease in energy intake through diet and a 10% 
increase in energy expenditure by exercise were combined with motivational 
strategies to encourage weight loss. The diet was self selected and comprised of 50-
60% carbohydrates, 20% protein, and <30% fat. 
Results: Participants lost an average of 11.7±2.5 kg (P<O.OOl). Whole body and 
regionallosses in tissue mass occurred after weight loss. After weight loss, 
cholesterol fractional synthesis rate (FSR) decreased (P=0.003) 3.86±9.33%, while 
rates of cholesterol absorption and turnover did not change. Changes in cholesterol 
turnover were positively correlated with changes in FSR. Visceral adipose tissue 
(VAT) and VAT:subcuataneous adipose tissue (SAT) was negatively correlated with 
cholesterol turnover. Losses in skeletal muscle (SM) and upper body SM predicted 
decreases in cholesterol absorption. 
Conclusions: Decreases in cholesterol synthesis after moderate weight loss is not 
compensated for by changes in cholesterol absorption or turnover. Changes in VAT 
and SM were associated with variations in cholesterol turnover and absorption, 
respectively. Understanding how losses in regional adipose tissue affect cholesterol 
metabolism will help in developing individualized treatment approaches that would 
result in more intensive therapy of obesity-associated dyslipidemia. 
Keywords: weight loss, women, cholesterol metabolism, body composition, 
magne tic resonance imaging, isotope kinetics study 
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5.2 Introduction 
The life expectancy of an obese individual has been found to be about seven years 
shorter than that of a normal weight counterpart (Peeters et al., 2003). If current 
trends in obesity continue, the present generation may have a lower life expectancy 
than their parents (Olshansky et al., 2005). Weight loss however, has recently been 
shown to increase mortality (Allison et al., 1999). One explanation may be that 
regional changes in body composition, rather th an absolute changes in weight, is 
important in assessing the potential efficacy of weight loss to lower the risk of 
associated comorbidities and death. Evidence also shows that the presence of large 
visceral adipose tissue (VAT) depots is associated with increased risk of hypertension, 
cardiovascular disease (CVD), and type 2 diabetes mellitus (DM) (Pi-Sunyer, 2004; 
Park et al., 2005). Lapidus et al. (1984) reported that women with the highest WHR, 
an indicator of visceral adiposity, had elevated relative risk of death from CVD. Thus, 
body composition is an important measure in determining potential health benefits of 
a weight loss program. 
Decreases in body weight of 10% to 15% have been shown to pro duce 
cardioprotective changes in blood lipid profiles of overweight individu ais (Wing et al., 
1995). Favourable changes in cho1esterollevels may be attributed to declines in body 
fat percent, as shown in previous trials (Janssen et al., 2002; Nieman et al., 2002). 
Additionally, decreases of VAT, resulting from weight loss, have been related to 
reductions in blood lipid level (Leenen et al., 1993). Such favourable changes may be 
explained by the effect of weight loss on cholesterol metabolism. Although very few 
studies have examined effects of weight loss on cholesterol kinetics, those that did 
have indicated that weight loss may decrease rates of cholesterol synthesis (Di Buono 
et al., 1999a; Raeini-Sarjaz et al., 2001). However, an unresolved question is whether 
weight loss affects other aspects of cholesterol metabolism, specifically cholesterol 
absorption and turnover. To our knowledge, no studies exist that examine effects of 
changes in body composition on cholesterol kinetics. The objective of this study is 
three-fold: 1) to determine how moderate weight loss through diet and exercise may 
affect changes in whole body and regional body composition, 2) to determine the 
effects of weight loss on cholesterol absorption, synthesis and turnover, and 3) to 
examine the relationship between cholesterol metabolism and regional changes in 
body composition. 
5.3 Methods 
Subjects 
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Forty-two hyperlipidemic overweight and obese women were recruited by newspaper 
advertisements and word of mouth from the Montreal area to participate in a six-
month weight loss trial. Inclusion criteria required that the women were 35 to 60 
years of age with body mass indices of 28-39 kg/m2• Since other analyses were being 
conducted, subjects were also screened for fasting plasma LDL-C concentrations of 
3.4-6.7 mmol/L and TAG concentrations >1.5 mmol/L. Use of oral anti-hypertensive 
agents and thyroid hormones were permitted, provided they were stable and continued 
throughout the duration of the study. The women were included regardless of 
menopausal status, provided they were stable on hormone replacement therapy if it 
was being taken. Fasting blood samples were collected for serum biochemistry and 
haematology and subjects were also required to undergo a complete physical 
examination by a certified medical doctor before acceptance into the study. Subjects 
were excluded if they underwent oral hyperlipidemic therapy less than six months 
prior to commencement or if they had a history of chronic illness, including hepatic, 
renal, gastrointestinal, and cardiac dysfunction. Additionally, those who were found to 
have previous history of eating disorders, chronic laxative use, or reported exercise in 
excess of 4000 kcal/week were excluded. Before commencing, a copy of the study 
protocol was given to subjects and any que ries were answered by the primary 
investigator or study co-ordinators before signing the consent form. Ethical approval 
for the experimental protocol was obtained from the Faculty of Medicine Ethics 
Review Board at McGill University, Montreal, QC, Canada and the Ruman 
Investigation Review Committee of Tufts University, Boston, MA, USA. 
Protocol 
Experimental design 
The trial was 24 weeks in duration and consisted of a two-week pre-Ioss stabilization 
period, a 20-week weight loss period, and a two-week post-loss stabilization period. 
Subjects served as their own con troIs in a longitudinal before and after study design. 
Participants were required to main tain a stable weight, as well as usual food and 
exercise habits during the two-week pre- and post-Ioss stabilization periods. During 
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the two-week stabilization periods subjects were weighed at days 1, 5, 8, 12, and 15 to 
ensure stable weight. Fasting blood samples were taken on days 1, 8, and 15 of each 
stabilization phase to measure circulating lipid concentrations. Cholesterol 
metabolism measurements were done between days 11 and 15 of each stabilization 
phase using stable isotopes. On day 11 of each stabilization phase, baseline fasting 
blood samples were collected before subjects received an intravenous injection of 15 
mg [25, 26, 26, 26, 27, 27, 27-D]cholesterol and a 75 mg oral dose of [3,4-13C]to 
assess cholesterol for cholesterol absorption and turnover. Cholesterol fractional 
absorption rate was determined by dual isotope ratio methodology which compared 
the ratio of ingested [13C]cholesterol to intravenous [D7]cholesterol enrichment in red 
blood cell cholesterol after ho urs 24, 48, and 72. Cholesterol turnover was measured 
by the rate of decay in enrichment of [D7]cholesterol of red blood cell (RBC) 
cholesterol taken after hours 12, 24, 48, and 72. Deuterium incorporation was used to 
measure cholesterol synthesis. After a fasting blood sample was taken on day 14 of 
the stabilization period subjects imbibed 0.7 g DzO!kg estimated body water (99.8 
atom percent excess; CDN Isotopes, Montreal). Body water was estimated at 60% of 
total body weight. Body composition was determined by MRI scans and dietary 
records were also taken during the two stabilization periods to ensure usual food 
habits were followed. 
Weight loss protocol 
A 20-week weight loss period was undertaken after the two-week pre-loss 
stabilization period. Energy expenditure was estimated using the Harris-Benedict 
equation multiplied by an activity factor (Harris, 1919). Weight loss was achieved 
through a 20% decrease in energy intake by diet restraint combined with a 10% 
increase in energy expenditure by exercise, resulting in a 30% total energy deficit. In 
general, prescribed energy intake was between 1400-1600 kcal/d. Dietary 
composition consisted of 50-60% of energy from carbohydrates, 20% of energy from 
protein, and <30% of energy from fat. The V.S. Exchange System consisting of 
grains, fruits and vegetables, meat and alternatives, milk, and fat food groups was 
used to help subjects adhere to dietary guidelines. Monthly individual consultations 
with nutritionists aided the participants in ensuring dietary adherence throughout the 
weight loss period. Semi-private meetings with a personal trainer were conducted at 
the beginning and midway through the weight loss period to help subjects establish 
exercise routines that would achieve a 10% increase in energy expenditure. Proper 
techniques were also demonstrated to ensure exercises were carried out safely. 
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Subjects were weighed once a week throughout the weight loss period. An award 
point system was created to help the subjects keep track of their progress and increase 
motivation. Additionally, participants were given a graph on whieh they were able to 
plot their weekly progress. To further increase motivation and adherence to the 
weight loss protocol, monthly group sessions were he Id where guest speakers taught 
subjects further exercise and nutrition knowledge. Two participants withdrew from 
the study before the weight loss period due to inability to undergo MRI scans and five 
participants dropped out because of diffieulty in following the weight loss regime and 
adhering to the scheduled study visits. 
Analyses 
Plasma lipids 
Collected samples were centrifuged at 1500 rpm for 15 min to separate RBC and 
plasma within 30 min of phlebotomy. Separated aliquots were immediately stored at 
20°C until analyzed. Plasma total cholesterol (TC), and high density lipoprotein 
cholesterol (HDL-C) concentrations were analysed as previously described, using 
enzymatic or immunoturbidometric reagents and a Hitachi 911 automated analyzer 
(Roche Diagnostics, Indianapolis, IN), as previously described (McNamara et al., 
1987b). The dextran/magnesium sulfate method was used to determine low density 
lipoprotein cholesterol (LDL-C) concentrations (Rifai et al., 1998; Wang et al., 
2001b). 
Cholesterol absorption 
Determination of cholesterol absorption is described elsewhere (Folch et al., 1957; 
Vanstone et al., 2002b). Briefly, lipids were extracted from RBC in duplicate using a 
modified Folch extraction procedure and free cholesterol was isolated by thin-layer 
chromatography (Folch et al., 1957). Free cholesterol was then combusted for 4 hours 
at 540°C to 13C-enriehed CO2, and D7enriched water. 13C-enriched CO2, and Dr 
enriched water was separated by vacuum distillation (Vanstone et al., 2002b). 
Isotopie enrichment of the [13C]cholesterol and [D7]cholesterol tracers was verified 
using nuc1ear magnetic resonance (CDN Isotopes, Pointe Claire, Canada) and were 
found to be >99 atom percent excess. 13C and D7 enrichment of free cholesterol was 
assessed by differential isotope ratio mass spectrometry (IRMS) (Vanstone et al., 
2002b). Cholesterol absorption was ca1culated for ho urs 48 and 72 by the following 
equation (Bosner et a1., 1993): 
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Cholesterol Ll13C x 7/46 x Drcholesterol IV dose (mg) x 0.0122 x 100 
Absorption (%) = LlD7 x 2/27 x 13C-cholesterol oral dose (mg) x 0.000155 
where Ll for 13C and D7 is the difference between samples at 48 and 72 hours and the 
baseline abundance (t=O) in parts per thousand relative to PDB and SMOW standards, 
respectively. The factors 7/46 and 2/27 reflect the ratio oflabeled atoms/mg dose and 
the constants 0.0112 and 0.000155 are conversion factors of the part per thousand 
units into atom percent excess for the PDB and SMOW scales, respectively. 
CAC at 48 h and 72 h were then averaged to determine overall cholesterol absorption. 
Cholesterol biosynthesis 
Free cholesterol from 72 h and 96 h erythrocytes were extracted, as explained earlier, 
to measure cholesterol synthesis by deuterium incorporation (Fo1ch et aL, 1957; Jones 
et aL, 1993a). Additionally, deuterium enrichment of plasma water was determined, 
as described elsewhere (Vanstone et aL, 2002b). Fractional synthesis rate (FSR) of 
cholesterol over 24 hours was determined using the following equation that corrects 
for cholesterol deuterium:protium ratio (Jones et aL, 1993a): 
FSR (%/d) = (Llcholesterol/Llplasma) X 0.478 *100, 
where Ll refers to deuterium enrichment above baseline level over 24 hours in parts 
per thousand relative to a SMOW standard. The factor 0.478 reflects to ratio of 
labelled H atoms replaced by deuterium during in vivo biosynthesis (Jones et aL, 
1993a). 
Cholesterol turnover 
Turnover of plasma free unesterified cholesterol is defined as the rate of influx from 
synthesis and dietary absorption compared to the rate of efflux from esterification, 
excretion or transfer from other body pools (Goodman et aL, 1973; Nestel et a1., 1973; 
Vanstone et al., 2002b). Therefore, turnover rates of erythrocyte free cholesterol was 
determined after subtraction of baseline D7, [D7 ]cholesterol enrichment of RBC at 12, 
24,48, and 72 h were fitted to exponential curves to determine the rate of decay. 
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Body composition measurement by magnetic resonance imaging (MRI) 
Magnetic resonance images were obtained using a Siemens 1.5 Tesla MRI scanner 
(Siemens, Mississauga, Canada) using a T-1 weighted spin-echo sequence with a 322 
ms repetition time and a 12 ms echo time (Ross et al., 1996). Scans of the truncal 
region, defined by the area between the femoral and humoral heads, were acquired 
with a scan time of 18 s. Appendicular regional scans, defined as the area above 
below the femoral heads and above the humoral heads, were acquired with a scan time 
of 24 s. The scan was conducted in two parts, divided into lower body and upper 
body by the 4th and 5th lumbar (L4-LS) vertebrae (Ross et al., 1996). For both parts, 
subjects laid in prone position inside the magnet. During the upper body scan, arms 
were extended overhead. Transverse slices of 10 mm thickness were obtained every 
40 mm from the intervertebral space of L4-LS with each pass of the magnet obtaining a 
set of seven slices. The body was divided into four compartments for analysis; the 
lower body defined as the region below but not including L4-LS, the upper body 
defined as the region ab ove and including L4-LS, the abdominal area defined as the 
slices one below and three above L4-LS, and the legs defined as any slice with leg 
bone (Ross et al., 1996). 
AH MRI data were analysed using the Slice-O-Matie v. 4.2 rev 8-2e pro gram 
(Tomovision Inc, Montreal, Canada), as previously described (Ross et al., 1996). The 
volume for each tissue was calculated with the foHowing equation as defined by Ross 
et al. (1996): 
N N 
V = ~ Ait + h/3 ~ [Ai-l + Ai + (Ai_lAi)1!2] 
i=l i=2 
where V represents total tissue volume, A represents tissue area, t represents sliee 
thickness, and h represents the distance between consecutive slices. Volumes were 
then divided by 1000 to convert to Land multiplied by the tissue density to convert to 
kg. The density factors used were 0.94 L!kg for AT and 1.1 L!kg for LT (Katch F, 
1993; Martin et al., 1994). 
Statistics 
AH data are expressed as me ans ± SDs. Data were tested for normality using the 
Shapiro-Wilk test. The statistical significance of changes in cholesterol metabolism, 
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body weight, and tissues within each compartment were determined using a Student's 
paired t-tests. Data that were found to have a non-Gaussian distribution were log 
transformed and retested for normality before the paired T-test was applied. The 
Wilcoxon signed rank test was used for data that did not have a Gaussian distribution 
after log transformation. Student's t-test was used to examine differences in percent 
changes in regional tissue distribution. The Mann-Whitney test was used to compare 
the percent changes in regional tissue distribution in the event that the data were non 
Gaussian. Spearman's rank correlation was used to determine the interactions 
between cholesterol absorption, FSR, and turnover. Linear regression analysis was 
used to examine the effects of regional changes in weight loss on cholesterol 
metabolism, as weH as, the effects of changes in cholesterol metabolism on plasma 
cholesterol. AH values were defined to be statistically significant at P < 0.05. Data 
were analysed using SPSS for Windows (version 12.0.0; SPSS Inc., Chicago, IL). 
5.4 Results 
Forty-two subjects were recruited to participate with 35 completing the study. 
Subjects had an average age of 49.4 ± 6.7 years, intial weight of 81.4 ± 9.5 kg, and 
BMI of 31.4 ± 2.8 kg!m2• During the pre-weight loss stabilization period, average 
body composition was found to be 44.2 ± 3.95% adipose tissue (AT) and 55.8 ± 
3.95% lean tissue (LT). Skeletal muscle (SM) made up 30.39 ± 2.80% of body 
composition, while subcutaneous adipose tissue (SAT) and VAT made up 36.98 ± 
4.19% and 3.05 ± 1.01 %, respectively (Figure 5-1a, b). 
Changes in cholesterol absorption, biosynthesis and turnover in response to weight 
loss 
TC and LDL-C levels declined by 0.62 ± 0.65 mmol/L (P < 0.001), and 0.32 ± 0.51 
mmol/L (P = 0.001), respectively, and HDL-C increased (P = 0.03) by 0.08 ± 0.21 
mmol/L after weight loss. 
After weight loss, FSR was reduced (P = 0.003) by 3.86 ± 9.33 %/d (15.2 ± 91.0% 
relative to initial). No significant changes in cholesterol absorption or rates of 
cholesterol turnover were found. Despite the lack of change found in cholesterol 
turnover, a relationship was found (P = 0.01) between FSR and turnover, where 
decreases in FSR correlated with declines in turnover rates of free cholesterol (r = 
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0.44) (see Figure 5-2). No relationship was detected between changes in cholesterol 
absorption and changes in FSR or between changes in cholesterol absorption and 
turnover rates. 
Overall changes in whole body composition after weight loss 
Overall, participants lost an average of 11.7 ± 2.5 kg (14.5 ± 3.1 % of original body 
weight) (P < 0.001) after following the 20 week weight loss protocol. Figure 5-1a, b 
shows the weight and percent whole body composition of SM, SAT, LT, and AT 
before and after the weight loss period. Who le body losses in tissue mass were 1.36 ± 
1.00 kg for SM, 8.67 ± 3.38 kg for SAT, 1.74 ± 1.73 kg for LT, and 9.85 ± 4.07 kg for 
AT (P < 0.001 for all). Percent composition of SM and LT increased (P <0.001) by 
3.35 ± 1.87% and 7.33 ± 3.35% (P < 0.001). Both SAT and AT percent composition 
decreased 6.80 ± 2.87% (P < 0.001) and 7.33 ± 3.35% (P < 0.001), respectively. 
Despite significant losses in muscle mass, the LT:AT ratio increased after weight loss 
by 0.47 ± 0.24 (P < 0.001) (Figure 5-3). 
Regional changes in body composition after weight loss 
Reductions in percentage SAT in the upper body (-33.3% ± 12.1 %) were greater (P = 
0.038) than those found in the lower body (-27.9% ± 8.81 %). Percent changes in the 
proportions of SM, LT and AT of upper body and lower body did not significantIy 
differ (Figure 5-4). 
In the abdominal region, the decline in AT after weight loss was 2.60 ± 1.14 kg (P < 
0.001), while there was no change in LT. SM, SAT, and VAT decreased (P < 0.001) 
by 0.17 ± 0.18 kg, 1.94 ± 0.86 kg, and 0.61 ± 0.47 kg, respectively. At the end of the 
weight loss treatment, the percent whole body AT composition of SAT from the 
abdominal region dropped by 1.18 ± 1.50% (P < 0.001), and the percent composition 
of AT from the abdomen was reduced 0.99 ± 1.63% (P < 0.001). No changes in 
percent composition of VAT were found. There were no differences in the V AT:SAT 
ratio after weight loss. 
Relationship between changes in whole and regional body composition and 
cholesterol metabolism 
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Larger reductions in V AT predicted rises in cholesterol turnover rate «(3 = -5.04, r = 
0.383; P = 0.03) (see Figure 5-5a). The changes in cholesterol turnover rate was also 
negatively predicted by greater declines in the VAT:SAT ratio «(3 = -147, r = 0.399; P 
= 0.03) (see Figure 5-5b). In regards to cholesterol absorption, larger losses in SM 
predicted greater decreases «(3 = 6.82, r = 0.357; P = 0.04) (see Figure 5-6a). 
Changes in cholesterol absorption were also positively predicted by changes in upper 
body SM «(3 = 14.7, r = 0.413; P = 0.01) (see Figure 5-6b). No other changes in 
whole or regional body composition were predictive of changes in cholesterol 
metabolism. 
5.5 Discussion 
The nove1 findings in this study are that changes in cholesterol turnover after weight 
loss were negatively predicted by changes in VAT and VAT:SAT. Changes in 
cholesterol absorption were positively predicted by changes in total and upper body 
SM. Moreover, percent cholesterol FSR decreases in absence of any changes in 
cholesterol absorption or turnover rate after moderate weight loss in women, and that 
decreases in FSR are related to decreases in cholesterol turnover. Weight loss resulted 
in favourable changes in plasma cholesterol concentrations suggesting an amelioration 
of CVD risk. 
The importance of regional body composition on morbidity and mortality has been 
well established. To our knowledge, this is the first study in women to examine 
effects of self-directed diet and exercise on regional body composition using MRI. 
Mean weight loss of about 12 kg in this trial resulted in who le body reductions in SM, 
SAT, LT and AT mass. Other trials that saw comparable weight loss achieved similar 
losses in SAT and AT to those found in the present study (Janssen et al., 2002; 
Janssen et al., 1999). Additionally, this study observed significant decreases in SM 
that were not found in similar trials (Janssen et al., 2002; Janssen et al., 1999; Ross et 
al., 1995). Of particular note, is that the se trials also inc1uded a diet only group, which 
had significant and comparable losses in SM as those found in the present study 
(Janssen et al., 2002; Janssen et al., 1999; Ross et al., 1995). The exercise 
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intervention however, in these weight loss trials was conducted under supervision, 
thereby allowing for control of the intensity and type of exercise conducted. The self 
selected exercises used in the present study may have been conducted at a lower 
intensity, which might explain differences in body composition changes between this 
and other studies (Janssen et al., 2002; Janssen et al., 1999; Ross et al., 1995). Despite 
losses in SM, increases in the LT:AT ratio in this study suggest that the proportion of 
lean tissue that is preserved is greater than the proportion of adipose tissue that is lost. 
This is especially important since losses in LT may be related to higher mortality, 
whereas losses in AT may be related to lower mortality (Allison et al., 1999). 
Sorne of the health benefits derived from weight loss are related to CVD risk factors. 
The moderate weight loss in this study was associated with decreases in TC, LDL-C, 
and TAG, as well as increases in HDL-C levels, apparently caused by shifts in 
cholesterol metabolism. Experiments in men indicate decreases in cholesterol 
synthesis after weight loss (Di Buono et al., 1999a; Raeini-Sarjaz et al., 2001). 
However, the declines in synthesis of about 4%/d found in the present study after an 
approximate 12 kg weight loss in women was less than those found in these other 
studies in men. One of the reasons for this may be because cholesterol metabolism 
measurements in this study were taken after stabilization periods that minimize the 
effect of the diet and exercise weight loss method. Di Buono et al. (1999a) found 
decreases in FSR of about 5-6%/d after a weight loss of 3-8 kg in six men following 
the AHA Step 1 diet with a calorie deficit of 1000 kJ/d. Another study in male 
participants that were fed a low-fat diet showed that losses of 3 kg of body weight 
were accompanied by larger reductions in FSR of compared to those found in the 
present study (Raeini-Sarjaz et al., 2001). Contrary to these findings, a trial by Griffin 
et al. (1998) that included men and women people with type 2 diabetes, found no 
differences in fasting cholesterol synthesis measured by C14-acetate after a diet-
induced weight loss of about 7-8 kg. Despite the fact that the present study included a 
larger number of subjects and achieved greater weight loss than previous trials, the 
decrease in cholesterol synthesis after moderate weight loss was attenuated. This was 
the only study however, to limit inclusion of subjects to women. Thus, though 
cholesterol synthesis decreases, this may indicate that its response to weight loss may 
be less pronounced in women than in men. 
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This is the first study to use MRI to determine how changes in body composition may 
affect cholesterol metabolism. While a relationship has been established between 
abdominal AT compartments and WHR, WHR cannot accurately predict changes in 
these compartments (Kamel et al., 2000). Accurate assessment of VAT is limited to 
use of MRI or computed tomography (Ross, 1996). Thus, in addition to assessing 
whole body composition, the use of MRI in this study allowed for a precise 
examination of abdominal tissue distribution. As a result, significant decreases in 
total abdominal AT, abdominal SAT and VAT were found. The loss of VAT in this 
study has positive implications on health since VAT has been positively associated 
with increased risk of metabolic aberrations and death (Lapidus et al., 1984; Pi-
Sunyer, 2004). Losses of 0.6 kg VAT observed in the present study were comparable 
to those found in other diet and exercise weight loss studies (Janssen et al., 2002; 
Janssen et al., 1999). Additionally, larger changes in VAT predicted smaller changes 
in cholesterol turnover. The ability ofthe V AT:SAT ratio to negatively predict 
changes in cholesterol turnover may be attributed mainly to changes in VAT, since 
changes in SAT did not independently predict changes in cholesterol turnover. A 
possible explanation for these observations is that cholesterol mobilized from visceral 
adipocytes is drained by the portal vein, which travel to the liver (Rebuffe-Scrive et 
al., 1990). Since the liver is a primary metabolic site, a greater influx of cholesterol 
from larger losses in VAT depots may decrease cholesterol turnover by increasing 
influx relative to a constant rate of efflux. 
The differences in cholesterol turnover were also positively related to cholesterol 
synthesis. Whether changes in one predict changes in the other cannot be determined 
since variations in cholesterol turnover are predicted by changes in VAT, which may 
in turn affect rates of biosynthesis. It is possible that differences in synthesis 
following weight loss may result in proportional changes in turnover because 
synthesis itself may be reduced as a direct cause of a decrease in liver size. 
Cholesterol synthesis per gram of hepatic tissue has been found to be equivalent in 
obese and non-obese individuals (Angel et al., 1979; Stahlberg et al., 1997). 
Additionally, liver biopsies from normal and obese individuals indicated that obese 
individu ais had higher expression of the HMG CoA reductase enzyme involved in 
cholesterol synthesis (Stahlberg et al., 1997). The activity of other enzymes which 
participate in synthesis were also elevated in obese individu ais (Stahlberg et al., 
1997). Thus, enlarged livers found in obese individuals may result in an increased 
rate of cholesterol synthesis and weight loss may result in decreased liver size 
(Stahlberg et al., 1997). 
101 
Neither a change in cholesterol absorption nor a relationship between change in 
cholesterol synthesis and absorption was detected after weight loss. However, 
previous studies in kinetics indicate the potential of a reciprocal relationship in 
cholesterol absorption and synthesis where change in one parame ter oppositely affects 
the other (Grundy et al., 1969b; Gylling et al., 2002a; Jones et al., 2000b; Miettinen et 
al., 2003c; Sudhop et al., 2002; Vanstone et al., 2002b). A paucity of studies exists 
which measure the effects of weight loss on both absorption and synthesis. The only 
studies found were in subjects with type 2 diabetes mellitus (DM) using plant sterols 
and cholestanols, precursors as indicators of absorption and synthesis (Simonen et al., 
2000; Simonen et al., 2002a). Though, both studies indicated a decrease in synthesis 
and an increase in absorption after weight loss, the methods offers only a crude 
estimation of cholesterol kinetics, since plant sterols and cholesterol precursors might 
be affected by diet and are not quantitative measures of metabolism (Simonen et al., 
2000; Simonen et al., 2002a). The use of isotope ratio methodology in this trial offers 
a more precise quantifiable measure of cholesterol metabolism and thus, may explain 
the differences in findings between this and other studies. 
Despite the absence of change in cholesterol absorption, increases in total body SM 
predicted increases in cholesterol absorption. The ability of total body SM to predict 
absorption is likely attributed to increases in upper body SM, since upper and not 
lower body SM was found to be a predictor of cholesterol absorption. Although the 
reason that changes in SM predicted changes in cholesterol absorption is unclear, we 
postulate that it might be due to an elevation in demand of cholesterol, which is 
needed to build myocytes. 
In summary, moderate weight loss achieved in female participants of the present study 
resulted in decreases in cholesterol biosynthesis in the absence of any changes in 
cholesterol absorption and turnover. The use of MRIs in this study showed that 
significant weight loss as a result of a self-directed diet and exercise pro gram resulted 
in favourable changes in regional and whole body SM, SAT, and VAT, as well as total 
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lean and adipose tissue. For the first time, we were able to examine how regional 
changes in regional body composition affected cholesterol metabolism. More 
specifically, decreases in VAT and VAT:SAT predicted increases in cholesterol 
turnover, and increases in whole and upper body SM predicted increases in cholesterol 
absorption. Understanding changes in cholesterol metabolism resulting from weight 
loss may help identify individuals at increased risk of cardiovascular disease and 
allow for earlier and more intensive therapy for the associated dyslipidemia. 
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5.7 Figure legends 
Figure 5-1a. Before and after weight (kg) of each tissue component in whole body. 
*** p < 0.001. 
Figure 5-1b. Before and after percent who le body composition (%) of each tissue 
component. * * * P < 0.001. 
Figure 5-2. Cholesterol FSR vs. cholesterol turnover rate (r = 0.44; P = 0.01). 
Figure 5-3. Individual whole body LT:AT ratio before and after weight loss. Mean 
difference of after LT compared to before LT:AT is 0.47 + 0.24; P < 0.001. 
Figure 5-4. Change of each tissue component relative to initial values in the lower 
body and upper body regions. * P < 0.05 
Figure 5-5a. Changes in cholesterol turnover in response to changes in VAT (/3 = -
5.04, r = 0.383; P = 0.03). 
Figure 5-5b. Changes in cholesterol turnover in response to changes in VAT:SAT (/3 
= -147, r = 0.399; P = 0.03). 
Figure 5-6a. Changes in cholesterol absorption in response to changes in who le body 
SM ([3 = 6.82, r = 0.357; P = 0.04). 
Figure 5-6b. Changes in cholesterol absorption in response to changes in upper body 
SM (~= 14.7, r = 0.413; P = 0.01). 
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Figure 5-1a. Before and after weight (kg) of each tissue component in whole body. 
*** P < 0.001. 
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Figure 5-1b. Before and after percent whole body composition (%) of each tissue 
component. *** P < 0.001. 
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Figure 5-2. Cholesterol FSR vs. cholesterol turnover rate (r = 0.44; P = 0.01). 
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Figure 5-3. Individual who le body LT:AT ratio before and after weight loss. Mean 
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Figure 5-5a. Changes in cholesterol turnover in response to changes in VAT 
(/3 = -5.04, r = 0.383; P = 0.03). 
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Figure 5-5b. Changes in cholesterol turnover in response to changes in VAT:SAT 
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Figure 5-6a. Changes in cholesterol absorption in response to changes in whole body 
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Figure 5-6b. Changes in cholesterol absorption in response to changes in upper body 
SM m = 14.7, r = 0.413; P = 0.01). 
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BRIDGE 4. 
The previous chapter found neither a change in cholesterol absorption nor an 
association between synthesis and absorption after weight loss. Though the 
methodology used might explain the variance in results between the previous and 
other studies, genetic factors may be another reason for the lack of change found in 
cholesterol absorption. Specifically, genetic variations in cholesterol transporters such 
as ATP binding cassette protein (ABC) G5 and G8 may affect the ability of 
cholesterol absorption to respond to changes in cholesterol synthesis (Klett et al., 
2004). ABCG5 and ABCG8 are heterodimers that promote the efflux of cholesterol 
from enterocytes and hepatocytes (Berge et al., 2000). Various single nuc1eotide 
polymorphisms (SNPs) on ABCG5 and ABCG8 have been indicated to affect lipid 
levels. However, the effect of SNPs on changes in cholesterollevels and metabolism 
as a result of weight loss has never been investigated. Therefore, the objective of this 
last study was to examine the effect of weight loss on changes in lipid levels and 
cholesterol absorption, synthesis, and turnover in the context of SNPs of ABCG5 and 
ABCG8. 
CHAPTER 6. Manuscript 6. 
Submitted in the Journal of Lipid Research 
ABCG5 and ABCG8 Single Nucleotide Polymorphisms Contribute to the 
Responsiveness of Cholesterol Kinetics to Weight Loss 
Short Title: Santosa et al ABCG5/G8 and cholesterol kinetics 
115 
Sylvia Santosa\ Isabelle Demonty\ Alice H Lichtenstein2, Jose M Ordovas2, Peter JH 
Jones1* 
lSchool of Dietetics and Human Nutrition, McGill University, 21,111 Lakeshore 
Road, Ste-Anne-de-Bellevue, Québec, Canada, H9X 3V9 
2Jean Mayer USDA HNRCA at Tufts University, 711 Washington Street, Boston, MA 
02111-1524 
*Corresponding author additional information: Phone: (514)398-7547, Fax: 
(514)398-7739, E-mail: peter.jones@mcgiILca 
116 
6.1 Abstract 
Objective: To examine whether changes in cholesterollowering and metabolism 
after weight loss were affected by common SNPs in ABCG5 and ABCG8 genes. 
Methods and Results: Weight loss was achieved in 35 hypercholesterolemic women 
through alterations in dietary and physical activity energy balance. Cholesterol 
kinetics was measured using stable isotope techniques. Mean weight loss was 
11.7±2.5 kg (P<O.OOl). Heterozygous D19H individuals had lower (P=Û.028, and 
P=Û.007, respectively), initial TC and LDL-C levels, and reduced (P=O.008) post-
weight loss LDL-C values than homozygous wild type individuals. Carriers of at least 
one C54Y variant had higher (P=O.047) post-weight loss LDL-C values compared 
with homozygous wild type individuals. Homozygous Q604E variant individuals had 
opposite (P<O.05) changes in cholesterol absorption and synthesis in contrast to 
heterozygous and homozygous carriers. Heterozygous C54Y carriers had smaller 
(P=O.047) reductions in FSR compared to homozygous mutant carriers. Subjects with 
at least one C54Y variant had higher (P=O.042) post-weight loss FSR in relation to 
ho mozy go us wild types. 
Conclusion: SNPs in ABCG5 and ABCG8 were found to regulate cholesterol 
concentration and metabolism after weight loss. Understanding the effect of these 
SNPs on cholesterol risk factors will help establish genetic screening tools to 
determine optimallipid lowering treatment routes for these patients. 
Condensed Abstract: We examined whether weight related changes in cholesterol 
metabolism were affected by SNPs in ABCG5/G8. D19H, C54Y, and Q604E SNPs 
affected cholesterollevels and metabolism. Understanding effects of these SNPs on 
cholesterol risk factors may have therapeutic implications in determining optimallipid 
lowering treatment routes for these patients. 
Keywords: cholesterol metabolism, weight loss, women, ABCG5, ABCG8 
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6.2 Introduction 
In North America, if the prevalence of obesity continues to increase, children will 
have a lower life expectancy than their parents (Olshansky et al., 2005). The shorter 
life expectancy associated with obesity may be attributed to the multitude of 
comorbidities associated with the disease. A common comorbidity of obesity is 
cardiovascular disease (CVD), often resulting from a chronic underlying dyslipidemia. 
Obesity associated dyslipidemia is likely caused by perturbed cholesterol metabolism, 
commonly found in these individuals (Di Buono et al., 1999a; Simonen et al., 2000; 
Stahlberg et al., 1997). It has been well established that weight loss ameliorates 
dyslipidemia in obese individuals (Dattilo et al., 1992b). Weight loss has been 
associated with changes in cholesterol metabolism, inc1uding decreases in cholesterol 
synthesis which are not compensated for by corresponding increases in cholesterol 
absorption (Di Buono et al., 1999a; Simonen et al., 2000; Simonen et al., 2002a). On 
the other hand, the extent by which individuals are able to decrease cholesterollevels 
through weight loss may be genetically predetermined (Aberle et al., 2005). 
Cholesterol homeostasis is maintained through the balance of cholesterol absorption, 
biosynthesis, and turnover. ATP-Binding Cassette (ABC) G5 (MIM 605459) and 
ABCG8 (MIM 605460) transporters have been identified as affecters of cholesterol 
metabolism (Berge et al., 2000). The location of these transporters in apical 
membranes of hepatocytes, and enterocytes in the proximal small intestine in humans 
make ABCG5 and ABCG8 ideally situated to regulate cholesterol kinetics (Klett et 
al., 2004). Indeed, expression of these transporters from 13 exon genes serves to 
reduce net cholesterol absorption by promoting efflux of cholesterol from the 
enterocyte into the intestinal lumen. This in turn results in an increased hepatic 
cholesterol synthesis (Klett et al., 2004). Genetic mutations in DNA that encodes 
these pro teins may affect the efficacy with which ABCG5 and ABCG8 function, 
thereby affecting the response of cholesterollowering therapies (Kajinami et al., 
2004a; Kajinami et al., 2004b). 
Recently, several single nuc1eotide polymorphisms (SNP) have been identified on 
introns and exons of ABCG5 and ABCG8. More specifically, these SNPs inc1ude 
Q604E (RS6720173), 118427 (RS4148189), 17892 (RS4131229), and M216 
(RS3806471) on ABCG5 and C54Y (RS4148211), D19H (RS11887534), T400K 
(RS4148217), and I14222 (RS6709904) on ABCG8. 
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Though dyslipidemia and perturbed cholesterol metabolism is common in overweight 
individu aIs, no study has examined the effect that SNPs in ABCG5 and ABCG8 may 
have in cholesterollowering and metabolism after weight loss. Understanding the 
role that the se SNPs may play in affecting dyslipidemia and cholesterol metabolism 
will help establish genetic screening tools to determine optimallipid lowering 
treatment routes for these patients. Therefore, the objective of this study was to 
examine whether changes in cholesterollowering and metabolism after weight loss 
were affected by common SNPs in ABCG5 and ABCG8 genes. 
6.3 Methods 
Subjects 
Newspaper advertisements and word of mouth was used to recroît women from the 
Montreal area to participate in a 24-week weight loss study. To be selected in the 
study women were required to be 35-60 years of age wîth body mass indices of 28-39 
kg/m2• Subjects who used oral anti-hypertensive agents, thyroid hormones, and 
hormone replacement therapy were also included, regardless of menopausal status, 
provided they were stable and continued on the same dose throughout the duration of 
the study. Potential subjects were screened for fasting plasma low density lipoprotein 
cholesterol (LDL-C) concentrations of 3.4-6.7 mmollL and triacylglycerol (TAG) 
concentrations> 1.5 mmollL. Exclusion criteria included treatment with oral 
hyperlipidemic therapy less than six months prior to the start of the study, any history 
of chronic illness, and previous history of eating disorders. AlI selected subjects were 
given an outline of the study protocol, and were required to sign a consent form before 
starting the study. The Faculty of Medicine Ethics Review Board at McGill 
University, Montreal, QC and the Human Investigation Review Committee of Tufts 
University, Boston, MA, USA approved the experimentai protocoi for ethics. 
Protocol 
Experimental design 
Subjects served as their own controis in a 24-week longitudinal study design. During 
the 24 weeks, participants were required to undergo three consecutive dietary periods: 
a two week pre-loss stabilization period, a 20 week weight loss period, and a two 
week post-loss stabilization period. 
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During the two-week stabilization periods, subjects were required to main tain a stable 
weight, as weIl as usual food and exercise habits. Changes in lipid levels were 
assessed as the difference between days 15 of each stabilization period. Analysis of 
cholesterol kinetics was measured with the use of stable isotopes between days 11 and 
15 in each phase. In measuring cholesterol absorption and turnover, baseline fasting 
blood samples were collected on day Il of each stabilization phase before subjects 
received an intravenous injection of 15 mg [25, 26, 26, 26, 27, 27, 27-D7]cholesterol 
and a 75 mg oral dose of [3,4-13C]cholesterol (>99 atom percent excess for both; CDN 
Isotopes, Montreal). Cholesterol fractional absorption was then determined by 
comparing the ratio of ingested [13C]cholesterol to intravenous [D7]cholesterol 
enrichment in red blood cell (RBC) on days 11, 12, and 13. Cholesterol turnover was 
taken as the rate of decay in enrichment of D7 in RBC cholesterol between day Il 
hour 12, and day 14. Cholesterol biosynthesis was measured on day 14 and 15 using 
the deuterium incorporation method, which involved ingestion of 0.7 g Dzü!kg 
estimated body water (99.8 atom percent excess; CDN Isotopes, Montreal). Body 
water was estimated at 60% of total body weight. 
Weight loss protocol 
Weight loss was accomplished in a free-living environment by decreasing dietary 
energy intake by 20% and increasing energy expenditure by 10% through physical 
activity. The diet was taught via an exchange system and consisted of 50-60% of 
energy from carbohydrates, 20% of energy from protein, and <30% of energy from 
fat. To help participants achieve a caloric deficit of 10% by energy expenditure, se mi-
private group sessions with a personal trainer were held at the beginning and midway 
through the weight loss period. Throughout the weight loss period, compliance was 
determined at weekly weigh-ins, where subjects wore the same clothes. Participant 
motivation was encouraged using an award point system and visual graphs on which 
they were able to monitor weekly weight 10ss. 
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Endpoint analyses 
After phlebotomy, blood samples were promptly centrifuged at 1500 rpm for 15 
minutes to separate RBC and plasma and immediately stored at -20°C until analyzed. 
Analysis of TC, and high density lipoprotein cholesterol (HDL-C) concentrations is 
described elsewhere (McNamara et al., 1987b). LDL-C concentration was measured 
using the dextran/magnesium sulfate method, as previously described (Rifai et al., 
1998; Wang et al., 2001b). 
Cholesterol absorption 
A detailed description of cholesterol absorption determination by dual isotope ratio 
methodology may be found elsewhere (Vanstone et al., 2002b). Briefly, lipids from 
RBC were extracted using a modified Fo1ch method, isolated and combusted to 
pro duce CO2, enriched with 13C and water, enriched with D7 (Fo1ch et al., 1957). The 
CO2 and water generated by combustion were separated using vacuum distillation. 
Drenriched water was further reduced with zinc reagent (Biogeochemical 
Laboratories, Indiana University, Bloomington, IN) to produce Drlabelled hydrogen 
gas. Enrichment of free cholesterol by D7 and 13C were measured by differential 
IRMS (VG Isomass 903D, and SIRA 12;Isomass, Cheshire, United Kingdom, 
respectively). The cholesterol absorption was ca1culated for days 12 and 13 by the 
following equation (Bosner et al., 1993): 
Cholesterol Absorption ~ 13C x 7/46 x Drcholesterol IV dose (mg) x 0.0122 x 100 
(%) = ~D7 x 2/27 x 13C-cholesterol oral dose (mg) x 0.000155 
where ~ for 13C and D7 is the difference between samples at 48 and 72 ho urs and the 
baseline abundance (t=O) in parts per thousand relative to PDB and SMOW standards, 
respectively. The factors 7/46 and 2/27 reflect the ratio of labelled atoms/mg dose and 
the constants 0.0112 and 0.000155 are conversion factors of the part per thousand 
units into atom percent excess for the PDB and SMOW scales, respective1y. 
CAC at 48 h and 72 h were then averaged to determine overall cholesterol absorption. 
Cholesterol biosynthesis 
The deuterium incorporation method was used to assess cholesterol biosynthesis, as 
previously described (Vanstone et al., 2002b). BrieflY' erythrocyte cholesterol was 
extracted and water from the extracted cholesterol was isolated, at which point 
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enrichment was determined using differential IRMS (VG Micromass 903D) for days 
14 and 15 of each stabilization period, as described above (Folch et al., 1957; Jones et 
al., 1993a). In addition, deuterium enrichment of plasma water was measured. 
The following equation, which corrects for cholesterol deuterium:protium ratio, was 
used to determine fractional synthesis rate (FSR) over 24 hours (Jones et al., 1993a): 
FSR(%/d) = (~cholesterol/~plasma) X 0.478 *100, 
where ~ refers to deuterium enrichment above baseline level over 24 hours in parts 
per thousand relative to a SMOW standard. The factor 0.478 reflects to ratio of 
labelled H atoms replaced by deuterium during in vivo biosynthesis (Jones et al., 
1993a). 
Cholesterol turnover 
Turnover of plasma free unesterified cholesterol is defined as the difference between 
the rate of influx from synthesis and dietary absorption, and the rate of efflux from 
esterification, excretion or transfer from other body pools (Goodman et al., 1973; 
Nestel et al., 1973; Vanstone et al., 2002b). Thus, the rate of erythrocyte free 
cholesterol turnover was assessed as the rate of decay of injected D7-cholesterol over 
hours 12 to 72. 
Assessment of ABCG5 and G8 SNPs 
Leukocyte DNA was extracted from 5 to 10 mL of whole blood as described by Miller 
et al. (1988). SNPs Q604E, 118429, 17892, and M216 on ABCG5, and C54Y, D19H, 
114222, and T400K on ABCG8 were determined using PCR-based TaqMan alle1e 
discrimination assays (Applied Biosystems (ABI), Foster City, CA) (McGuigan et al., 
2002). The primers used for PCR have been described previously (Hubacek et al., 
2001; Kajinami et al., 2004a). A GeneAmp PCR System 9700 thermal-cycler (ABI, 
Foster City, CA) was used for PCR analysis. A 7900HT sequence detection system 
(ABI, Foster City, CA) was used to carry out PCR analysis. Reactions were subject to 
50°C for 2 min, 95°C for 10 min, and 40 cycles, each of 95°C for 15 s and 60°C for 1 
min. 
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Statistics 
AIl data are expressed as means±SD. Student's paired t-tests were used to determine 
statistically significant changes in lipid and cholesterol metabolism. The Wilcoxon 
signed rank test was applied where appropriate. To test whether there was a 
difference in lipid and cholesterol kinetic changes within an SNP, one-way analysis of 
variance (ANOVA) with post hoc Scheffe analysis was applied. The Kruskal-Wallis 
test was used where appropriate. Data from homozygous mutant carriers and 
heterozygous individuals were then regrouped and tested for associations. 
Homozygous mutant groups with less than three individuals were automatically 
collapsed into the heterozygous group. A Student's t-test for unpaired groups or a 
Mann-Whitney U test was then applied to the regrouped data, depending on whether a 
normal distribution was present. AlI values were defined to be statistically significant 
at P<0.05. Data were analysed using SPSS for Windows (version 12.0.0; SPSS Inc., 
Chicago, IL). 
6.4 Results 
Forty-two subjects were accepted into the study with 35 comp1eting the study. 
Participants withdrew due to inability to fulfill study requirements (n:::2), and 
difficulty adhering to the weight loss protocol and schedu1ed study visits (n:::5). The 
35 participants who completed the study had an average age of 49.4±6.7 years, BMI 
was 31.4±2.8 kg!m2, and body weight was 81.4±9.5 kg. Overall, participants lost an 
average of 11.7±2.5 kg (14.5±3.1 % of original body weight) (P<O.OOl). 
Changes in lipid and cholesterol metabolism 
TC and LDL-C levels decreased post weight loss (P<O.OOl) by 0.62±0.65 mmol/L, 
and 0.32±0.51 mmollL (P:::O.OOl), respectively, and HDL-C increased (P:::0.03) by 
0.08±0.21 mmollL. In response to weight loss, FSR fell (P:::0.003) by 3.86±9.33%/d. 
No changes were seen in cholesterol absorption (3.31±19.4%; p::: .32) or rates of 
cholesterol turnover (-0.17±9.56%; P:::0.92). 
SNP distribution and frequency 
Genotype distribution and frequency of SNPs of ABCG5 and ABCG8 are shown in 
Table 6-1. AlI genotypes were distributed according to the Hardy-Weinberg 
equilibrium. 
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Effects of genotypes on lipid levels 
The D19H SNP on ABCG8 was associated with pre-weight loss TC values. 
Heterozygous individu aIs had lower (P=O.028) initial TC levels (5.49±O.85 mmollL) 
than those who were homozygous for the wild type (6.28±O.90 mmol/L) (Figure 6-1). 
Subjects who were heterozygous for the D19H SNP also had lower pre- and post-
weight loss LDL-C values (Figure 6-2). Initial LDL-C concentrations for 
heterozygous participants were 3.25±O.50 mmollL compared to 3.94±O.65 mmollL 
(P=O.007) in those who were homozygous wild type. Similarly, post-weight loss 
LDL-C values in heterozygous subjects were 3.05±0.47 mmol/L, which was lower 
(P=O.008) than in those who were homozygous for the wild type (3.57±0.48 mmol/L). 
When those who were homozygous for the variant alle1e were grouped with 
participants who were heterozygous, the C54Y SNP on ABCG8 was found to be 
associated with post-weight loss LDL-C values (P=O.047) (Figure 6-3). More 
specifically, LDL-C in individuals who were homozygous wild type (3.25±0.45 
mrnol/L) was lesser than that of subjects who were carriers of the variant alle1e 
(3.60±O.54 mmollL). 
There were also trends seen for initial LDL-C in the 114222 SNP on ABCG8, where 
subjects who were homozygous for the wild type (3.90±O.65 mmol/L) tended to have 
higher levels (P=O.058) of LDL-C before weight loss than subjects who were 
heterozygous (3.42±O.66 mmol/L). Similarly, a trend was also seen for the T400K 
SNP on ABCG8, where decreases in LDL-C leve1s in participants who were 
homozygous for the wild type tended (P=O.061) to be smaller (-O.20±0.48 mmol/L) 
than in participants who were heterozygous (-O.53±O.52 mmollL). 
No SNPs on ABCG5 were found to be associated with initial, end or changes in lipid 
values. 
Effects of genotypes on cholesterol metabolism 
Changes in cholesterol absorption were related to Q604E SNP on ABCG5 (see Table 
6-2). More specifically, individu aIs who were heterozygous (7.33±15.6%) and 
homozygous wild type (5.94±18.3%) carriers had larger increases than those who 
were homozygous for the variant (-30.8±1.90%) (P=O.017 and P=O.OlO, respectively). 
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Individuals who were homozygous for the Q604E SNP also had higher initial 
cholesterol absorption (86.5±13.3%) compared to heterozygous (57.2±11.8%), and 
homozygous wild type (59.7±18.5%) subjects (P=O.026 and P=O.039, respectively). 
Changes in cholesterol FSR were also seen where those who were homozygous for the 
mutation had increases (1.69±1O.0%) after weight loss and subjects who were 
heterozygous decreased in FSR after weight loss (-7.39±9.36%) (P=O.041). When 
individuals who were heterozygous were grouped with individuals that were 
homozygous for the Q604E SNP variant, no significant differences were identified in 
indicators of cholesterol metabolism. 
A trend existed in the 17892 SNP on ABCG5 where initial FSR values tended to be 
higher in participants who had at least one mutation (12.4±9.03%) than in those who 
were homozygous for the wild type SNP (7.75±5.08%) (P=O.058). 
The C54Y SNP on ABCG8 was also associated with changes in FSR. More 
specifically, heterozygous carriers had lesser reductions in FSR (-O. 17±7.60%) 
compared to participants who were homozygous for the mutation (-8.09±1O.3%) 
(P=0.047) (refer to Table 6-2). Combining heterozygous and homozygous variant 
individuals resulted in lower post-weight loss FSR (5.18±4.88%) in homozygous wild 
type subjects in relation to subjects who carried at least one variant (7.76±4.90%) 
(P=0.042). 
No further differences in cholesterol metabolism were found to be associated with 
SNPs in ABCG5 or ABCG8. 
6.5 Discussion 
This study is the first to show that changes in cholesterol metabolism after weight loss 
are associated with SNPs in ABCG5 and ABCG8. The results indicate that 
cholesterollevels pre- and post- weight loss were related to SNPs in ABCG8, but not 
ABCGS. More specifically, the D19H SNP on ABCG8 was found to be associated to 
lower pre-weight loss TC and LDL-C, as well as decreased post-weight loss LDL-C 
concentrations. Another SNP that was associated with lesser post-weight loss LDL-C 
levels was the CS4Y SNP on ABCG8. This study also found that the homozygous 
carriers of the Q604E SNP on ABCGS experienced larger decreases in cholesterol 
absorption and increased FSR after weight loss. Individuals homozygous for the 
C54Y SNP on ABCG8 exhibited lower post weight-Ioss FSR. 
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ABCG5 and ABCG8 are two half transporters which likely function as heterodimers 
to promo te cholesterol and non-cholesterol sterol efflux at the level of the intestine 
and to pump sterols into bile at the level of the liver (Hazard et al., 2006). Point 
replacement of an amino acid residue by another of different charge and structure may 
result in changes to physiological protein function. Indeed, the nonsynonymous 
cSNPs examined in this trial affect highly conserved amino acid residues, suggesting a 
possible alteration of the function of these transporters through these SNPs (Hazard et 
al., 2006). Understanding how the roles of SNPs in ABCG5 and ABCG8 in 
cholesterol kinetics can be altered may be important in defining optimal routes of 
treatment of dyslipidemia. 
The finding that individuals heterozygous for the mutation encoding histidine in the 
D19H SNP had lower initial TC and LDL-C levels and lesser post-weight loss LDL-C 
than individuals who were ho mozy go us for the wild type is consistent with the 
outcome of previous studies (Gylling et al., 2004b; Kajinami et al., 2004a; Kajinami et 
al.,2004b). A non-intervention study by Gylling et al. (2004b) involving 263 mild to 
moderately hypercholesterolemic subjects found that TC and LDL-C levels were 
higher in homozygous wild type carriers compared to carriers who had at least one 
mutant variant. Another intervention trial, which examined the potential effect of 
genetics on lipid lowering by 10 mg of atorvastatin, showed that individuals who had 
at least one variant allele had lower initial TC and lower post treatment TC and LDL-
C (Kajinami et al., 2004a). Though the overall change in LDL-C was not different 
between D19H SNPs in the present trial, the percent decrease of LDL-C in the 
aforementioned study was larger in those that carried the H19 variant compared to 
wild type (Kajinami et al., 2004a). The lack of association between the D19H SNP 
and change in TC or LDL-C in the present study may be due to the smaU sample size 
that was used compared to other trials. 
Sorne studies showed no differences in plasma cholesterollevels depending on the 
C54Y polymorphism (Gylling et al., 2004b; Kajinami et al., 2004b). However, a 
study in a Czech population, in which lower lipid levels were observed after reducing 
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the consumption of animal fat over eight years, showed that in female carriers of the 
C54Y variant on ABCG8 encoding tyrosine, decreases in TC and LDL-C were larger 
(Hubacek et al., 2001). The difference in initial and final TC and LDL-C between 
genotypes was not discernible. In contrast, the present study demonstrated that 
females who were homozygous for the cysteine alle1e had lower final LDL-C 1evels 
than those who had at least one tyrosine allele. There were no associations however, 
between the C54Y SNP and changes in TC or LDL-C. Thus, further investigation is 
required to determine whether nutrient-gene interactions may modulate the impact of 
C54Y SNP on TC and LDL-C concentrations. 
In the present study, the data indicate no association between cholesterol 
concentrations and Q604E or T400K SNPs. Though one study by Weggemans et al. 
(2002) found a connection between Q604E and TC, where those who were of 
homozygous wild type had lower TC than carriers of at least one mutant alle1e, other 
studies did not find the same association (Gylling et al., 2004b; Plat et al., 2005). No 
relationships were observed between T400K and blood cholesterollevels in any trials 
that examined baseline values (Gylling et al., 2004b; Hubacek et al., 2001; Plat et al., 
2005). The atorvastatin intervention did not discern variations in changes in blood 
cholesterollevels and the Q604E and T400K SNPs. A relationship was seen in the 
experiment by Hubacek et aL (2001), where male participants homozygous for the 
threonine alle1e had a larger decrease in TC and LDL-C concentrations over eight 
years in contrast to individu aIs who had at least one K400 mutation. However, this 
relationship was not found in fema1e participants, suggesting that sex may affect the 
impact of the K400 mutation on cholesterol concentrations. 
A study in mice indicated that ABCG5 and ABCG8 expression may be upregulated 
via the intestinal estrogen receptor a pathway (Duan et al., 2006). However, evidence 
shows that there may be inconsistencies between the murine promo ter sequences and 
those in humans (Hazard et al., 2006). Thus, regulation of the murine ABCG5 and 
ABCG8 may be different. Whether there is a gender difference in the regulation of 
ABCG5 and ABCG8 in humans and the role of SNPs in this scenario is yet to be 
determined. 
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Changes in cholesterol metabolism have never been examined in the context of 
ABCG5 and ABCG8 SNPs. Only studies that investigated the effect of these SNPs on 
baseline cholesterol absorption exist. In contrast with our results showing no relation 
between initial cholesterol kinetic levels and D19H, one study ascertained a 
connection between the D19H SNP, where the H19 allele was associated with higher 
cholesterol absorption (Gylling et al., 2004b). Another study did not detect any 
differences between cholesterol absorption and ABCG5 and ABCG8 SNPs (Miwa et 
al., 2005). One explanation for the deviations in the findings was that the subject 
population varied between studies with one including only Japanese participants 
(Miwa et al., 2005) and the other including men and women (Gylling et al., 2004b). 
A novel finding of this trial is that change in cholesterol absorption and synthesis after 
weight loss, measured by stable isotopes, were affected by the Q604E and C54Y 
SNPs. There were only three subjects that were homozygous carriers for the E604 
alle1e, because the estimated population frequency of the allele is only 3.5%. It would 
be difficult to obtain a large number of homozygous individuals, and despite their 
small number, those who were homozygous for the variant were examined as a group 
in the present study to see if there may be any differences in cholesterol metabolism 
among these individuals. Participants who were homozygous for the glutamine allele 
had decreases in cholesterol absorption and increases in cholesterol synthesis 
compared to carriers of at least one wild type allele, who had increases in cholesterol 
absorption and decreases in cholesterol synthesis. These results suggest that the 
Q604E SNP has an affect on cholesterol metabolism. The use of stable isotopes for 
determination of cholesterol kinetics in this study is unique and allows for the direct 
quantification of associated parameters. However, the time and co st related to using 
stable isotopes does not allow this technique to be utilized with large sam pIe sizes. 
Thus, further studies are required to confirm this conclusion. 
Homozygous carriers of the mutation that results in the transcription of tyrosine in the 
C54Y SNP were observed to have larger reductions in FSR in response to weight loss 
than those who were heterozygous for the mutation. Additionally, participants with at 
least one variant had smaller post-weight loss FSR than homozygous wild type 
subjects. Since individu ais who had at least one variant also had 10wer post-weight 
10ss LDL-C concentrations than homozygous wild type participants, it appears that 
lower cholesterol FSR in the carriers of the C54Y mutation was responsible for the 
10wer post-weight 10ss circulating concentrations of LDL-C. 
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This study was the first to examine the potential of ABCG5 and ABCG8 SNPs in 
regulating changes of lipid concentration and metabolism after weight loss. In doing 
so, it was observed that the D19H and C54Y SNP may be connected to lipid 
concentrations pre- and post-weight loss, and the Q604E and C54Y was associated 
with changes in cholesterol metabolism. The regulation of lipid 1evels and 
metabolism by SNPs in ABCG5 and ABCG8 make them a target in determining 
optimallipid lowering treatment routes for hyperlipidemic patients undergoing weight 
10ss. 
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6.7 Figure Legends 
Figure 6-1. Initial and final TC according to the D19H SNP. *Significant at P = 
0.028 between groups. 
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Figure 6-2. Initial and final LDL-C according to the D19H SNP. Significant at *P = 
0.007; **P = 0.008 between groups. 
Figure 6-3. Initial and final LDL-C according to the C54Y SNP. *Significant at P = 
0.047 between groups. 
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Table 6-1. Genotype distribution and frequency of SNPs of ABCG5 and ABCG8 in 
studied population. 
Homozygous 
SNP: Homozygous Wild Heterozygous Variant 
ABCG5 (n) (%) (n) (%) (n) (%) 
Q604E 19 54.3 13 37.1 3 8.6 
I18429 22 62.9 13 37.1 0 0 
17892 15 42.9 13 37.1 7 20.0 
M216 18 51.4 10 28.6 7 20.0 
ABCG8 
C54Y 16 45.7 12 34.3 7 20.0 
D19H 26 74.3 9 25.7 0 0 
I14222 25 71.4 10 28.6 0 0 
T400K 22 62.9 11 31.4 2 5.7 
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Table 6-2. Cholesterol metabolism and change according to exon SNPs in ABCG5 and 
ABCG8. 
Cholesterol Absorption (%) Cholesterol Biosynthesis (%) 
Initial Final Change Initial Final Change 
Q604E 59.7±lS.5* 65.7±13.7 5.94±18.3* 8.48±6.76 6.16±5.66 -2.32±8.86 
QQ 
QE 57.2±11.St 64.5±18.0 7.33±15.6§ 13.9±9.05 6.48±3.95 -7.39±9.36* 
EE * 86.5±13.3 ' 55.7±13.5 -30.8±1.90*'§ 7.91±4.91 9.60±5.09 1.69±lO.O * 
t 
QEIEE 62.6±16.6 62.8±17.2 O.lS±20.7 12.8±S.63 7.07±4.18 -5.69±9.84 
C54Y 64.9±15.4 67.5±16.4 2.67±22.0 9.96±S.83 5.18±4.88* -4.78±9.62 
CC 
CY 54.2±13.5 65.4±12.2 11.2±12.9 8.95±5.34 8.79±5.35 -O.17±7.60 * 
YY 64.1±25.6 55.3±15.6 -S.80±17.9 14.1±9.07 5.99±3.74 -8.09±lO.3* 
CY/Y 57.9±18.8 61.7±14.0 3.85±17.5 lO.S±7.16 7.76±4.90 * -3.08±9.28 
y 
D19H 58.S±15.9 61.8±13.3 3.00±17.2 lO.1±6.68 6.54±5.28 -3.55±8.28 
DD 
DH 67.5±21.2 71.7±18.S 4.19±25.9 11.4±11.O 6.68±4.35 -4.76±12.4 
T400K 64.4±19.4 63.6±17.2 -O.76±20.2 lO.4±S.91 6.91±5.51 -3.53±10.9 
TT 
TKjK 55.4±12.2 65.6±11.6 1O.2±16.5 lO.4±5.99 6.01±4.12 -4.42±6.29 
K 
*,TSignificant difference between groups P<O.05. USignificant difference between groups 
P<O.Ol. 
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Figure 6-1. Initial and final TC according to the D19H SNP. *Significant at P = 0.028 
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Figure 6-2. Initial and final LDL-C according to the D19H SNP. Significant at 
*P = 0.007; **P = 0.008 between groups. 
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DISCUSSION & CONCLUSION 
Overweight and obesity exerts a to11 on the Canadian health care system costing an 
estimated $4.3 billion in direct and indirect costs (Katzmarzyk et al., 2004). The World 
Health Organization predicts the impact of the obesity will have an equal impact on 
health as the smoking epidemic (Statistics Canada, 2002). It is we11 established that these 
individuals are at greater risk for various .comobidities inc1uding sleep apnea, infertility, 
dyslipidemia, hypertension, type 2 diabetes me11itus (DM), infertility in women and CVD 
(Must et al., 1999). There is no question as to the dire impact of obesity on health; many 
uncertainties remain in determining the best course of treatment of its associated 
comorbidities. The key to unlocking the effective routes of treatment is to understand the 
mechanism behind obesity-related metabolic changes. 
The main objective of this thesis was to characterize changes in cholesterol metabolism as 
a result of moderate weight loss in overweight, hyperlipidemic women. This thesis 
demonstrates a successful method for moderate weight loss through self-selected diet and 
exercise. As a result, we were able to conduct an original study that examined the effects 
of significant weight loss on various aspects of cholesterol kinetics. The knowledge of 
hyperlipidemia may be important in determining weight loss success since baseline lipid 
values were shown to predict total weight loss. In conducting the research, the lack of an 
association found between insulin, leptin, adiponectin, and ghrelin indicates that though 
these hormones are a11 involved in regulating energy balance, they may contribute to 
weight loss independently of each other. Moderate weight loss in hyperlipidemic 
overweight and obese females also resulted in cardioprotective changes in cholesterol 
levels, despite minimal effects on LDL partic1e size. Since absorption and turnover did 
not change, amelioration of lipid levels is likely due to decreases in cholesterol synthesis. 
Additiona11y, the research conducted provides evidence that weight-related variations in 
cholesterol absorption, synthesis, and turnover are affected by alterations in regional body 
composition and SNPs in ABCG5 and ABCG8. 
One of the key treatments in a11eviating obesity related comorbidities is weight loss. This 
is the case with CVD where weight loss has been shown to resuIt in cardioprotective 
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changes in blood lipid concentrations (Dattilo et al., 1992b). Despite the established 
benefits of weight loss, the kinetics and regulation of cholesterollevels is not known. 
The characterization of cholesterol trafficking was investigated in this thesis through the 
inclusion of women. 
In observing favourable changes in cholesterollevels, we set out to determine the kinetics 
behind these changes. Stable isotope ratio techniques were used to examine cholesterol 
absorption and turnover, and deuterium incorporation was used to determine synthesis 
rates. This the sis was the first to apply these techniques to the examination of cholesterol 
kinetics with respect to weight loss. Other studies that examined the effects of weight 
loss on cholesterol metabolism in people with type 2 diabetes used serum sterols as 
indicators of absorption and synthesis. There is still concern in using sterols as indicators 
of cholesterol absorption in situations where dietary plant sterol intake may be altered 
(Matthan et al., 2004). Additionally, the dual isotope ratio method allows for the 
quantification of absorption, synthesis, and turnover, while serum sterols indicate changes 
relative to the levels that were initially present. Use of the dual isotope method provides 
an accurate determination of changes in cholesterol kinetics in response to weight loss. 
Significant weight loss in this thesis resulted in decreases in cholesterol synthesis without 
any changes in absorption or turnover. Though not directly examined, it is postulated that 
increased mobilization of adipose tissue stores of cholesterol due to weight loss may 
provide negative feedback to HMG CoA reductase resulting in decreased rates of 
synthesis and consequently, lower concentrations of blood cholesterol (Dattilo et al., 
1992b). The previously observed presence of enlarged livers and elevated HMG CoA 
reductase suggest that any changes in absorption may be secondary to higher synthesis 
rates. Differences in cholesterol absorption after weight loss may not have been seen in 
this study due to high inter subject variability, or other extraneous factors such as 
variations in body composition changes or in SNPs of ABCG5 and ABCG8. Indeed, the 
data indicate that variations in cholesterol absorption were positively related to changes in 
SM and that changes in cholesterol turnover were negatively related to differences in 
VAT. Additionally, the data provide evidence that the Q604E SNP in ABCG5 and the 
D19H SNP in ABCG8 were related to alterations in cholesterol kinetics. These 
138 
observations suggest that development of a genetic screening tool that includes SNPs of 
ABCG5 and ABCG8 may be beneficial in developing a more aggressive treatment 
approach to dyslipidemia in overweight individuals undergoing weight loss. In looking at 
the overall picture of cholesterol kinetics, these findings suggest that more aggressive 
treatment of dyslipidemia in individuals undergoing weight loss might include agents that 
inhibit absorption. Future studies that examine whether incorporation of absorption 
inhibitors with weight loss would further reduce cholesterollevels need to be conducted 
to confirm this hypothesis. 
The investigation of weight related changes in cholesterol trafficking in women adds a 
unique aspect to this study, since most studies in this are a have focussed on men. The 
tendency toward central distribution of adipose tissue in men and lower body distribution 
in women may indicate a potential for gender-related differences in cholesterol kinetics 
since central adipose tissue is thought to be more metabolically active. As weIl, the 
concentrations of hormones such as adiponectin have been shown to be higher in women 
compared to men (Nishizawa et al., 2002). As a result of these differences, variations 
may exist in how weight 10ss affects cholesterol trafficking in women. Unfortunately, the 
number of females included in the study did not provide enough power to diversify the 
parameters based on menopausal status. Therefore, future studies may aim to further part 
out discrepancies between pre and postmenopausal women. 
This thesis did not compare the effects of weight loss on various parameters to a constant 
weight control group. A meta-analysis by Datillo and Kris-Etherton (1992b) showed that 
changes in lipids by weight loss were not dependent on a control group, therefore, 
exclusion of a control group in this thesis was justified. 
A unique aspect of this research was the attempt to isolate effects of weight loss and 
minimize the effect of diet and exercise treatments on measured parameters through the 
inclusion of two-week pre- and post- weight loss stabilization periods. Two-weeks were 
chosen as the duration of the stabilization periods because previous studies indicate that 
changes in lipid levels occur within two weeks after commencing a new dietary period 
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(Hodson et al., 2002). Several other groups have also incorporated washout and run-in 
periods lasting two weeks in duration in experiments that examine changes in cholesterol 
levels (Binkoski et al., 2005; McCombs et al., 1994; Sacks et al., 1981). A longer period 
was not used because it was suspected that, since subjects had to return to pre-weight loss 
diet and physical activity habits, lower compliance might occur during post loss 
stabilization due to fear of weight regain. Repeated measures ANOV A on cholesterol 
levels indicated that subjects were in a steady state. Weights taken during stabilization 
remained within 1 kg of the average weight during the period. Therefore, stability was 
achieved for cholesterollevels and body weight throughout both these periods. 
The findings from this research add to our current knowledge of obesity-related 
dyslipidemia by elucidating how significant moderate weight loss in overweight and 
obese hyperlipidemic women affects cholesterollevels and metabolism, and 
characterizing factors that may influence these changes. Observations that weight related 
decreases in blood lipid levels may be attributed to reductions in cholesterol synthesis 
suggest that more aggressive treatment of dyslipidemia in overweight and obese women 
should inc1ude therapies that target cholesterol absorption such as plant sterols and 
ezetimibe. Use of therapies that target cholesterol absorption might also be considered 
with weight loss protocols that aim to decrease AT while maintaining or increases SM, 
since increases in SM were associated with increases in absorption. This research project 
also found that SNPs in ABCG5 and ABCG8, specifically the D19H, C54Y, and Q604E 
polymorphisms, may be associated with weight related response of cholesterollevels and 
metabolism. Knowing how such polymorphisms affect cholesterol kinetics will help in 
the development of genetic screening tools that will result in more individualized 
treatment approaches to lower blood lipid risk factors of CVD. Thus, understanding the 
mechanism associated with cholesterol trafficking in obesity will help in the development 
of more effective treatment approaches for dyslipidemia in these individuals. 
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SUBJECT CONSENT FORM OF RESEARCH PROTOCOL 
Impact oF Weight Loss on Lipid Kinetics in Ove/Weight, Hyperlipidemic Women 
Subject name : ________________ Protocol number : ____ _ 
School of Dietetics and Human Nutrition, Macdonald campus, McGiII University 
Principal Investigator. Dr. Peter Jones 
Phone: (514) 398-7547, 398-7527 
Contact Physician : Dr. William Parsons 
Phone: (514) 694-4869 
1. NA TURE AND DURATION OF PROCEDURE 
The CUITent study objectives are to assess the effects of 5-months of weight loss, achieved through 
combined dietary food restriction and exercise activity, and genetic patteming for cholesterol 
metabolism on blood lipid profiles and movement of these lipids between compartments within the 
body. 
As part of a pre-screening visit, a fasting blood sample of 20 mL (4 teaspoons) will be taken for the 
laboratory to confirm the absence of health abnormalities. The sample will aIso be used to measure 
your blood lipid levels, which will indicate the level of various fats in your blood. Following 
qualification for the study, you will be invited back for further screening where a fasting blood 
sample of 20 mL will he obtained to measure yOuf genetic status for a marker that may be related to 
the responsiveness of your blood lipids to diet. As weIl, a complete blood count will be performed. 
An electrocardiogram may be done at the discretion of the physician in charge. Prior to beginning the 
study, you will be examined by a physician to ensure that your are in good heaIth and sorne questions 
about your medicaI history will be asked. 
You will aIso need to ensure that you (1) have not consumed any lipid lowering drugs, including 
fish oils, fihers, or laxatives within the last 6 months, and (2) have not developed thyroid disease, 
diabetes mellitus, kidney disease or liver disease within the past 3 months. 
Once you start the clinicaI triaI, you will be asked to consume only the diet as instructed by the 
study coordinators for a period of roughly 5 months. At the start and termination of experimental 
period, your dietary food consumption will allow you to keep a constant weight for twO periods of 
two weeks each. Between these two weight stabilization periods you will adhere to a weight 10ss diet 
for 20 weeks, where it is anticipated that you willlose up to 15 kilograms (33 pounds) of body. For the 
weight 10ss diet period you will receive information on how to adjust your home diet to pro vide less 
calories. In addition to this weight loss diet, it is expected that you will commence an exercise 
program where you will conduct regular physical activity (e.g. ride a stationary bike, climb the stair 
master, walk, etc.) 3 times per week. To establish how much energy to provide ta you during the 
different phases of the study, you will have your metabolic rate measured using a canopy placed over 
yOuf head for 30 minutes, during which time the rate of use of oxygen will be monitored. At that 
point, we will aIso ask you about your dietary habits. During the five-week :weight 10ss period, you 
,'\~ 
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will be asked to come at the Research Unit once a week ta be weighted and once a month to have a 
blood draw. 
Also, at the end of each period of stable weight (ie at close to the beginning and end of the overall 
study) your lipid levels and parameters of whole body lipid metabolism will be determined through 
the collection of blood samples and provision of sorne tagged materials. AlI of these tags are non-
radioactive and pose no toxicity hazard.(As well we will measure the amount of fat in your body 
using magnetic resonance imaging): For this procedure, you will need to lie in a horizontal position for 
about 40 minutes while a series ofmagnetic sc ans are taken. There is a risk of discomfort while in the 
magnetic resonance imaging machine, most likely in the form of claustrophobia. A separate consent 
from the hospital will be required for this procedure, 
Ta measure lipid metabolism, four days before the end of each of these 2 week controlled dietary 
phases, you will receive an injection containing a small amount of tagged cholesterol. At the same 
time, you will also be requested to consume a small quantity of a similarly tagged cholesterol. The 
movement of these tagged materials will permit assessment of how much cholesterol your body 
absorbs from the diet. On the last day of study, you will also be requested to consume three 
tablespoons of water tagged with deuterium (hydrogen containing an extra neutron, 2Hl) in order to 
establish the amount of cholesterol being produced inside your body. Blood samples (20 mL) will be 
collected daily on the momings of each of the la st four (4) days of the study, as well as the moming of 
completion of the study, in order to examine the movement of these tags across body compartments. 
A further blood sample (20 mL) will be obtained 12 h after giving the tagged cholesterol 4 days before 
the end of the study. In addition ta blood samples, fecai samples will be required on days 11, 12, 13 
and 14 of the third period ta measure the amount of tagged and untagged cholesterol, in order ta 
determine cholesterol absorption. 
The total amount of blood drawn during each of the two phases of the study will be 250 mL 
(about 1 cup). The total blood volume, including the screening sample, required for this trial will be 
510 mL (a little more than 2 cups). No more than 300 mL (about 1 % cups) will be drawn in anyeight-
(8) week period. 
2. POTENTIAL RISKS AND/OR BENEFITS 
The weight 1055 regimen can be expected ta have no negative side effects on health, based on 
many previous animal and human experiment5. The magnetic resonance imaging procedure is 
routine and without hazard, as long as you have no metal containing items 5urgically placed within 
your body cavity. Bruising and pain is associated with venipuncture and injection of the tagged 
cholesterol. Volunteers may run the risk of becoming anemic, but this will be tested at the end of each 
diet phase, and anemic volunteers will receive iron supplementation (ferro us gluconate, 325 mg 
orally, once a day, for 2 weeks). In case you feel any discomfort during the experimental trial, a 
physician, Dr. Parsons, will be available ta contact at any time. Dr. Parsons can be reached at (514) 
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694-4869. If any health abnormalities are identified in the clinical tests conducted during the 
experiment, you will he informed of such by the doctor associated with the study. 
CONSENT OF THE SUBJECT 
The substance of the project and procedures associated with it have been fully explained to me, and 
aIl experimental procedures have been identified. 1 have had the opportunity to ask questions 
concerning any and aIl aspects of the project and procedures involved. 1 am aware that no guarantee 
or assurance has been given by anyone as to results to he obtained. Confidentiality of records 
concerning my involvement in this project will he maintained in an appropriated manner. Samples 
will not he utilized for any additional analyses, nor stored for any prolonged period, nor shared with 
any other group, other than is indicated in the protocoI, without my specific consent. 
1, ________________ ---', have read the above description with one of the 
investigators , . 1 fully understand the procedures, 
advantages and disadvantages of the study, which have been explained to me. 1 understand that, in 
compensation for the inconvenience of the study schedule, 1 will receive $1,000. 1 will aIso receive 
access to my test results when they become available. If 1 decide to withdraw hefore completion or 
should the study be terminated early, 1 will receive an appropriate pro-rated fraction of this amount. 
1 acknowiedge receiving a copy of this consent form and aIl appropriate attachments and 
agree to be contacted by a member of the Research Ethics Committee. 
Investigator Signature of Subject 
Witness 
Date Time 
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Sylvia Santosa <sylviasantosa@gmail.com> 
Ethics certificate for thesis submission 
5 messages 
Sylvia Santosa <sylviasantosa@gmail.com> 
To: vanessa.fabris@mcgill.ca 
Dear Vanessa, 
Tue, May 9,2006 at 12:10 PM 
My name is Sylvia Santosa (student# 110247748) and 1 am a Ph.D. student with the School of Dietetics 
and Human Nutrition. 1 am in the process of preparing my thesis for submission and the issue of 
inclusion of an ethics certificate arose. 1 have the letter of ethics approval from the IRB and 1 also have 
the subsequent approved renewal forms. Unfortunately, 1 have been unable to obtain the actual 
certificate and the IRB does not have a copy, nor are they able to issue a replacement. Ethics approval 
was issued by the Faculty of Medicine IRB and they have record of ethics approval. Is the letter and/or 
renewals sufficient in lieu of the certificate? Please let me know what 1 can include. Thank you for your 
attention to this matter. 
Sincerely, 
Sylvia 
Sylvia Santosa, BASc 
PhD Candidate 
School of Dietetics and Human Nutrition 
McGili University, Macdonald Campus 
21 111 Lakeshore Road 
Ste. Anne de Bellevue, QC 
H9X 3V9 
Tel: (514) 805-1759 
Fax: (514) 398-7739 
E-mail: sylviasa.ntosa(Q!grnaiLcotTl 
Vanessa D Fabris, Miss <vanessa.fabris@mcgill.ca> 
To: Sylvia Santosa <sylviasantosa@gmail.com> 
Dem Sylvia, 
Wed, May 1 0, 20~6 at 9:21 AM 
1 discussed yout" situation with our Thesis !\c1rninstrato: and he sugçjested that Vou inforrn us (via email) 
as to whV the certificate itself wdi not b(} providecl with the thesis copies and other forms, so ! can put the 
f'xplanation in yOUf file. I\inthing cornp!ic8ted. Just reiterate what Vou wTote be!ow and mention the 
reason why your supervisor can't pmvide vou \!vith it (you rnentioned that he's left the province 8nd ail of 
his documents are in boxes.) 
1 hope this helps and wil be waiting for your ernaiL Vou Gan rep!y to this one. 
8est, 
Vanessa Fabris 
Thesis Coordinator 
5/10/20069:47 Al\ 
· Ethics certificate for thesis submission http://mail.google.com/mail/? &ik=911f5514aO&view=pt&th=lOble. 
Graduate & Postdoctoral Studies Office 
Registration, Records & Theses 
James Administration Building, Room 400 
Tel.: 398-3990. ext. 094220 
Fax: 398-6283 
Email: l,f[:lfJG~§g.fgbrj~_@mçgill.ç8 
From: Sylvia Santosa [mailto:sylviasantosa@gmaiLcom] 
Sent: Tuesday, May 09,2006 12: 11 PM 
To: Vanessa D Fabris, Miss 
Subject: Ethics certificate for thesis submission 
[Quoted text hidden] 
Sylvia Santosa <sylviasantosa@gmail.com> 
To: "Vanessa D Fabris, Miss" <vanessa.fabris@mcgill.ca> 
Dear Vanessa, 
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Wed, May 10, 2006 at 9:28 AM 
My name is Sylvia Santosa (student# 110247748) and 1 am a Ph.D. student with the School of Dietetics 
and Human Nutrition. 1 am in the process of preparing my thesis for submission and the issue of 
inclusion of an ethics certificate arose. 1 have the letter of ethics approval fram the IRB and 1 also have 
the subsequent approved renewal forms. Unfortunately, 1 have been unable to obtain the actual 
certificate and the IRB does not have a copy, nor are they able to issue a replacement. 1 have not been 
able to obtain one fram my supervisor because he has relocated to Winnepeg and as a consequence, ail 
files are in boxes there. Thus, it would be extremely difficult to find. Ethics approval was issued by the 
Faculty of Medicine IRB and they have record of ethics approval. 1 can include the letter and/or renewal 
forms in my thesis. Please let me know whether this'~s sufficient. Thank Vou for your attention to this 
matter. 
Sincerely, 
Sylvia 
[Quoted text hidden] 
Sylvia Santosa <sylviasantosa@gmail.com> Wed, May 10, 2006 at 9:29 AM 
To: "Vanessa D Fabris, Miss" <vanessa.fabris@mcgill.ca> 
Dear Vanessa, 
1 just sent Vou the e-mail. Is that what Vou meant? Let me know if Vou need anything further and thank 
Vou for looking into this. 
Sylvia 
On 5.110/06, Vanessa 0 Fabris, Miss <vanessa.fabris@rncgi!Lc8:> wrote: 
[Quoted text h idden] 
[Quoted text hidden] 
Vanessa 0 Fabris, Miss <vanessa.fabris@mcgill.ca> 
To: Sylvia Santosa <sylviasantosa@gmail.com> 
Wed, May 10, 2006 at 9:36 AM 
5/10/20069:47 i\J 
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Hi Sylvia, 
Received your emaii anditwilidofine.i.llinciude it in yom thesis file and everything shouirj go srnoothly. 
8est. 
Vanessa Fabtis 
Tbesis Coordinator 
Graduate ,'1 Postdodoral Studies Office 
Reg:stmt:on, Flecords & Theses 
James /\dministration Building, Floom 400 
Tel.: :398-3990, ext. 094220 
Fax: 39l'l-6283 
Email: \,!gnQ~sg.fabJl~@mçgilLc.Q. 
From: Sylvia Santosa [maiito:sylviasantosa@gmail.com] 
Sent: Wednesday, May 10, 20069:30 AM 
Ta: Vanessa Ci Fabris! ~/liss 
Subject: Re: Ethics certificate for thesis submission 
[Quoted text hidden] 
5/10/20069:47 Al\ 
~'..." ... " .. , "~/'Y"'" 'w. w'J 1 nt" '-'II.JU .... ..,"', 
"McGill 
Facu!tv ef M'diçlrl' 
:36SI5 Prgrr,enede SirW,i_am o,r., 
Montreel. oc 113G 1 Va 
September 30. 2002 
Dr. Peter J. H. Jones 
Professor of Nutrition 
,.' ... .., .. "'.,' .. " ... wt.ntl~I', .'I~ 
~aculté de ",.o,çÎl'l' 
3655. P,otllltnade SlrWII1~m OSret 
Montrèet, OC. M3G lYS 
School of Oletetlos and Human Nutrition 
21,111 Lakeshore 
Ste-Anne-De-Bellevu8. auebec H9X 3V9 
Dear Or. Jones, 
.... - ... -. ~ .. -
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We have reoeived correspondence ln support of the research proposai AOO.M81-02A 
JJntitled "Impact of Weight Loss on Upid Kinetics in Overweight Hyperllpidemic Women" 
'which r.ce/vedfull· Board approval by the Institutional Review Board, Faculty of 
.' Medidne at lta meeting of September 9, 2002. 
The responses and ravisions wera tound to be ac:ceptable and we are pleased to inform 
you that final approval for the revised protocol (September 25, 2002), English and 
french recrultment ad (September 27,2002) and revlsed consent form (September 23, 
2002) was provided on September 30,2002, vaUd until September 2003. You will find 
the certification document (executed) enclosed. 
A review or ail research tnvolving human subjects is requirad on an annual basls in 
accord wlth the date of initial approval. ShOuld any modification to the study or 
unanticlpated development occur priorto the neld review, please advise IRB promptly. 
We ask you to note that it i5 the responsfbility of the investlgatcr to deposit a copy of the 
approved researcn protocol and consent fonn with the Researeh Ethlcs Board of each 
hospltal where subject recrultrnent or data collection wfll take place. 
YourslÎncereIY.~ ~6'f1'----'-­
Neil MacDonald, M.Q., 
Chair, 
Institutlonal Review Board 
cc: A09-M81..Q2A 
~'McGill 
FaCi.illy of M,dlclne 
:)1$1)5 Pr.')'"l1Ilnlde Sir Will:.m Oskot 
Mor.!raa:. OC H3:3 iY6 
Odober 7, 2003 
Dr. Peter J. H. Jon.as 
Profesaor of Nutrition 
Faculté de médeCine 
3656, Promenade Sir Willam Osier 
Mor.tteal, OC. H3G 1'1'6 
School Of DietmlCs end Human Nutrition 
21,111 lIlkeshore 
'C Sf8-Anne-de-Bellevue, Quebec H9X 3V9 
Da Dr. Jones: 
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w. 8Ai writing in rssponse to your request for oantinuing raview by the InstItUtionai Raview 
Board of the study A09--M81-02A entit!ed ....... pact of Welght LotIon Lipld Klnetloa ln 
Ov.weight Hyperllpldemlo Women". 
The progresa rvport wu revtewed and we are pleasad to Inlorm VOU thlt full board re-approval 
for the ItUdy wu proVÎded on ~obtII B, JOD3. vallet until....".,., IDIH. Th8 certification of 
annual raview "'as bMn enelaeed. 
Waaalc that VOU tek. note of the invft$tigators l'fllponelbifity to assure thal the current protocol. 
study amandments and consent doCument 81'8 deposited on an annual basis with the Research 
Ethica Boards of each hospital wherll patlant enrollment or data coIIactlon ta earrted out 
Should luther stUdy revi8i0n or an unantic/rJated develOpment occur prier to the neltt review, 
pie ... advIIe the IAB promptty. 
Neil MacDonald. M.D. 
Oh81r 
InsUtutional ReviBW Board 
cc: A09-M81-o2A 
·-. _____ ....... , ........ ·., ..... 11' ...... ... ,. ~ • r ..... _ 
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, t'" ""." 
.... n."' ........ _ ...... " ................... i ...... '_ ... I11'""' ....... ~ Or.l r;) l,..,:.: 
... !" .. ~Itf* ••• I ••• 
. Il. • .............. _ ..... " ......... k ........ ~ .............. "" ••• _ .... • •• ~ ••• 
Faculty Of Medicine 
.. c •• ta ...... eyle.- McGill University 
Prll"IClpa1lnvHtlg.mr: 'Pf:t!!!& :l k' :SAnaa Deptll1mentnn_Uicm: -oiD~Ha.:N~ __ _ 
IRB ReIliewNumDel"; Ao1-I47\ -ov.. Study N~(if"'y): Re\Mw...,..,..: -'U'V\1..U!:'v.d..""""" ...... __ 
TitleofResearctl Study: Ln_ .. ! al! 'V11QP!T l.Oi .. 0 .... L-If'~ Il''iIXIC,,i lM OtMleWûU, 
\o\1M.&.l1'\beM\'" W OM.II!.~ 
o.w of ini1IIIt IR8~: SïfE 30 2Ôi: :0. of previou$conti"uIng nNIew (if .~): _____ _ 
INTERIM RePORt (PuMa C;MIQ( 0fIt .... ..,. 
OYrIWIt StaIJt tA Study: 
Ac\1V8 SWy: __ ')C_____ _ OnM~, ____ ~ ________ _ 
FII"IIAMlytIl: _____ _ StulSyNot~:~ __ _ 
JGH: 0 MUHCIMCH: 0 MUHCIMGH; 0 MUHCA.4NH.uN1: CI 
MUHCIRVH: 0 SMH: 0 Ooualfts 0 Other. tlI ~ EMlW Cwt.i\cA ... ~,,'ffU1\0IJ, 
ct.s e'ca ~W-' "',..,,. 
McGiI ~.) whete lIIUdy hM "Dt M08hIed eppt'OlMl of bel! R-.rch Ettlia Boerd(s) (il ~): N !It 
"etI.Idy .,.",.0I'Ih1j) «fNttCieI "'PpoI'! hae chIn8Id, pIMee ptOVidt ccrr~ tG qI/Iin; etICIoect. lIJh. 
NumbIr of tIUbJeI* 111 bt r.1rc11ed by the MaGII PI: _ fUnblr ~ IUbjtc:tl enroIfIct by tht McGI PI to dite: Ai 3 
Number cl lIWbjedIa.enRIhd b, tM ~GIlI Pt.n.1nt nwiew: ~ 
~ ."y d ~ ... eubjeda WiN'aWft th!m the atudy?: ï.::J.. 
..... 1M.uty bHn ~ a/ra 1tIe lat 1Wcw7: aJA.- Have the .. mllioml bMn appt'Wed by .... IR8?: NI" 
Hu" consent ~ been nwiud eince the lut ...-w?: t.1 Oeta ~tn. o.mnt oonMI'lt form: ____ _ 
Are 1tIenI MW da .. 8ince .. lat t'aVIIrtv lhIIt œuId infIuln08 • ~. wllinQnMt to provlGe ccntIrllJiIG 00MtI'I\?: ..!l.-
Have.,.,. .pt'/IY NriIIu& IdVeru ~ (SAh)?: __ N..:..-~~ 
H8W! .H Mriow .m..w uperienQft ( Er) .nd ..r.tr r8pUl'!rt r.levant to the G1LIdy beIn nlpozt«I te .. IRB?: ~ __ 
, _ ~ !o 'I~J 
IR8CNir:--fJ.lle:2..-U.~~~~_o.: ~tLV ~ d-t;lJ3 
) 
81GNATURl8: 
Flculty of Mec/lei.,. 
36!! Pro~nade Sir William Osier 
Montre.l, OC H3G 1 VI 
SepbKnber14.2004 
Dr. Peter J. H. Jones 
Professor of Nutrition 
FecuM cie tnu.Qi". 
SeS!. Promenade Sir William 01'" 
Montr(l.,. OC. H3G 1YS 
School of Dletetlcs and Human Nutrition 
21.111 Lakeshore 
Ste-Anne-de-Bellevue. Qu'bec H9X 3V9 
Dear Dr. Jones: 
....... ,.. 0' ........ 
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We are writing in response lo your request for çentinuing reView by the Inltitutional Review 
Irl~ of the .wdy ~Og..Me 1.()2A entltled "Imptlcl of W.lght Losa on Upld K"'-Uos ln 
OV' ..... ght Hypetllpid.mic Women". 
The prograu report was revlewed and we are pleased to inform yeu that full board re-
approval for the studV was provided on Sep,.",,,., 13, 2004. valld until S.,.",,.,. 12, 
. 2QOa. The certifîcation of annual review ha. been enclosed. 
w. ask that you take note of the inveatigator'a responslbility to assure that the current 
protocol. ltudy amendments and consent cocument 8re d.poaited on an annual .,... with 
the Research Ethlcs Boards of each hospltal where patient enrollment or data coIr.ctIort 1. 
carrled out. 
Should further etudy revialon or an unantidpated develoJ;1ment oc;c;ur prlar to the next review. 
pu .. advfse the IRB promptly. 
Yeu. sincerely, 
CalateJohnston. OEd, RN 
CoooChair 
Inatitutionat Review Board 
cc: A09-M81-02A 
YOJI , " ",1,11,10 10. 1 Q rllil ~\:IQ 001,1' ~~U~v~"~ ~t~tA~~"/~"O l1li YV;JI YYO 
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~---------------------~~~ 
_____ RtYIIWII*Mt ____ • 
.rWei&kte. .. LfpWK ..... ·.O"·IIPtB.1 ......... CW_ 
On~ ______________ _ 
FfttII~: ____ _ 
CIIIted 101i'MItINnt---X...--
~No\~: __ .....,._ 
_ .......... __ 1D __ ~ ____________ _ 
JGH: 0 MUHC/MCH: 0 MUICIMGH: 0 MIJHCIM'4 ....... = 0 
00u0Iu C Ohr." ~ e.,i~ Cl'-';wJ tJ.Jri~ 
""""'s4. J..t-\" MlJIoICIJMt. 0 SMN: 0 
MaGiII ,..,..., wftIfe IIU Id,**-,~ tJJIOC*R •••• rl2ll ........ )_ .... W.): ____ _ 
"1fIIII)' ... ...,0I ~ .. cfIIt1gId. ...... ~OOIC.",.,.,..,~ ___ : ___ _ 
NunlMird ...... tD_ ...... ,,1: _G_ ~ of ......... ""_MOIIiII PI'" date: _:'2-
NumllarClf ...... .".,.,.. .. MCQIII-11IMe 1eQ,..", _0_ 
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........ «IUIdInlulnal • ...., ...... _ID ...... ~~:-fl_ 
................... (&0q8)?;_N __ 
..................... I_~.,.. ................ ID ... Mudy~AlClllridto .. M?:_Y_ 
- Ttn1'L """*... *'" 
1 
"McGill 
Faeulty oT Medicine 
3666 PrO""",de Sir William O.ler 
Montreal. OC HlG 1 ve 
$eptember 13. 2005 
Dr. Peter J. H. Jones 
Profesaor of Nutrition 
P:.c:ultt d. m~.eil'l. 
3655. P'omtntde Sir Willitl'l'l Osier 
Mcultrbl. OC. t-I3G 1Y6 
School of Dietetics and Human Nutrition 
21,111 Laksshore 
ste·Anne-d.Bellevue, Quebeç H9X 3V9 
Cear Or. Jon .. : 
j. 
.. -v ... , vv.., 
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~lIt/1"èI.cOP"\jr: 45141 398-3595 
W'8rewritingin,~pons. to your request for continuing revlew by the Institutionat Revlew 
Board of the study AOg.M81a02A entitled "Impact of Welght Los. on L'pid Kinetlc. In 
overwelght HrPerllpldemlc Women·~. 
The progrels report was reviewed and we are pleased to înform you that fuB board rfl-
approvat for the study weI proVided on Septem"" 11. 2005. \tafia until Septemb", 11. 
200f. The certification of annuel review ha. been enclosed. 
w. aslc thet yeu tek. note of "'e investigator's responsibility to assure that the current 
protocol. study amendments and consent document are depoeited on an annual basls wlth 
the R •• earch Ethics Boards r:I eaeh hospital where patient enrolJment or data collection ta 
carried out. 
Should furtl'l .. study;revision or an U'lantlcipated development oocur prlor to the next revlew. 
plèase advlse the 'RB promptty. 
Vours tinœrely, 
~~ 
leste JOhnston,'OEd. RN 
Co·Chair 
Institutions! ·AevIew Board 
cc: . A09~S1"()2A 
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May 23, 2006 
To Suhad AbuMweis: 
The purpose of this letter is to confIrm that Suhad AbuMweis, eo-author of the bclow mcntioned 
manu script, agrees to the inclusion of these manuscripts in the thesîs of Sylvia Santosa, PhD 
candidate. 
Manuscripts to be included: 
1. Physiologieal and therapeutic factors affectÏng cholesterol mctabolism: Does a reciprocal 
rclationship betwcen cholesterol absorption and synthesis really cxist? 
The candidate' s role in writing this manuscript was in writing the sections on how body weight 
affccts cholesterol metabolism and therapeutic factors affecting absorption and synthcsis. The 
candidate also coordiriatcd the rcvision of the manuscript betwecn eoauthors. 
Sylvia Santosa 
l, the co-author, agree that the candidate, Sylvia Santosa, includc the above mentioned 
manuscripts in her PhD Ihesis. 
~ ... , • r. ~.. 'l'W' 1 t" .. l ''-'l'. QI r1r:t"1I... n 
183 
May 8. 2006 
To Dt. Isabelle Demonty: 
The PurpoIC of this lette! is 10 con.fum tbat lsabeUtfix.roonty. CO-iJ,uth(,,'r of the bc:low mentiol1l!ld 
manuscripts, aSTees to the inclusion ofthese manu~.:r'ptç; in the thesis of Sylvia Santosa, PhD 
. candidate. 
MMuscripts tu bt included: 
• Santola S. Demonty l, Lichtenstein AH. Ci.,nf)ofle K. Jones P.IH. An jnvestigation of 
honnone and lipid ns50ciation.~ after wc4thtJos!' ill \\iomen, .1 Am Coll Nutr. (uccepted 
pending revisioD) 
• Varady KA. Lamarche B, Santosa S, Demur)f)i l, JNICS.P JH. Effeçt of weigbt loss 
resulting &am a combîn.ed low fat dletiex~rt.~:se regimen on LD!. partide site and 
distribution in ()be8~ women. MeraboUtm.(:itècepted pendisiS revision) 
• SanIo9a S, Demonly T. Lichtenstein AH, J.ones l'JlI. An effective sclf-dircctcd protocol 
for moderate weiçhtlœs throuSb diet and exen:ise in wonu:n, C.Submitted to Can J Diel 
Pract Res) 
• Santosa.S, Demonly l, Lichtensœin AH, J(trl~~s '.JI{. Chailles in cholesterol metabolism 
and body composition as a result of moderain ~ ~ight IOlis through met and cxcrcise in 
women. (Subanilted 10 J'l' J Ohes) 
• Santosa S. Demollty 1, Lichtenstein AH, O~.:k!Vas Thl, JObt:~ PJH. ABCGS andABCQ8 
single: ftuclcoùde polymorphisms contributé 1.<'> the responsiv.:ncss of cholesterol kineti.cs 
I() weipt loss. (Submitted 10 A.rterioscJer Tt,romb 1I,jI,~'c Biot) 
The candidate', role in these studic:s included sbaÜhbi r<sp<m:;jbiliry for the screelÙJlg and 
~nùtment of subja:ts from the Montreal area. C(ij'lr~uclin.g tiw clùùcal trial, aodS&QlJ)le 
cotlectiolL The candîdale W8S fully m~ponsibJe for Ihe àtlaÎ yS1N of S3n1p)esfor cholesterol 
kinetics and body composjtio~ and $latisti(:al analysiHof data. rh~ ..::andidatc wrotc the 
manuc;crlpt wlth guidfmc~ :md feedback of the C<Ht.d1hN5 . 
. Sylvia SUltosa 
1. the co·author. &grec that the candidate. Sylvia Safit<lstl, indude the abovememioned 
1lUU\ua.-nptS iD ber PhD the~is. 
~LÇQ{n~,,_. __ 
Isabelle Demonty 
TOTAL P.132 
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May 2, 2006 
To Amélie Charest: 
The purpose ofthis lel1er i-s to COnfunl that Amélie Charest, co-author of the bel,;,w mentioned 
manuscripts. agrees to the inclusion of these maml.c;cripts in the thesis of S)'lvia Santosa, PhD 
candidate. 
Manusctipts to be included: 
• Vatady KA. Lamarche B. S2Dtosa S~ Demonty 1. Charest A, Jonc:il PJH. Etrect of weigh: 
10ss resulting nom a çombined !ow fat diet/ex~rçise rcaimen on LDL pa.'1icle size and 
distributioD in obese women. Metaoolism. (accepted pending .revision) 
The candidatcts Iole in tbese studies ÎDciudcc1 sharing responsibüity for the screening and 
recruirment ofsubjects from the :Montreal area, collductillg the clinical trial, alld s.ample 
colleotion. The mmuliCnpt was wtitten with guidance and feedback from the candidate. 
Sylvia Saruosa 
1, the co~au.tho:r, 8.greethat the candidate, Sylvia ~antosa. include the abovementJon:4 
manuscripts ln ber PhD thesis. 
Amélie Clmrest 
.:I\1NI 
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May2~2006 
To Dr. Katherine Cianflone: 
Tne purpose of this letter is to confirm that Katherine Cianflone, co-author of the below 
mentioned manuscripts, agrees to the inclusion ofthese manuscripts in the thesis of Sylvia 
Santosa, PhD candidate. 
Manuscripts to be included: 
• Santosa S, Demonty l, Lichtenstein AH, Cianflone K, Jones PJH. An investigation of 
hormone and lipid associations after weight loss in women. J Am Coll Nutr. (accepted 
pending revision) 
The candidate's role in these studies included sharing responsibility tor the screening and 
rccruitment of subjects from the Montreal area, conducting the clinical trial, and sarnple 
collection. The candidate was fully responsible for the analysis of samples for cholesterol 
kinetics and body composition, and statistical analysis of data. The candidate wrote the 
manuscript with guidance and feedback of the co-authors. 
Sylvia Santosa 
1, the co-author, agree that the candidate, Sylvia Santosa, include the above mentioned 
Katherine Cianflone 
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May 31,2006 
To Whom It May Concern: 
The purpose ofthis letler is to confirm that Peter JH Jones, co-author of the below mentioned 
manuscripts, agrees to the inclusion of these manuscripts in the thesis of Sylvia Santosa, PhD 
candidate. 
Manuscripts to be included: 
• Santosa S, Varady KA, AbumWeis S, Jones PJH. Physiological and therapeutic factors 
affecting cholesterol metabolism: Does a reciprocal relationship between cholesterol 
absorption and synthesis really exist? 
• Santosa S, Demonty I, Lichtenstein AH, Cianflone K, Jones PJH. An investigation of 
hormone and lipid associations after weight loss in women. 
• Varady KA, Lamarche B, Santosa S, Demonty I, Charest, A, Jones PJH. Effect ofweight 
loss resulting from a combined low fat dietlexercise regimen on LDL particle size and 
distribution in obese women. 
• Santosa S, Demonty I, Lichtenstein AH, Jones PJH. An effective self-directed protocol 
for moderate weight loss through diet and exercise in women. 
• Santosa S, Demonty I, Lichtenstein AH, Jones PJH. Changes in cholesterol metabolism 
and body composition as a result of moderate weight loss through diet and exercise in 
women. 
• Santosa S, Demonty I, Lichtenstein AH, Ordovas JM, Jones PJH. ABCG5 and ABCG8 
single nucleotide polymorphisms contribute to the responsiveness of cholesterol kinetics 
to weight loss. 
The candidate's role in writing the absorption/synthe sis manuscript was in writing the sections 
on how body weight affects cholesterol metabolism and therapeutic factors affecting absorption 
and synthesis. The candidate also coordinated the revision of the manuscript between coauthors. 
The candidate' s role in these studies included sharing responsibility for the screening and 
recruitment of subjects from the Montreal area, conducting the clinical trial, and sample 
collection. The candidate was fully responsible for the analysis of samples for cholesterol 
kinetics and body composition, and statistical analysis of data. The candidate wrote the 
manuscript with guidance and feedback of the co-authors with the excepJion of the LDL particle 
size manuscript that was written under the guidance of the candidate. 
I, the co-author, agree that the candidate, Sylvia Santosa, include the above mentioned 
manuscripts in her PhD thesis. 
Peter Jones 
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May 2,2006 
To Dr. Jose Ordovas: 
The purpose of this letter is to confirm that Jose Ordovas, co-author of the below mentioned 
manuscripts, agrees to the inclusion of these manuscripts in the thesis of Sylvia Santosa, PhD 
candidate. 
Manuscripts to be included: 
• Santosa S, Demonty l, Lichtenstein AH, Ordovas JM, Jones PJH. ABCG5 and ABCG8 
single nucleotide polymorphisms contribute to the responsiveness of cholesterol kinetics 
to weight loss. (Submitted to Arterioscler Thromb Vase Biol) 
The candidate's role in these studies included sharing responsibility for the screening and 
recruitment of subjects from the Montreal area, conducting the clinical trial, and sample 
collection. The candidate was fully responsible for the analysis of samples for cholesterol 
kinetics and body composition, and statistical analysis of data. The candidate wrote the 
manuscript with guidance and feedback of the co-authors. 
Sylvia Santosa 
l, the co-author, agree that the candidate, Sylvia Santosa, inc1ude the above mentioned 
manuscripts in her PhD thesis. 
Jose Ordovas 
..... ., ....... ...,v .... _ 
May 2, 2006 
To Dr. Alice Lichtenstein: 
The pwpose of dUs Mtcr ia to confirm that Alice H. Licherenstein, co-aalhor of the betow 
mf'I1ricned manUicripts, aarees to the inoiusion ofthese maDuscripts ill the thM1S of Syl\1a 
SlDtosa, PbD candidate. 
Martuscrittts ta he inclucled: 
• SatuOIi S. Demonty I. Licbtm.tcin AH, Cianflone K. Jones PIH. An Ul"vl'StiptiOO oC 
hormone and 1i.pld MSCciation$ aft.er wei&ht 10S8 in womcn. J.4.,.. C()ll 1\-..w. (acccpwd 
pcn4ins teVisioll) 
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• $&ntou S. Demonly 1. Lithtenstein AH, Jones PJH. An eftèetive self-difMcd protocoJ 
for modeIate wei,ht Iota throup dict and cxereise ÏP womet1. (Submitted tu Calf J Di.et 
p,.aCI R • .s) 
• San10sa S. Demon1y 1. Lichtenstein AH. Jonti PIH. ChaIl,. iD cholestetollDEUboU.m 
and bocly COutpOlitiOll as a R'lIult of moderate weiaht Joss th."Ough ciet and .xerei" in 
women. (Submitted to 1,,, JONS) 
• Sllltou S. DaDonty 1. Lichknttein AH, Ordovu lM. Jones PlB. ABCGS md ABCG8 
slngle nueleotide polymorpbisli'lS ,oQUiblitc te cho teipOIl5.ivent5lof choltltcrol kinell.t$ 
to weigbt lois. (Submittod to ArlmOlcl". 1'hro",b Vase BiDI) 
The candidate'. role in these ItUdics inc;ll.ldcd IhariDi relJ)01UibiUty for the lçreening and 
recrwlment of subjects fhnn th~ Montreal arc&, .;onductm, the elinic&1 trial, and SImple 
collection. The cilldidate wu full)' responsible for the malyti. of slml'les for choleS1Crol 
bneucs and body CompositiOil. and. statiltiCal analyals of data. The candidate WfOtCthe 
manuscript with l'lidance andfcedback of the co-authors. 
Syh,;a Santou 
i, the co-allthor, Agree that the çandi~te. Sylvia Saotosa, mdude rhe above memioned 
manuscripœ in her PhD thesis . 
. .I\lice Lichteostcm 
I-Q8-2006 16:19 DE- INAF +418 656 5877 T-198 P.002/002 F-972 
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1 
May 2,2006 
To Benoit Lamarche: 
The purpose ofthîs letter îs to confirm that Benoit Lamarche, co-author of the below mentioned 
1 
manuscripts, agrees to the inclusion of these manuscripts in the thesis of Sylvia Santosa, PhD 
candidate. ! 
Manuscripts to be included: 
1 -
• Varady KA, Lamarche B, Santosa S, Demonty I, Charest A, Jones PJH. Effect ofweight 
10ss resulting from a combined 16w fat dietlexercise regimen on LDL particle size and 
1 
distribution in obese women. M,etabolism. (accepted pending revision) 
1 
The candidate's role in these studies indluded sharing responsibility for the screening and 
1 
recruitment of subjects from the Montreal area, conducting the clinical trial, and sarnple 
collection. The manuscript was wrinenlwith guidance and feedback frQm the candidate. 
1 
1 
1 
1 
1 
Sylvia Santosa 1 
1 
l, the co-author, agree that the candidatJ, Sylvia Santosa, include the above mentioned 
1 
Benoit Lamarche 
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May 23, 2006 
To Krista Varady: 
The purpose of this letter is to confirm that Krista A. Varady, co-author of the below mentioned 
manuscript, agrees to the inclusion of these manuscripts in the thesis of Sylvia Santosa, PhD 
candidate. 
Manuscripts to be included: 
1. Physiological and therapeutic factors affecting cholesterol metabolism: Does a reciprocal 
relationship between cholesterol absorption and synthesis really exist? 
2. Effect ofweight loss resulting from a combined low fat dietlexercise regimen on LDL particle 
size and distribution in obese women 
The candidate's role in writing the absorptionlsynthesis manuscript was in writing the sections 
on how body weight affects cholesterol metabolism and therapeutic factors affecting absorption 
and synthesis. The candidate also coordinated the revision of the manuscript between coauthors. 
The LDL particle size manuscript was put together under the guidance of the candidate. 
Sylvia Santosa 
l, the co-author, agree that the candidate, Sylvia Santosa, include the above mentioned 
manuscripts in her PhD thesis. 
Krista Varady 
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Note: 
Nom: 
----------------------------------------------
Date: ____________________________ ___ 
Temps Quantité Aliments et quantités d'ingrédients 
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le groupe des protéines (viandes et substituts) 
importance dans l'alimentation: Les aliments de ce groupe sont pour la plupart une 
excellente source de vita..'1lines du groupe B, de fer et de minéraux essentiels. Ils sont riches 
en protéines et généralement pauvres en glucides complexes (exception faite des pois et 
fèves). Une portion de ce groupe contient approximativement 65 calories, 7 g de protéines et 
4 g de gras. 
les meilleurs choix 
1 on (309) de poulet ou dinde (sans la peau) 
1 on (30 g) de veau (sauf escalopes) 
1 on (30 g) de bœuf maigre 
(ronde, surlonge, filet. steak de -rkmc) 
Ion (30 g) de porc maigr'e 
(jambon frais, fjlet) 
1 on (309) de poisson (frais ou congeié) 
i tasse de thon en conserve dans l'eau 
l on (30 g) de fromage Ié.ger (moins de 20% M.G.) 
~ tasse de fromage cottage 1 '10 M.G. 
1 œuf entier ou 3 blancs d'œufs 
1 c. a soupe de beut're d'arachide (de temps en temps) 
à éviter autant que possible (plus riches en gras et en sel) 
r coupes de bœuf grasses .~, ~ 
1 (<< "Ibs,» ou côtes, corned beef, jambon) 
1 coupes de porc q>'Qsses 1 '-({< scareribs N. porc haché saucisses) 
1 agne~u haché " ' 
i poisson frit 
1 $auci~ses et cho,'~:uterics 
1 
1 
1 
(ex: saucisses itclieniles, saucisses de Fral1cTOd, 
fromages régulie.rs en AkG. 
(ex; cheddar, suisse, bleu. etc.) 
• I..._~-,<~.~.~. ~ 
l 
1 
! 
! 
1 
~ 
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le groupe des glucides complexes 
(céréales et grains u pâtes, légumes riches en amidon) 
- ) 
importance dans l'alimentation: Les aliments de ce groupe sont pour la plupart une 
excellente source de fibres, de vitamines du groupe B et de fer. rIs sont habituellement 
pauvres en gras et en cholestéroL Une portion de ce groupe contient approximativement 80 
calories, 3 g de protéines et des traces de gras. 
les meiUeurs choix 
;i tasse de cél'~a:es à déjeuner a grain: entiers non sucréesl 
1/3 tasse de cereales de son concentrees (ex : Ali Bran) j 
i tasse de céréales de son en flocons (ex: Bran Flakes) l' 
f tasse de gruau ou céréales chaudes . 
1. tranche de pain de blé entier' ! 
1 
f pai n pita de 6 pc de diamètre 
1 tortilla de 6 po de diamètre 
1 tasse de cr'outans faibles en gras 
3 tasses de mars édaté (popcorn) sans gras ajouté 
5 toasts meiba 
3 galettes de riz soufflé nature, sans sucre ajouté 
î tasse de noui Iles ou pâtes alimentaires 
t tasse de riz, de bu!ghur, curts 
i 
i 
1 
i 
! 
i 
l 
È 
! 
.1 
1 
! t tasse de rna"fs 1 
i tasse de pois verts, congelés ou en conserve 1 
1/3 tasse de légumineuses cuites f 
(pois chiches, h:1f'icots ,'cuges, haricots blancs, fe'les de Lima) ./1 
1 petite pomme de t'erre cuite (1 on ou 30 g) . 
t tasse de purée de pommes de terre faible en g!:'as ~ 
à éviter autant que possibie (pius riches en gras, er! se! et/otE e~ S~Jcr~) 
I
f Croissants 
Muffins commerciaux,. beignes, biscuits 
Céréales du genre 9f4cno 1o, 
1 
Pâtes et riz frits 
Pommes de terTe frites 
1 Chips 
L Ch i ps de. mC!Ïs_.. "_ _. >~_~c~~ .. _>,~~.~., .. ___ _ 
Popcorn pour' le micro-ondes 
Céréales à déjeuner pré-sucrées 
Coqui Iles c tacos 
Gaufres 
roupes 
.. .. 
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fruits et 
îpëJ-.t(}OCe dans t'aUmerrhltian; Les aliments de ce groupe sont pour la plupart une 
:cellente source de fibres, de vitRmines et de minérau:-c essentiels. Ils sont une bonne source 
~ vitruiline A et de vitamine C. Ils contiennent aussi beaucoup de glucides, mais contiennent 
ibituellement peu de gras et de seL Une portion de frults contient approximativement 60 
ùories et 15 g de glucides. Uue portion de légumes contient environ 25 calories, 5 g de 
ucides et 2 g de protéines. 
les meiiieurs choix 
r'-~"" 
~ FRUITS 
'
Il fruit frais de gf'CtS$€Ut' moye!'ifle 
(e-x: pomme, nectarine, orangë t poire, pêche, gros kivvL .. ) 
1 2 pc'unes 
! l i 
a - tariCln..Sf" parnpj?..i~lt)U.s,Se'i r;,cngue 
1 ; tasse de cubeS' de cantaloup, de papayes, de framboises 
! 1 i taSSe de melon d'eau 
1. t tasse d'O.tlÛl.'1aS f~'(li$ 
, 1/3 tasse dianancs en conserve ! {-'Îûsse 
1 t -rasse 
1 
1 
;r. J' 
me!anges en conserlie 
1 ± tasse de bfeuets frais 
1 t tasse & jus de pomme pampJemoosse, o'Farrge ou ûi1ûnû:5 
1 1/3 tasse de jus de canneberges, t'arsins, ou pruneaux 
,,1 ~ LEGUfAES 
• .:.. tosse dg. ~1l€-S .cru:", ! "2 tasse d.z tégumes cuits 
1 
1 
! 
î- tasse de jus dé légumes 
exemoJe:;; :. uSt>erae5 cr«-YJX de 
; f.,.) l 
~ i carottes, cheu fteür. Guber'gine: poivrons verts{ be:~7er~\fe:) 
Î . >( t"(ti'rh,'"!()rl.t:: .-~n;ir'\~n....ie ZU .... t..:r:iS ,;~+r Î pOire.ou:, ... ~-'--"'''::J-'''''~ t;..r~jl\J.' u.,}!" " 'WLL j;.~ '.' '(.,v"'~. 
1 ., "'--, ••• ~ .. 
! j. 1 ViI<'" il;:. 
! J 0 /' 'i' Ir' , ! t" ,v r--Z gt'lOL1C,z: r:e cOln/Jreild !Jas' leS' !e7{l&j1~:7 rre .. eS e/l t1lr;:C'/Ol1 L~-~_~ ___ '__ ~_~~,_·_. __ .. ~:.o. ___ , ___ =_,,_ ... , __ ,.~~_~ ... __ . ~ ___ ~=~~J 
Ice dans j'alimentation: Les aliments de ce groupe sont püUT la plupart une 
e source de céücium, de phosphore, de :ribollavine, dfO vit8Jl1:!ne A et de vitamine D. 
ennent aussi beaucoup de protéines et rie glucides. Une portion de ce groupe 
appro:dmativement 90 calories, 12 g de gh.rcides et 8 g de protéines. 
--. 
lait entier (3.25% M.G,} t 
yogourt sucré t 
r ~ ! ici! entier évaporé 
1 
1 fCtt condensé sucré 
,1
:.: !(,d' nL'1r; 
.u. .. J'~-~ 
! yogourt glacé 
l ~ r' 
1 creme gwcee ; 
!_~--,~~~---
l 
f 
~ 
~ 
~ 
t 
\ 
1 
t 
t 
r 
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importance dans j'aÎimerrtaticfl: Les alünents de œ groupe sont pour la pluplli-t une 
excellente source de vita.mines A et K Ils. contiennent des acides gras essentiels. Une petite 
qU&l.ltité de gras est donc né.cessaire cr18q1Je J(}ur~ Une portion àe CP ,groupe contient 
approximativement 45 calories et 5 g fie gras. 
r-=-~--~---""""-==~· ---,,=,~.---"_._~ . ~~~~, 
à GRAS 
1 beurte 
• 
i bacon ;.~ 
1 lard 
I~ ,......t..- __ ..!.. ..... _;,-rô .,J·;-u.; ::'/lVl l ti IlIly <.k n.", 
~ 
hUi te de coco 
,L,.-l' "·<()t~f} rnn~t> M~ _ ....... _,.. •. __
tûî"j condensé sucr~é 
l.~·;+ r"<,I_!;-.':; 
'LUt ~lU~ ... 
'logCiuri·t~ giacé 
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:efinition: Les aliments de ce groupe contiennent mmns d~ 2D calories par portion. 
euvent être indus dans le régi..rne alimentaire dJ.l1al!';ilSSrult, avec modération toutefois. 
,ouiiions pauvres en sodium et en gr~-;-· --1 
d ' l ,oissons gazeuses ietes , 
t au gazeuse 1 
(lfé. thé 1 
• f 
c. a soupe de poudre de cacco non sucré 1 
. . --_.~ 
tasse de canneberges, M~ sucrée::: 
tasse de rhubarbe, non sucrée i ___________________________________________ 1 
:hou 
:nou chinois 
:éleri 
:clFlcombre 
. • r '-
"menrs TOrTS 
~chalotes 
~scarc!z 
i TASSE l i ; 
j 
germes de h(w]Cûts 1 
radis 
:zucchinis 
-~--~~-i 
il1ii"II.O ir.:>nera 1 
..$- •• --'---~-.~ f 
iC1tue rt"3i5ée. ! 
~ 
éDinGrd,·; j 
"'~"'<~ 
Autres 
~·"-_·,,~·~---~~î 
r-lÛnstick vegetabJe Pail sprc)/ y> ':., 
Condiments 
1 
11 c. a tab1e de ketchup 
:,: 1 L a tobie de moutarde 
1 c. a tabie de sauce barbecue 
1 
i 1 c. 0 Tobie de sauce Ci taco i 
1 i 1 Co -a table de "it1a~gre 
j 
t 
~4\ssajsonnements 
- _. - . ' . --·=,"""~'1 
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Calculating Exchanges For Ambiguous Foods 
Sometimes we run into foods (such as meal replacements) that 
don 't fit into any one particular category. 
Here is an easy way to calculate 
how these foods fit into your exchange system. 
1. Start with Carbohvdrates. 
J 
Take the arnount of carbohydrates (g) and divide by 15 g. 
This is the number of Starch Exchanges the food has. 
2. Calculate the Protein Exchanges. 
Take the number of Starch Exchanges and multiply it by 3 g. 
Subtract this nurnber from the total arnount of protein (g). 
Divide by 7 g. 
This is the number of Protein Exchanges the food has. 
3. Calculate the Fat Exchanges. 
Take the nurnber of Starch Exchanges and rnultiply it by 1 g. 
Take the number of Protein Exchanges and multiply it by 4 g. 
Subtract this nurnber from the total amount of fat (g). 
Divide by 5 g. 
This is the number of Fat Exchanges the food has. 
Note that sometimes the numbers don 't work out evenly. 
Nothing is perfecto 
Just use your best judgement! 
A Sample Calculation T 0 Get You Started ... 
A food that you yvant to eat has: 
30 g Carbohydrates 
13 g Protein 
10 g Fat 
Hoy\! do es it fit into your exchange system? 
1. Start with Carbohydrates. 
Take the all/OUlLt of carbohydrates (g) alld divide by 15 g. 
This food has 30 g of Carbohydrate 50 ... 30 g -:-15 g = 2 
Ther~forc, this food has 2 Starch Exchanges. 
2. Calculate the Protein Exchanges. 
raki' tlIt! Illl11lba of5tarch Exclulilges !Tlld /lwltiply if i JI!:3 g. 
2 Starch Exchanges x 3 g = 6 g 
5ubtmct tlzis 1ll/lIliJer JÎ'OIlI tlIc total alllO/lIlt ofprotcill (g). 
This food has 13 g Protein 50 ... 13 g - 6 g = 7 g 
Oiuide by 7 g. 
7g-:-7g=1 
Thcreforc, this food lIns 1 Protein Exchange. 
3. Calcula te the Fat Exchanges. 
TIl/œ tlie Il Il 111 ber ofStnrell ExclIiIllgCS fllln 1I11l/hp/y if /llJl g. 
2 Starch Exchanges x 1 g = 2 g 
Takc the llul11ber of Protci Il ExcJuZIlgcs il/ut Illlliti ply i t i7y 4 g. 
1 Protein Exchange x 4 g = 4 g 
5/1[Jtmcf fhis lIl/mberfrom the total nlllO/lllt ofJilt (g). 
This food has 10 g Fat 50 ... 10 g - 1 g - 4 g = 5 g 
Oiuidc liy 5 g. 
5g-:-Sg=1 
Tllt>rete)/'c' tli islcwd lins 1 Fat Exchange. 
Total Exchanges for this food is ... 2 Starches, 1 Prote in, 1 Fat. 
N.B. They don't always work out so evenly. 
You can round for an estinlate. 
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Abstmct 
Weight loss resulting ttom diet interventions has been shown to favorably allect low-density lipoprotein (LOL) particle size and 
distribution, and, hence, decrease cardiovascular disease risk. However, the effect of a dietary weight loss strategy when combined with 
exercise, on LOL electrophoretic characteristics, has yet to be tested. This study examined the et1ect of a weight 108s intervention that 
combined a low-fat diet with moderate endurance training, on LOL parti cie size and distribution in obese women. Thirty obese, 
hypercholesterolemic women participated in a controlled longitudinal weight los8 trial, which consisted of (1) a 2-week pre-stabilization 
phase, (2) a 20-week weight loss phase, and (3) a 2-week post-stabilization phase. Weight reduction resulted ttOin a low-fat diet « 30% fat, 
50%,-60% carbohydrate, 20% protein) combined with an endurance training program (>40 minutes moderate training, 3 times per week). 
Mean weight loss was 14.8% (P < .01) of initial body weight. Total, LOL cholesterol, and triacylglycerol concentrations decreased (P < .01) 
by 8.9%, 7.5%, and 27.1%, respeetively, whereas high-density lipoprotein cholesterol concentrations increased (P < .01) by 9.9%. No 
significant ditTerences were noted for LOL peak or integrated particle size. The relative proportion of smal\. medium, and large particles was 
not significantly diffèrent posttreatment. Estimated cholesterol concentrations in large- and medium-sized LDL particles decreased (P < .05) 
by 15.3% and 5.9%, respectively, as a result ofweight !08S. No effect was noted for estimated cholesterol concentrations in small size LOL 
particles. In conclusion, these findings suggest that weight loss, resulting from a low-fat diet/exercise program, has only a minimal effect on 
LDL particle size and distribution. 
(g 2006 Elsevier lne. Ail rights reserved. 
-------------_ .. __ .. __ .. _-----_._--_._ .. _-_._- .. __ ..... _._-_ ..... _-_ ... _ .._--------------_ ... _---------------------_._---
1. Introduction 
Results from several reeent epidemiologie and clinical 
intervention trials indieate that obesity is a major indepen-
dent risk factor for cardiovascular disease [1]. Accordingly, 
weight 10S5 has been shown to favorably affect several 
indicators of cardiova8cular risk, such as plasma lipid [2,3], 
homocysteine [4], and C-reactive protein [5J concentrations. 
ln addition to these eommonly investigated parameters, 
weight 10s8 has also been shown to beneficially modulate 
low-density lipoprotein (LDL) size and distribution [6-10]. 
More specifically, Archer et al [6] demonstrated that a low-
* Corresponding author. Tel.: +1 2044748883; fax: +12044747552. 
E-mail address:petcLjones@umanitoba.ca (P.J.H. Jones). 
0026-0495/$ - see front matter <{) 2006 Elsevier [ne. Ali right, reserved. 
doi: 10.1 0 16/j.metabo1.2006.05.014 
tàt/high-carbohydrate diet reduced the average body weight 
of overweight men by 2%, while causing reductions in the 
cholesterol content of small- and medium-sized LDL 
particles. Similarly, Markovic et al [71 found that after 
consuming a low-fat diet for 28 days, mildly obese patients 
10st an average of 6.2 kg and increased the proportion of 
large LDL particles in plasma. Furthermore, in a study by 
Katzel et al [8 J, it was shown that an average loss of 10 kg 
of body weight, induced by a low-fat diet, resulted in a 
significant increase in LDL peak particle diameter. Although 
these data indicate that diet-induced weight loss positively 
alters LDL electrophoretic characteristics, the effect of a 
low-fat diet when placed in combination with exercise, 
another commonly implemented weight loss strategy, on 
LDL particle diameter, has yet to be tested. ln addition, the 
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eftect of substantial weight loss, that is, loss of more than 
10% of initial body weight, on LDL size and distribution 
still needs further clarification. 
Thus, the objective of the present study was to examine 
the effect of a 24-week weight los8 intervention that 
combined a low-fat diet with moderate endurance training, 
on LDL paItic1e size and distribution in obese, hypercho-
lesterolemic women. In addition, the extent to which 
substantial changes in body weight modulated LDL 
electrophoretic was also examined. 
2. Subjects and methods 
2.1. Subjects 
Subjects were recruited l'rom the greater Montreal area by 
means of newspaper advertisements. After a preliminary 
questionnaire, blood screening, and physical examination, 
42 subjects were deemed eligible to partake in the trial. Key 
inclusion criteria were as follows: nonpregnant women; age 
of 35 to 60 years; body mass index (BMI) between 28 and 
37 kg/m2; LDL cholesterol (LDL-C) concentrations of 
greater than 4.5 mmol/L; triacyIglycerol concentrations of 
greater than 1.5 mmol/L; free of cardiovascular disease; free 
of gastrointestinal, renal, pulmonary, hepatic, or biliary 
disease; free of cancer; no history of disordered eating; 
alcohoJ iotake of Jess than 2 drinks per day; use of fiber or 
stimulant laxatives of less than 2 doses per week; not taking 
lipid-lowering medications for the past 6 months; and less 
than 16736 kJ/wk (4000 kcallwk) expended by endurance 
training. The protocol was approved by the human ethical 
review committee of the Faculty of Medicine at McGill 
University (Montreal, Quebec, Canada). Before the com-
mencement of the study, ail voll.lllteers gave their written 
infom1ed consent to participate in the trial. 
2.2. Experimental design 
A 24-week longitudinal design was implemented as a 
means of testing the study objectives. Each subject acted as 
her own control, and therefore, no control group was 
required [II]. The trial consisted of 3 consecutive dietary 
periods: (1) a 2-week pre-Joss stabilization phase, (2) a 
20-week weight loss phase, and (3) a 2-week post-Joss 
stabilization phase. During the first and third phases, 
subjects were required to main tain a stable weight and were 
instructed to continue with their usual food habits. In 
contrast, during the second phase, subjects were required to 
reduce their ener!":,')' intake by 20% and increase their ener!":,')' 
expenditure by 10%. As a result, target weight loss was 
approximately 0.75 kg/wk. Premenopausal women started 
each of the 3 phases at identical points during their 
menstrual cycles. 
2.3. Dietary profocol 
Each subject attended individual dietary counseling 
sessions with a registered dietician or nutritionist on a bi-
weekly basis to decrease energy intake by 20% throughout 
the weight loss phase. During these sessions, volunteers were 
taught how to attain daily energy goals using an exchange 
system that provided 50% to 60% of energy from carbohy-
drates, 20% of energy from protein, and less than 30% of 
energy From fat. Teaching aids, which outlined the energy 
contents ofcommonly ingested food items, as well as sample 
menus and recipes, were distributed to the volunteers. 
2.4. Exercise protocol 
As a means of increasing energy expenditure by 10% 
throughout the 20-week weight loss phase, subjects were 
instmcted to perform moderate aerobic training 3 times per 
week, for a minimum of 40 minutes. During the trial, each 
subject met with a personal trainer and was taught proper 
training techniques and routines. The exercise was per-
formed independently at home or at the Mary-Emily 
Clinical Nutrition Research Unit. 
2.5. Weight loss assessment and compliance 
Compliance with both the dietary and exercise proto col 
was determined by way of weigh-ins that took place once 
per week throughout the trial. Continuous, regular weight 
108s throughout the second phase of the study was 
encouraged by means of a point system as weil as visual 
graphs, which plotted weekly weight changes. 
2.6. Blood collection protocol 
Twelve-hour fasting blood samples were collected on the 
momings of days 0, 13, 14, 15 (phase 1), and 167, 168, and 
169 (phase 3) of the trial. Blood was centrifuged for 
15 minutes at 520g and 4°C to separate plasma from red 
blood ceUs, and was stored at -20°C l.llltii analyzed. 
2. 7. Analyses 
2.7.1. Plasma lipid pnJfile determination 
Plasma total cholesterol, high-density lipoprotein cho-
lesterol (HDL-C), and triacylglycerol concentrations were 
measured in duplicate by automated methods through a 
Hitachi 911 automated analyzer (Roche Diagnostics, Indian-
apolis, IN) using enzymatic or immunoturbidometric 
reagents [12]. Low-density lipoprotein cholesterol was 
detennined directly by the dextran/magnesium sulfate 
method to separate it from HDL-C (N-geoeous LDL-C 
as say, Equal Diagnostics, Exton, PA) [13,14]. 
2.8. Low-density lipoprotein particle size determination 
Low-density lipoprotein particle diameter analysis was 
performed on whole plasma using nondenaturing 2% to 
16% polyacrylamide gradient gel electrophoresis [15]. 
Plasma samples (3.5 ilL) were mixed with a sampling 
buffer containing 20% sucrose and 0.25% bromophenol 
blue in al: 1 (vol/vol) ratio. The 6 samples, representing 
days 13, 14, 15, 167, 168, and 169, for each individual 
subject were placed on one unique gel. After a 15-minute 
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prerun, electrophoresis was performed at 150 V for 3 hours. 
Gels were then stained for 1 hour with Sudan black (0.07%) 
and stored in a 0.81% acetic acid/4% methanol solution 
until analysis. The Imagemaster I-D Prime computer 
software (Amersham Phanuacia Biotech, Piscataway, NJ) 
was used to analyze the gels. Mean LDL particle size was 
computed by integratillg the relative contribution of each 
LDL particle subfraction within a sample and correspond-
ing to the weighted mean of aIl LDL subfi-actions. Inte-
grated LDL particle size was calculated as the sum of LDL 
subspecies' diameter multiplied by its relative proportion. 
The relative proportion of LDL having a diameter of less 
than 25.5 nm (telmed LDL%<255 À) was obtained by com-
puting the relative area of the densitometric scan of less 
than 25.5 mu. The absolute concentration of cholesterol 
within the LDL subfraction characterized by a diameter 
of less than 25.5 nm (termed LDL-C <.25.5 lin,) was crude1y 
estimated by multiplying total plasma LDL-C concentra-
tions by LDUYO<25.5 mu as previously described [15J. A 
similar approach was used to assess the relative and abso-
lute concentrations of cholesterol in the LDL subfrac-
tions with a diameter of more than 26 nm (LDL%>26 nm 
and LDL-C>26 nm, respectively) and in those with a di-
ameter between 255 and 26 nm (LDL% 25.5-26 nm and 
LDL-C 25.5-26 nn" respectively). 
2.9. Statistics 
Results are presented as means ± SEM. A paired t test 
was implemented as a means of comparing baseline and 
posttreatment weight, lipid, LDL particle size, and distribu-
tion values. Pearson correlation coefficients were calculated 
to test for associations between treatment-induced changes 
in body weight, plasma lipid concentrations, and LDL 
electrophoretic characteristics. A level of statistical signif-
icance at P < .05 was used in al! analyses. Data were 
analyzed using SAS software (version 8.0; SAS Institute, 
Cary, NC). 
3. ResuIts 
3.1. Subject baseline characteristics and compliance 
Forty-two subjects commenced the study, with 35 
completing the entire 24-week trial. The 7 subjects who 
did not complete the trial dropped out because of an 
inability to comply with the study protocol. In addition, data 
from 5 subjects were not analyzed because of plasma 
sample loss. Therefore, after accounting for these loses, a 
total of 30 complete subject data sets were used for LDL 
partic1e size and distribution analysis. On day 0 of the 
Hial, the mean age, body weight, and BMI of the 30 parti-
cipants was 48.9 ± 1.24 years, 82.1 ± 1.74 kg, and 31.5 ± 
0.52 kg/m2, respectively. During the weekly meetings with 
the registered dietician/nutritionist, compliance with the 
energy-reduced, low-fat diet was reported to be adequate, as 
demonstrated by proper use of the checklist exchange 
system. Also during these meetings, reported increases in 
energy expenditure during the weight loss phase of the study 
were shown to be satisfactory, as the subjects reported 
increasing their physical activity levels by a minimum of 
120 minutes per week. 
3.2. Body weight and plasma lipid pn~flles 
Changes in body weight, BMI, and plasma lipid profiles 
over the course of the 24-week trial are presented in Table 1. 
The mean rate of weight loss over the 20-week weight loss 
phase was 0.59 kg/wk (Fig. 1). From the beginning to the 
end of the trial, the 30 volunteers experienced a significant 
(P < .01) mean reduction in body weight of 12.0 ± 0041 kg. 
When expressed as the difference between day 15 and day 
169 values, subjects were shown to have decreased their 
overall body weight by 14.8%. Body mass index decreased 
significantly (P < .01) from 31.5 to 26.9 kg/m2 from 
baseline to posttreatment. 
As reported previously [16], plasma lipid parameters 
were significantly altered as a result of weight loss. Total 
cholesterol and LDL-C concentrations decreased signifi-
cantly (P < .01) by 8.9% and 7.5%, respectively, after the 
intervention period. In addition, HDL-C concentrations 
increased (P < .01) by 9.9%, whereas triacylglycerol 
concentrations decreased by 27.1 % from baseline to the 
end of the trial. 
3.3. Low-density lipoprotein peak particle size, integrated 
size, and distribution 
Low-density lipoprotein peak partic1e size, integrated 
size, and distribution over the course of the trial are 
presented in Table 2. No differences were noted with 
respect to LDL peak partic1e size from the beginning to the 
end of the trial. Similarly, no significant ditferences were 
noted for LDL integrated size when baseline values were 
compared with posttreatment values. Furthermore, the 
relative distributions of cholesterol among small «25.5 nm), 
medium (25.5-26 nm), and large (>26 nm) LDL partic1es 
showed no significant differences from baseline to post-
treatment. However, with respect to the absolute distribution 
of the different LDL partic1e subfractions, the estimated 
Table 1 
Body weight, BM1, and plasma lipid concentrations at baseline and 
posttreatment 
n = 30 Baseline Posttreatment % Change pa 
Mean ± SEM Mean ± SEM Mean ± SEM 
Body weight (kg) 82.14 ± 1.74 70.09 ± 1.71 -- 14.80 ± 0.52 <.01 
BMI 31.53 ± 0.52 26.90 ± 0.52 -14.80 ± 0.52 <.01 
Total cholesterol 6.05 ± 0.16 5.46 ± 0.11 ·8.94 ± 1.78 <.01 
(mmol/L) 
LDL-C (11111101;1.) 3.77 ± 0.12 3.44 ± 0.09 --7.54 ± 2.21 <.01 
HDL-C (mmolfL) 1.17 ± 0.04 1.27 ± 0.05 9.92 ± 3.01 <.01 
Triacylglycerol 1.80 ± 0.13 1.25 ± O.OS -27.14 ± 3.59 <.01 
(mmol!L) 
a P value within group: Student paired t test comparing day 15 values 
10 day 169 values. 
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Fig. 1. Body weight reduction during the 20-week weight 10ss phase. The data presented are the mean body weight values al each week of the trial. The mean 
rate of weight loss over the 20-week weight Joss phase was 0.59 kg/wk. Posttreatment body weight values were shown to be significantly different (P < .01) 
wlwn compared with baselinc (Student paired i test). 
cholesterol concentration in large-sized LOL particles was 
shown to decrease significantly (P < .05) by 15.3% (0.80-
0.68 mmollL) from the begillllÎng to the end of the trial. In 
addition, the estimated cholesterol concentration in medium-
sized LOL paliicles was shown to decrease (P < .05) by 
5.9% (1.39-1.31 mmol/L) posttreatment. No significant 
changes were noted for the estimated cholesterol concen-
tration in small LOL particles. 
3.4. Correlation between body weight and LDL particle size 
Body weight has been shown to correlate with variations 
in LOL particle size and distribution. For this reason, 
analyses were performed to see if the substantial decrease in 
body weight resulting from the diet/exercise intervention 
had an effect on LOL electrophoretic characteristics. 
Correlational analysis revealed that the gTeater change in 
body weight over the course of the trial was associated with 
Table 2 
increased LOL peak particle size posttreatment (r = -0.14, 
P = .03). 
3.5. Correlation hetween triacylgzvcerol concentrations and 
LDL particle size 
Posttreatment triacylglycerol concentrations were not 
significantly cOlTelated with any of the posttreatment LOL 
particle size or distribution parameters measured. In 
addition, posttreatment triacylglycerol concentrations 
showed no significant associations with either percent body 
weight change or posttreatment body weight. 
4. Discussion 
The results of the present study indicate that a substantial 
amount ofweight 10ss, that is, loss of approximately 15% of 
initial body weight, resulting from a low-fat diet combined 
Low-density lipoprotein peak particJe size, integrated size, and distribution at baseJinc and after a 24-week diet'exerciseweight Joss intervention 
n = 30 Baseline!l P osttreatmenth % Changee pd 
Mean ± SEM Mean ± SEM Mean ± SEM 
LDL peak particJe size (mn) 25.626 ± .041 25.623 ± .026 -0.01 ± 0.12 .913 
LDL integrated size (mn) 25.627 ± .040 25.615 ± .ü20 -0.05 ± 0.11 .678 
LDL%>2h mn (%) 20.93 ± 2.34 20.07 ± 1.37 -4.12 ± 6.20 .574 
LDL%26_25.5 znn (%) 36.96 ± 1.47 37.95 ± 1.34 2.68 ± 4.07 .317 
LDL%<25.5 nn> (%) 42.26 j: 2.27 42.10 ± 1.81 -0.38 ± 5.36 .909 
LDL-C>26 mn (mmol/L) 0.80 ± 0.10 0.68 ± 0.05 -15.35 ± 7.96 .043 
LDL-C25.5_26 nrn (mmollL) 1.39 :l: 0.07 1.31 ± 0.06 -5.87 ± 3.79 .048 
LDL-C"25.5 nm (mmoIlL) 1.58 ± 0.09 1.46 ± .09 -7.82 ± 5.37 .100 
" Mean of day 13, 14, and 15 values. 
h Mean ()fday 167. 168, and 169 values. 
C Percent change comparing the mean ofday 13, 14, and 15 values to the mean ofday J67, 168, and 169 values. 
cl P value within group: Student paired t test comparillg the mean of day 13, 14, and 15 values to the mean of day 167, 168, and 169 values. 
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with exercise, decreases the estimated cholesterol concen-
trations oflarge and medium LDL particles. The relative pro-
portion of small, medium, and large particles, however, were 
not significantly altered by this decrease in body weight. 
Results of several recent c1inical trials show that losing a 
considerable amount of body weight has favorable eflects 
on certain indicators of cardiovascular disease lisk [17-19]. 
Therefore, it would be expected that in the present 
intervention trial, which produced a substantial amount of 
weight 10ss, certain cardiovascular risk factors such as LDL 
particle size would be ameliorated. Although such favorable 
alterations have been previously reported [6-9], the results 
of the present study demonstrate that this magnitude of 
weight 108S has a minimal effect on LDL particle 
disttibution. More specifically, this study reports a decrease 
in cholesterol concentrations in both large and medium LDL 
particles, as a result of a 15% dietiexercise-induced weight 
reduction. No increase in the cholesterol content of small 
LDL particles, however, was noted in response to these 
cholesterol shifts between subfractions. There are several 
possible explanations that may account for these unexpected 
findings. Pirst and foremost, these results could partially be 
explained by the low-fat diet regimen. Recent findings 
suggest that LDL partic1es shift from larger, less atherogen-
ic, to smaller, more atherogenic, particles in direct propor-
tion to the degree to which dietary fat is replaced by 
carbohydrate [20]. Thus, because the subjects were required 
to lower their fat intake to less than 30% of total energy, and 
hence, increase their carbohydrate intake to approximately 
60% of total energy, it can be assumed that this shift in 
macronutrient distribution may be responsible for the 
present findings. Secondly, it is possible that the decrease 
in cholesterol within large and medium LDL subfractions 
may be attributed to the physical activity component of the 
study. More specîfically, in a recent study by Varady et al 
[21], it was demonstrated that participation in a moderate-
intensity exercise pro gram decreased the peak particle size 
of previously sedentary, hypercholesterolemic adults. How-
ever, contradictory to these findings [21], other studies that 
have examined this rc1ationship have reported either an 
increase in LDL peak particle size as a result of exercise 
[22-25] or no etTect [26]. For instance, in 2 trials [22,231 that 
examined the eftèct of endurance training on LDL particle 
size in obese men, the number of small, dense LDL paliic1es 
was shown to decrease as a result of training. In line with 
these findings, Kang et al [24] demonstrated that physical 
activity had a beneficial effect on LDL particle diameter in 
obese adolescents. ln contrast, Elosua et al [26] demon-
strated that after a 16-week training period, no changes were 
observed with regard to LDL particle diameter in previously 
sedentary men and women. In view of these findings, 
because most of the studies in the area suggest a beneticîal 
effect of exercise on LDL e1ectrophoretic characteristics, it 
is unlike1y that the exercise intervention produced these 
slightly deleterious changes in LDL particle size. Thus, 
before it can be concluded that exercise is responsible for 
tbese unfavorable eftects, it is essential that the results of the 
Varady et al [21] trial be supported by other independent 
studies testing similar objectives. 
Interestingly, correlational analysis revealed a weak but 
significant association between greater weight 10ss and an 
increase peak LDL particle size (r = -0.14, P = .03). 
These associative findings are, evidently, contrary to the 
causal findings reported in the present article. The reason for 
these conflicting results is not clear. However, one possible 
explanation for these contt'adictory findings may again be 
the change in diet composition. Because replacing fat with 
carbohydrate leads to a decrease in particle size, it can be 
hypothesized that, if this change in diet was not imple-
mented, LDL size may have increased in respOllse to weight 
Joss. Then again, because these findings are merely 
associative, and also quite weak, these correlational results 
should not put into question the results of the causative 
findings. Nevertheless, these contradictory results may 
suggest that, when attempting to assess the effect of weight 
loss on vascular disease risk, LDL particle size analysis 
should be performed in conjunction with other more well-
established indicators [27]. 
In summary, results of the present study demonstrate that 
a substantial amount ofweight loss resulting from a low-fat 
diet and exercise regimen has no effect on the distribution of 
small, medium, and large LDL particles. In addition, these 
data suggest that this weight loss regimen decreases the 
estimated cholesterol concentrations of large- and medium-
sized LDL particles. However, no increase in cholesterol 
within small LDL particles was observed in response to 
these cholesterol shifts between subfractions. These findings 
suggest that low-fat diet/exercise-induced weight loss only 
minimally aftècts LDL particle size and distribution. 
Therefore, when viewed in terms of modulating LDL 
electrophoretic characteristics, the effect of low-fat dietl 
exercise-induced weight loss on cardiovascular risk reduc-
tion cannot be inferred from the present data. 
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